
<html lang="en"     class="pb-page"  data-request-id="ca179bcb-f5ec-4748-ac45-7bb290d894c4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2017.60.issue-23;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.7b01135;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties" /></meta><meta name="dc.Creator" content="Tony  Siu" /></meta><meta name="dc.Creator" content="Jason  Brubaker" /></meta><meta name="dc.Creator" content="Peter  Fuller" /></meta><meta name="dc.Creator" content="Luis  Torres" /></meta><meta name="dc.Creator" content="Hongbo  Zeng" /></meta><meta name="dc.Creator" content="Joshua  Close" /></meta><meta name="dc.Creator" content="Dawn M.  Mampreian" /></meta><meta name="dc.Creator" content="Feng  Shi" /></meta><meta name="dc.Creator" content="Duan  Liu" /></meta><meta name="dc.Creator" content="Xavier  Fradera" /></meta><meta name="dc.Creator" content="Kevin  Johnson" /></meta><meta name="dc.Creator" content="Nathan  Bays" /></meta><meta name="dc.Creator" content="Elma  Kadic" /></meta><meta name="dc.Creator" content="Fang  He" /></meta><meta name="dc.Creator" content="Peter  Goldenblatt" /></meta><meta name="dc.Creator" content="Lynsey  Shaffer" /></meta><meta name="dc.Creator" content="Sangita B.  Patel" /></meta><meta name="dc.Creator" content="Charles A.  Lesburg" /></meta><meta name="dc.Creator" content="Carla  Alpert" /></meta><meta name="dc.Creator" content="Lauren  Dorosh" /></meta><meta name="dc.Creator" content="Sujal V.  Deshmukh" /></meta><meta name="dc.Creator" content="Hongshi  Yu" /></meta><meta name="dc.Creator" content="Joel  Klappenbach" /></meta><meta name="dc.Creator" content="Fiona  Elwood" /></meta><meta name="dc.Creator" content="Christopher J.  Dinsmore" /></meta><meta name="dc.Creator" content="Rafael  Fernandez" /></meta><meta name="dc.Creator" content="Lily  Moy" /></meta><meta name="dc.Creator" content="Jonathan R.  Young" /></meta><meta name="dc.Description" content="The discovery of a potent selective low dose Janus kinase 1 (JAK1) inhibitor suitable for clinical evaluation is described. As part of an overall goal to minimize dose, we pursued a medicinal chemi..." /></meta><meta name="Description" content="The discovery of a potent selective low dose Janus kinase 1 (JAK1) inhibitor suitable for clinical evaluation is described. As part of an overall goal to minimize dose, we pursued a medicinal chemi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 4, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01135" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01135" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01135" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01135" /></link>
        
    
    

<title>The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01135" /></meta><meta property="og:title" content="The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0016.jpeg" /></meta><meta property="og:description" content="The discovery of a potent selective low dose Janus kinase 1 (JAK1) inhibitor suitable for clinical evaluation is described. As part of an overall goal to minimize dose, we pursued a medicinal chemistry strategy focused on optimization of key parameters that influence dose size, including lowering human Clint and increasing intrinsic potency, bioavailability, and solubility. To impact these multiple parameters simultaneously, we used lipophilic ligand efficiency as a key metric to track changes in the physicochemical properties of our analogs, which led to improvements in overall compound quality. In parallel, structural information guided advancements in JAK1 selectivity by informing on new vector space, which enabled the discovery of a unique key amino acid difference between JAK1 (Glu966) and JAK2 (Asp939). This difference was exploited to consistently produce analogs with the best balance of JAK1 selectivity, efficacy, and projected human dose, ultimately culminating in the discovery of compound 28." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="The discovery of a potent selective low dose Janus kinase 1 (JAK1) inhibitor suitable for clinical evaluation is described. As part of an overall goal to minimize dose, we pursued a medicinal chemistry strategy focused on optimization of key parameters that influence dose size, including lowering human Clint and increasing intrinsic potency, bioavailability, and solubility. To impact these multiple parameters simultaneously, we used lipophilic ligand efficiency as a key metric to track changes in the physicochemical properties of our analogs, which led to improvements in overall compound quality. In parallel, structural information guided advancements in JAK1 selectivity by informing on new vector space, which enabled the discovery of a unique key amino acid difference between JAK1 (Glu966) and JAK2 (Asp939). This difference was exploited to consistently produce analogs with the best balance of JAK1 selectivity, efficacy, and projected human dose, ultimately culminating in the discovery of compound 28." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0016.jpeg" /></meta><meta name="twitter:title" content="The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01135"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01135">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01135&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01135&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01135&amp;href=/doi/10.1021/acs.jmedchem.7b01135" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 9676-9690</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01097" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01151" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3<i>R</i>,4<i>S</i>)-4-cyanotetrahydro-2<i>H</i>-pyran-3-yl)-1<i>H</i>-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tony++Siu">Tony Siu</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-5149-7457" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Brubaker">Jason Brubaker</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Fuller">Peter Fuller</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luis++Torres">Luis Torres</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hongbo++Zeng">Hongbo Zeng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joshua++Close">Joshua Close</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dawn+M.++Mampreian">Dawn M. Mampreian</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Feng++Shi">Feng Shi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>◆</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Duan++Liu">Duan Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xavier++Fradera">Xavier Fradera</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Johnson">Kevin Johnson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nathan++Bays">Nathan Bays</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elma++Kadic">Elma Kadic</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fang++He">Fang He</a></span><span class="author-xref-symbol author-aff-symbol"><sup>◇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Goldenblatt">Peter Goldenblatt</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lynsey++Shaffer">Lynsey Shaffer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sangita+B.++Patel">Sangita B. Patel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Charles+A.++Lesburg">Charles A. Lesburg</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carla++Alpert">Carla Alpert</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lauren++Dorosh">Lauren Dorosh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sujal+V.++Deshmukh">Sujal V. Deshmukh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hongshi++Yu">Hongshi Yu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joel++Klappenbach">Joel Klappenbach</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fiona++Elwood">Fiona Elwood</a></span><span class="author-xref-symbol author-aff-symbol"><sup>$</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+J.++Dinsmore">Christopher J. Dinsmore</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rafael++Fernandez">Rafael Fernandez</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lily++Moy">Lily Moy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>¶</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jonathan+R.++Young">Jonathan R. Young</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Department of Medicinal Chemistry, <sup>‡</sup>Department of Discovery Process Chemistry, <sup>§</sup>Department of Modeling & Informatics, <sup>∥</sup>Department of In Vitro Pharmacology, <sup>⊥</sup>Department of Structural Chemistry, <sup>#</sup>Department of Pharmacokinetics Pharmacodynamics and Drug Metabolism, <sup>∇</sup>Department of Discovery Pharmaceutical Sciences, <sup>○</sup>Department of Molecular Biomarkers, <sup>¶</sup>Department of In Vivo Pharmacology, <sup>$</sup>Department of Respiratory and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span></div><div class="aff-info" id="aff2"><span class="aff-text"><sup>◆</sup>Department of Chemistry and <sup>◇</sup>Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div><div class="corresp-info"><strong>*</strong>Tony Siu: phone, 617-992-2386; e-mail, <a href="/cdn-cgi/l/email-protection#7b0f1415022408120e3b161e09181055181416"><span class="__cf_email__" data-cfemail="582c373621072b312d18353d2a3b33763b3735">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01135&amp;href=/doi/10.1021%2Facs.jmedchem.7b01135" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 9676–9690</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 20, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 August 2017</li><li><span class="item_label"><b>Published</b> online</span>4 December 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 December 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01135" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01135</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9676%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DTony%2BSiu%252C%2BJason%2BBrubaker%252C%2BPeter%2BFuller%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D23%26contentID%3Dacs.jmedchem.7b01135%26title%3DThe%2BDiscovery%2Bof%2B3-%2528%25284-Chloro-3-methoxyphenyl%2529amino%2529-1-%2528%25283R%252C4S%2529-4-cyanotetrahydro-2H-pyran-3-yl%2529-1H-pyrazole-4-carboxamide%252C%2Ba%2BHighly%2BLigand%2BEfficient%2Band%2BEfficacious%2BJanus%2BKinase%2B1%2BSelective%2BInhibitor%2Bwith%2BFavorable%2BPharmacokinetic%2BProperties%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9690%26publicationDate%3DDecember%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01135"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2654</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">8</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01135" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Tony&quot;,&quot;last_name&quot;:&quot;Siu&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Brubaker&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Fuller&quot;},{&quot;first_name&quot;:&quot;Luis&quot;,&quot;last_name&quot;:&quot;Torres&quot;},{&quot;first_name&quot;:&quot;Hongbo&quot;,&quot;last_name&quot;:&quot;Zeng&quot;},{&quot;first_name&quot;:&quot;Joshua&quot;,&quot;last_name&quot;:&quot;Close&quot;},{&quot;first_name&quot;:&quot;Dawn&quot;,&quot;last_name&quot;:&quot;M. Mampreian&quot;},{&quot;first_name&quot;:&quot;Feng&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Duan&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Xavier&quot;,&quot;last_name&quot;:&quot;Fradera&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Johnson&quot;},{&quot;first_name&quot;:&quot;Nathan&quot;,&quot;last_name&quot;:&quot;Bays&quot;},{&quot;first_name&quot;:&quot;Elma&quot;,&quot;last_name&quot;:&quot;Kadic&quot;},{&quot;first_name&quot;:&quot;Fang&quot;,&quot;last_name&quot;:&quot;He&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Goldenblatt&quot;},{&quot;first_name&quot;:&quot;Lynsey&quot;,&quot;last_name&quot;:&quot;Shaffer&quot;},{&quot;first_name&quot;:&quot;Sangita&quot;,&quot;last_name&quot;:&quot;B. Patel&quot;},{&quot;first_name&quot;:&quot;Charles&quot;,&quot;last_name&quot;:&quot;A. Lesburg&quot;},{&quot;first_name&quot;:&quot;Carla&quot;,&quot;last_name&quot;:&quot;Alpert&quot;},{&quot;first_name&quot;:&quot;Lauren&quot;,&quot;last_name&quot;:&quot;Dorosh&quot;},{&quot;first_name&quot;:&quot;Sujal&quot;,&quot;last_name&quot;:&quot;V. Deshmukh&quot;},{&quot;first_name&quot;:&quot;Hongshi&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Joel&quot;,&quot;last_name&quot;:&quot;Klappenbach&quot;},{&quot;first_name&quot;:&quot;Fiona&quot;,&quot;last_name&quot;:&quot;Elwood&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;J. Dinsmore&quot;},{&quot;first_name&quot;:&quot;Rafael&quot;,&quot;last_name&quot;:&quot;Fernandez&quot;},{&quot;first_name&quot;:&quot;Lily&quot;,&quot;last_name&quot;:&quot;Moy&quot;},{&quot;first_name&quot;:&quot;Jonathan&quot;,&quot;last_name&quot;:&quot;R. Young&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;04&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;9676-9690&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01135&quot;},&quot;abstract&quot;:&quot;The discovery of a potent selective low dose Janus kinase 1 (JAK1) inhibitor suitable for clinical evaluation is described. As part of an overall goal to minimize dose, we pursued a medicinal chemistry strategy focused on optimization of key parameters that influence dose size, including lowering human Clint and increasing intrinsic potency, bioavailability, and solubility. To impact these multiple parameters simultaneously, we used lipophilic ligand efficiency as a key metric to track changes in the physicochemical properties of our analogs, which led to improvements in overall compound quality. In parallel, structural information guided advancements in JAK1 selectivity by informing on new vector space, which enabled the discovery of a unique key amino acid difference between JAK1 (Glu966) and JAK2 (Asp939). This difference was exploited to consistently produce analogs with the best balance of JAK1 selectivity, efficacy, and projected human dose, ultimately culminating in the discovery of compound 28.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01135&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01135" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01135&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01135" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01135&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01135" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01135&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01135&amp;href=/doi/10.1021/acs.jmedchem.7b01135" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01135" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01135" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01135%26sid%3Dliteratum%253Aachs%26pmid%3D29156136%26genre%3Darticle%26aulast%3DSiu%26date%3D2017%26atitle%3DThe%2BDiscovery%2Bof%2B3-%2528%25284-Chloro-3-methoxyphenyl%2529amino%2529-1-%2528%25283R%252C4S%2529-4-cyanotetrahydro-2H-pyran-3-yl%2529-1H-pyrazole-4-carboxamide%252C%2Ba%2BHighly%2BLigand%2BEfficient%2Band%2BEfficacious%2BJanus%2BKinase%2B1%2BSelective%2BInhibitor%2Bwith%2BFavorable%2BPharmacokinetic%2BProperties%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D23%26spage%3D9676%26epage%3D9690%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291155" title="Bioavailability">Bioavailability</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/23" title="Go to Volume 60, Issue 23"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/jmcmar.2017.60.issue-23/20171214/jmcmar.2017.60.issue-23.largecover.jpg" alt="Go to Volume 60, Issue 23"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The discovery of a potent selective low dose Janus kinase 1 (JAK1) inhibitor suitable for clinical evaluation is described. As part of an overall goal to minimize dose, we pursued a medicinal chemistry strategy focused on optimization of key parameters that influence dose size, including lowering human Cl<sub>int</sub> and increasing intrinsic potency, bioavailability, and solubility. To impact these multiple parameters simultaneously, we used lipophilic ligand efficiency as a key metric to track changes in the physicochemical properties of our analogs, which led to improvements in overall compound quality. In parallel, structural information guided advancements in JAK1 selectivity by informing on new vector space, which enabled the discovery of a unique key amino acid difference between JAK1 (Glu966) and JAK2 (Asp939). This difference was exploited to consistently produce analogs with the best balance of JAK1 selectivity, efficacy, and projected human dose, ultimately culminating in the discovery of compound <b>28</b>.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65856" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65856" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathway is a well-studied signaling pathway that regulates cytokine and growth factor production.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Signaling in this pathway is mediated by four tyrosine kinases, JAK1, -2, and -3 and non-receptor tyrosine-protein kinase 2 (TYK2). These cytoplasmic JAK isoforms are associated with cytokine receptors as homo- and heterodimers and -trimers. Upon activation through cross phosphorylation, they recruit and phosphorylate STAT transcription factors, which translocate to the nucleus and activate gene transcription. Impressively, only four JAK isoforms are needed to regulate the vast number of signaling cytokines including interferons, interleukins, endocrine factors, and growth factors. These cytokines regulate a host of biological functions including T and B cell activation and differentiation, inflammation, and hemopoiesis. The JAK-STAT pathway has a vast role in regulating crucial cellular events and is a key contributor to and extensively linked with immune and malignant-related diseases.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the synovial membrane of joints.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> RA associated inflammation leads to severe joint pain along with stiffness, and over time chronic inflammation leads to destruction of the joint and loss of function. Central to the pathogenesis of RA is the inflammatory function of immune cells that are coordinated and maintained by cytokines regulated by the JAK family of kinases. To combat the inflammatory etiology of the disease, there are commercial therapies that target both the cytokines (e.g., anti-TNFα agents, infliximab and entanercept) and the JAK pathway (e.g., pan-JAK inhibitor, tofacitinib (<b>1</b>), <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Despite the success of these safe and efficacious treatments, an unmet medical need still remains for safe small molecule disease modifying antirheumatic drugs (DMARDS) that can achieve greater efficacy and provide more convenience than the current therapies.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> However, a limiting factor for achieving greater efficacy with tofacitinib is the dose limiting anemia observed in clinical trials, which is associated with JAK2 inhibition and its effects on erythropoiesis.<a onclick="showRef(event, 'cit4a'); return false;" href="javascript:void(0);" class="ref cit4a">(4a)</a> These data suggest that an inhibitor selective for JAK1 over JAK2 may offer greater clinical benefit by increasing the therapeutic margin over erythropoietin (EPO) inhibition. A key assumption in this approach is that JAK1 inhibition alone is sufficient to achieve similar anti-inflammatory efficacy as pan-JAK inhibition. A distinct challenge to develop JAK1 selective inhibitors is the high sequence homology between JAK1 and JAK2 in the catalytic domain. Despite these challenges, numerous research groups have reported their strategies and progress in this area.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selectivity profile for tofacitinib (<b>1</b>) and <b>2</b>. For entries marked with “a” values were determined by the HTRF assay; for those marked with “b” values were determined by GeneBLAzer assay; all values are the mean of <i>n</i> = 2 experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In this paper, we describe our strategy toward the identification of a small molecule JAK1 selective inhibitor with drug-like properties and low projected human dose. Due to the differences in <i>K</i><sub>M</sub> values for ATP in the various JAK isoforms, the most relevant measurement of isoform selectivity is to differentiate against tofacitinib on key pathways of efficacy (e.g., interleukin-6 (IL-6)) relative to anemia (e.g., EPO). By differentiating compound selectivity using cell-based assays, we sought to improve the potential for clinical translation of efficacy over anemia. Recently, we disclosed pyrazole carboxamide <b>2</b> as a potent JAK1 selective tool compound with a modest 10-fold selectivity over JAK2 in both enzymatic and pathway cell-based assays (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> As a proof of concept, compound <b>2</b> demonstrated a larger therapeutic window over tofacitinib in the collagen induced arthritis (CIA) efficacy and reticulocyte anemia models.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> These initial efforts supported the strategy that selectivity for the IL-6 pathway through JAK1 inhibition is sufficient to achieve efficacy while sparing anemia biomarkers.</div><div class="NLM_p">While achieving our goal of a pathway JAK1 selective inhibitor, extensive characterization of <b>2</b> revealed a high human predicted daily dose (343 mg QD) and a potential hERG liability (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Minimizing the daily dose reduces body burden and the risk for idiosyncratic toxicities as well as improves patient compliance.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Furthermore, the high dose of <b>2</b> resulted in a relatively high dose number (D<sub>0</sub> = 80), which often complicates formulation options and risk assessment for clinical compounds.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Characterization and liabilities of compound <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Considering the potential issues with a high daily dose drug and the need for enabled formulation, our goal in the current effort was to identify a lead candidate with predicted daily dose ≤100 mg while decreasing D<sub>0</sub>. To optimize for a lower dose of an AUC driven target, we focused on the key parameters of intrinsic clearance (Cl<sub>int</sub>) and unbound AUC (AUC<sub>u</sub>), fraction absorbed (<i>f</i><sub>a</sub>), and fraction escaping gut metabolism (<i>f</i><sub>g</sub>), whose relations are expressed by the equation in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Thus, reduction of the dose of <b>2</b> required decreasing human Cl<sub>int</sub> and AUC<sub>u</sub> (by increasing intrinsic potency), as well as increasing <i>f</i><sub>a</sub> through improvements in solubility and permeability.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Parameters that affect human dose calculation for AUC driven protein target. AUC unbound (AUC<sub>u</sub>), intrinsic clearance (Cl<sub>int</sub>), fraction absorbed (<i>f</i><sub>a</sub>), fraction escape from gut metabolism (<i>f</i><sub>g</sub>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In addition to the high daily dose of compound <b>2</b>, modest affinity for the hERG channel (MK499 IC<sub>50</sub> = 12 200 nM) was confirmed in the functional patch clamp hERG blockade assay (hERG IC<sub>50</sub> = 3000 nM).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Ultimately, the unacceptable safety margin for QTc prolongation shown in a guinea pig study (8 fold margin over predicted human <i>C</i><sub>max</sub>) combined with its high daily dose precluded <b>2</b> from further progression.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Blockade of the hERG channel has the potential to alter the QT interval and trigger life threatening tosades des pointes; therefore further optimization was necessary to identify a suitable clinical candidate.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80643" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80643" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Initial strategies for reducing hERG channel binding focused on applying destabilizing SAR derived from the 3D QSAR model for hERG channel activity.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> This strategy included structural modifications including removing or attenuating the basicity of the most basic amine in <b>2</b> as well as increasing overall polarity of the inhibitor. These approaches successfully led to multiple SAR advances resulting in weakened hERG binding but unfortunately negatively impacted other dose related parameters, which hindered progress (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Replacing the basic amine with a hydroxyl group (e.g., compound <b>3</b>) led to improved MK499 (IC<sub>50</sub> = 26 000 nM) while maintaining intrinsic potency (JAK1 IC<sub>50</sub> = 1.2 nM), but the bioavailability was compromised (F% = 10). A similar effect on hERG binding was achieved through steric hindrance by shielding the basic amine with methyl oxetane (e.g., compound <b>4</b>) (MK499 IC<sub>50</sub> = 46 000 nM, JAK1 IC<sub>50</sub> = 0.6 nM) but did not improve the Cl<sub>int</sub> compared to <b>2</b>, presumably due to the increased lipophilic substituents compared to <b>2</b>. Maintaining the basic amine while increasing the overall polarity of the compound (e.g., compound <b>5</b> (HPLC Log D = 1.54 vs 2.15 for compound <b>2</b>) MK499 IC<sub>50</sub> = 32 000 nM, JAK1 IC<sub>50</sub> = 0.3 nM) improved the hERG signal, albeit with negative impacts on cellular permeability and overall fraction absorbed when dosed orally. The team explored many SAR permutations to balance hERG binding, Cl<sub>int</sub>, and bioavailability but ultimately failed to deliver compounds with the required balance profile within the compound <b>2</b> chemotype.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Strategies to address hERG binding negatively impacted dose-related parameters.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although compound <b>2</b> possessed adequate properties to achieve proof of concept and demonstrate in vivo functional selectivity, the challenges around modification of the basic amine to attenuate hERG and lower dose motivated the team to remove the amine entirely. This led to the identification of truncated compound <b>6</b> with high ligand binding efficiency (LBE = 0.50).<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Removal of the basic amine completely ablated hERG binding activity and provided an encouraging starting point for optimization despite relatively high clearance parameters (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). As such, the team embarked on a design strategy to simultaneously optimize multiple parameters by improving the physicochemical properties while maintaining efficient drug–enzyme interactions.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> To that end, lipophilic ligand efficiency (LLE) was employed as a key parameter to aid in the design process and track compound progression.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Through this approach, tetrahydropyran <b>7</b> was discovered with the high LLE (7.9) that reflected significant improvement in potency through the introduction of a polar oxygen heteroatom (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). The subtle decrease in polarity (HPLC Log D = 2.08) also translated to improved Cl<sub>int</sub> in both rat and human (r; h Hept Cl<sub>int</sub> = 70; 6 mL/min) and a large decrease in unbound in vivo rat clearance. This improved approach focused on physicochemical property considerations to simultaneously address off-target liabilities as well as refine key parameters central to drive down dose.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Minimal pharmacophore has high LBE and LLE.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Tetrahydropyran pyrazole analogs can efficiently be synthesized in a few short steps (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Tetrahydro-2<i>H</i>-pyran-4-one (<b>8</b>) was converted to carbonitrile (<b>9</b>) by first forming the cyanohydrin with TMS-CN and TMS-OTf followed by subsequent treatment of the cyanohydrin with POCl<sub>3</sub> and elimination. Conjugate addition with pyrazole carboxamides induced by DBU afforded racemate <b>10</b>, which was separated by chiral SFC to afford enantiomerically pure <b>10</b> in 14% overall yield. With enantiomerically pure intermediate <b>10</b> in hand, Buchwald coupling with various halogenated arenes using Pd<sub>2</sub>(dba)<sub>3</sub> and <i>t</i>-Bu X-Phos smoothly and selectively arylated the 3-amino pyrazole nitrogen.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Tetrahydropyran Pyrazole Analogs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) TMS-CN, TMS-OTf, 0 °C; (ii) POCl<sub>3</sub>, pyridine, 0 °C, CH<sub>2</sub>Cl<sub>2</sub>, 60% (two steps); (b) (i) 3-amino-4-pyrazole carboxamide, DBU, 70 °C, EtOH; (ii) chiral SFC separation of active enantiomer 14% (two steps); (c) t-Bu XPhos, KOAc, Pd<sub>2</sub>(dba)<sub>3</sub>, 60 °C, iPrOH, 30–80%. Abbreviations: trimethylsilyl cyanide (TMS-CN), Trimethyl silyl trifluoromethansulfonate (TMS-OTf), Phosphoryl chloride (POCl<sub>3</sub>), 1,8-Diazabicycloundec-7-ene (DBU), 2-Di-tert-butylphosphino-2′,4′,6′-triisoporopylbiphenyl (t-Bu XPhos).</p></p></figure><div class="NLM_p">To confirm that the new chemotype was indeed a superior series, the analogs in the tetrahydropyran chemotype (<b>11</b>) were compared to those in the earlier cylohexylamine chemotype (<b>12</b>) using a pie chart visualization analysis (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Consistent with the comparison in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>, the tetrahydropyran chemotype generated a higher percentage of analogs with LLE > 0.5 (87.7%) compared to the cyclohexylamine chemotype (14.5%). The increase in LLE translated to an enrichment of tetrahydropyran analogs with a cleaner hERG profile (79% with MK499 IC<sub>50</sub> > 20 000 nM vs 41% cyclohexylamine series) and increased metabolic stability (64% with Cl<sub>int</sub> < 20 mL/min/kg vs 32% in the cyclohexylamine series). Bioavailability did not improve between the two series. Taken together, these analyses highlighted the enrichment of overall compound quality toward our goals of reduced hERG liability and lower projected human dose. With an efficient template in hand, we next undertook a systematic exploration of the solvent exposed aromatic ring to further optimize on LLE and understand its impact on the PK parameters, specifically rat and human Cl<sub>int</sub>, bioavailability in rat, and FASSIF solubility.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binned analysis comparing LLE, MK499 IC<sub>50</sub> distribution, human hepatocyte Cl<sub>int</sub>, and F% between tetrahydropyran and cyclohexylamine chemotypes. Filter settings: JAK1 Enzyme IC<sub>50</sub> < 100 nM, Cell IL6 IC<sub>50</sub> < 1000 nM, 897 samples for LLE and MK499, 350 samples for human hepatocyte Cl<sub>int</sub>, 88 samples for F%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">From the data shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, lipophilic substituents on the aromatic ring such as compounds <b>14</b>, <b>15</b>, <b>16</b>, and <b>17</b> possessed good LLE and acceptable bioavailability; however, the increase in lipophilicity was associated with lower FASSIF solubility and higher rat and human intrinsic clearance. On the other hand, polar substituents containing heteroatoms (<b>18</b>, <b>19</b>, <b>20</b>, <b>21</b>) generally improved rat and human intrinsic clearance (<b>19</b> r; h Hept Cl<sub>int</sub> = 4.8; 2.5 mL/min/kg, <b>20</b> r; h Hept Cl<sub>int</sub> = 5; 1.5 mL/min/kg, and <b>21</b> r; h Cl<sub>int</sub> = <40; <20 mL/min/kg). Optimizing clearance by reducing lipophilicity was consistent with established medicinal chemistry strategies.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Additionally, the added heteroatom polarity contributed to increased FASSIF solubility as demonstrated by compound <b>20</b> (FASSIF = 159 μM). Despite the benefits of increased polarity in improving intrinsic clearance and solubility, the significant lower Log D and polarity negatively impacted the rat bioavailability with compounds <b>18</b>, <b>19</b>, <b>20</b>, and <b>21</b> showing F% < 20. Ultimately, optimizing for PK properties proved to be a significant challenge since the desired physicochemical profile for low Cl<sub>int</sub> and high F% did not align.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structure–Activity Relationship of Tetrahydropyrans</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0013.gif" alt="" id="GRAPHIC-d7e955-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0014.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Values in this table are determined by the HTRF assay and are the means from at least <i>n</i> = 2 experiments.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Values in this table are determined by GeneBLAzer assay and are the means from at least <i>n</i> = 2 experiments.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Values are calculated from pIC<sub>50</sub> – ALogP98.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">hERG binding assay, ref <a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">13</a>.</p></div><div class="footnote" id="t1fn5"><sup>Table f</sup><p class="last">Dose; rat iv 0.5 mg/kg as a solution in PEG400:H<sub>2</sub>O (60:40 (v/v)), po: 1 mg/kg as a solution in PEG400:H<sub>2</sub>O (60:40 (v/v)).</p></div><div class="footnote" id="t1fn6"><sup>Table g</sup><p class="last">See <a href="/doi/suppl/10.1021/acs.jmedchem.7b01135/suppl_file/jm7b01135_si_001.pdf" class="ext-link">Supporting Information</a>. NA = not available.</p></div></div><div></div></div><div class="NLM_p">To overcome the PK obstacle, we visualized the issue by plotting the impact of HPLC Log D and bioavailability and hCl<sub>int</sub>. <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a> highlights the challenge of balancing the conflicting relationship of lipophilicity and polarity. As HPLC Log D increased, the frequency of compounds with F% > 20 increased at the expense of compounds with hCl<sub>int</sub> < 20 mL/min/kg. The plot also revealed that HPLC Log D 1.50–2.50 was the optimal range for both bioavailability and hCl<sub>int</sub> properties. This analysis provided a targeted range to enable design of inhibitors in the desired property space.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Analysis of %F and Cl<sub>int</sub> frequency plotted against HPLC Log D. HPLC Log D between 1.50 and 2.50 is the optimal range. Filter settings: JAK1 Enzyme IC<sub>50</sub> < 100 nM, Cell IL6 IC<sub>50</sub> < 1000 nM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With a target physicochemical range in mind, we turned our attention to identifying SAR that fit within the desired HPLC Log D range. The introduction of a nitrile is a useful functional group that embodies polar features without significantly reducing Log D.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> To explore this concept, <b>22</b> was prepared and exhibited a balanced HPLC Log D (1.77) without compromising LLE (8). This balanced profile translated to a low r; h intrinsic clearance (r; h Hept Cl<sub>int</sub> = 6; 3 mL/min/kg) with a desired aqueous solubility (FASSIF = 130 uM) without compromising the bioavailability (F% = 47).</div><div class="NLM_p">The favorable profile of <b>22</b> warranted further animal and human ADME data as well as human whole blood potency to inform on human dose prediction (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Gratifyingly, in vitro Cl<sub>int</sub> correlated well with the in vivo unbound clearance (Cl<sub>u</sub>) across species, allowing for confidence in human in vitro–in vivo extrapolation (IVIVE). Allometric scaling and translatable exposure to higher order species combined with the human whole blood potency (HWB IL7 IC<sub>50</sub> = 220 nM) informed to project the predicted human dose for <b>22</b> at 15 mg QD with an excellent D<sub>0</sub> = 2. The excellent dose and dose number for <b>22</b> validated our approach of optimizing on intrinsic potency, Cl<sub>int</sub>, solubility, and bioavailability in order to identify a low dose lead molecule.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Pharmacokinetic Parameters of Compounds <b>22</b> and <b>28</b> in Preclinical Species</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">rat<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center">dog<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="2" align="center">cyno<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="rowsep1 colsep0" colspan="2" align="center">predicted human<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>22</b></th><th class="colsep0 rowsep0" align="center"><b>28</b></th><th class="colsep0 rowsep0" align="center"><b>22</b></th><th class="colsep0 rowsep0" align="center"><b>28</b></th><th class="colsep0 rowsep0" align="center"><b>22</b></th><th class="colsep0 rowsep0" align="center"><b>28</b></th><th class="colsep0 rowsep0" align="center"><b>22</b></th><th class="colsep0 rowsep0" align="center"><b>28</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl<sub>p</sub> (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Hept Cl<sub>int</sub><a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">35</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">122</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PPB %</td><td class="colsep0 rowsep0" align="left">81</td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="left">82</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#tbl2-fn1" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">79</td><td class="colsep0 rowsep0" align="left">96.7</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="left">97.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl unbound (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">350</td><td class="colsep0 rowsep0" align="left">67</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#tbl2-fn1" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">581</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vd<sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">2.7</td><td class="colsep0 rowsep0" align="left">2.7</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (hr)</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">5.6</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">F (%)</td><td class="colsep0 rowsep0" align="left">47</td><td class="colsep0 rowsep0" align="left">47</td><td class="colsep0 rowsep0" align="left">51</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">72</td><td class="colsep0 rowsep0" align="left">56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Human Whole<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a> Blood (nM)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">220</td><td class="colsep0 rowsep0" align="left">1760</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Dose (QD) (mg)<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Dose Number<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">25</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Dose (rat): iv 0.5 mg/kg as a solution in PEG400/H<sub>2</sub>O (60:40 (v/v)); po 1 mg/kg as a solution in PEG400/H<sub>2</sub>O (60:40 (v/v)).</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Dose (dog): iv 0.25 mg/kg as a solution in DMSO/PEG400/water (20:60:20); po 0.5 mg/kg as a solution in PEG400/TWEEN80/H<sub>2</sub>O (20:60:20)</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Dose (cyno): iv 0.25 mg/kg as a solution in DMSO/PEG400/water (20:60:20); po 0.5 mg/kg as a solution in captisol 30%.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">See ref <a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">9</a>.</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last">See <a href="/doi/suppl/10.1021/acs.jmedchem.7b01135/suppl_file/jm7b01135_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t2fn6"><sup>f</sup><p class="last">See ref <a onclick="showRef(event, 'cit11a'); return false;" href="javascript:void(0);" class="ref cit11a">11a</a>.</p></div><div class="footnote" id="tbl2-fn1"><sup>g</sup><p class="last">Not available.</p></div></div></div><div class="NLM_p">Despite the successful approach of focusing on physicochemical properties and dose to identify <b>22</b> with favorable drug-like properties, the optimization process eroded the JAK1 pathway selectivity of <b>22</b> (7-fold), precluding further development of the molecule. During the rapid SAR screening process of the aromatic vector of the inhibitor, compound <b>23</b> with 50-fold selectivity for JAK1 over JAK2 was identified. Examining the structural uniqueness of <b>23</b>, we hypothesized that projecting into the southeast region of the aromatic ring might account for the enhanced selectivity. To further test this hypothesis and exploit this potential unique interaction, we combined the findings from <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> with SAR at the southwest region of the aromatic ring (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Consistent with the same strategy as in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, we were mindful of optimizing for selectivity while maintaining desirable LLE in order to refine PK parameters that related to lowering dose. Using <b>22</b> as a baseline with 8-fold selectivity in enzyme activity and 7-fold in cellular activity, introduction of a meta methoxy group (<b>24</b>) enhanced the JAK2/JAK1 selectivity to 46-fold in the enzyme and 23-fold in the pathway assay. Additional changes including Cl, CN, and cyclopropyl as exemplified by <b>25</b>, <b>26</b>, and <b>27</b> led to modest improvements in selectivity, which suggest the unique positioning of a methoxy group was critical for selectivity. Additionally, this SAR was translatable to other promising aromatic analogs such <b>28</b>, <b>29</b>, and <b>30</b>. Notably, accessing the same vector by constraining small substituents using fused rings led to even greater selectivity as demonstrated by <b>31</b>, <b>32</b>, and <b>33</b>, achieving >50-fold in enzyme and >80-fold selectivity in cell assays. Despite the exquisite selectivity from the fused ring analogs, these compounds did not possess the desired in vitro and in vivo PK properties to progress further.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structure–Activity Relationship of Tetrahydropyrans</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0015.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Values in this table are determined by the HTRF assay and are the means from <i>n</i> = 2 experiments.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Values in this table are determined by GeneBLAzer assay and are the means from at least <i>n</i> = 2 experiments.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Values are calculated from pIC<sub>50</sub> – ALogP98.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Dose; rat iv 0.5 mg/kg as a solution in PEG400:H<sub>2</sub>O (60:40 (v/v)), po: 1 mg/kg as a solution in PEG400:H<sub>2</sub>O (60:40 (v/v)).</p></div><div class="footnote" id="t3fn5"><sup>Table e</sup><p class="last">See <a href="/doi/suppl/10.1021/acs.jmedchem.7b01135/suppl_file/jm7b01135_si_001.pdf" class="ext-link">Supporting Information</a>. NA = not available.</p></div></div><div></div></div><div class="NLM_p">The new meta substituent discovery expanded our SAR resulting in numerous highly selective compounds with desirable PK properties. Notably, the balanced properties of compound <b>28</b> with a para chloro and meta methoxy not only imparted improved JAK1 selectivity (39-fold enzyme and 25-fold cell) but also retained favorable rat Cl<sub>u</sub> (350 mL/min/kg) with low hept hCl<sub>int</sub> (6 mL/min/kg) and desirable bioavailability (F% = 47). The overall selectivity and dose parameters for <b>28</b> were superior to other analogs and consequently progressed to full PK determinations (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Evaluation of <b>28</b> in multiple species across a panel of studies revealed a good correlation between in vitro hept Cl<sub>int</sub> and in vivo Cl<sub>u</sub>, leading to a confident low human predicted total clearance of 0.6 mL/min/kg with a half-life of 20 h and bioavailability of 56%. Furthermore, the predicted human PK properties combined with the human whole blood (IC<sub>50</sub> = 1760 nM) led to the predicted human dose of 81 mg QD with a D<sub>0</sub> = 25.</div><div class="NLM_p">Having significantly altered the structure from starting point <b>2</b>, the off target kinase profile of <b>28</b> was assessed in a broad kinase panel consisting of 265 kinases.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Kinase selectivity of <b>2</b>, <b>22</b>, and <b>28</b> is depicted using a radar plot where the distance from the center is proportional to the fold selectivity over JAK1 in log10 units. As shown in <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>, <b>28</b> was more selective and differentiated from 2 since its curve lies outside that of <b>2</b>. In addition to the radar plot, several additional metrics were also used to analyze kinase selectivity from different perspectives. While the percentage of kinases with at least 100-fold selectivity is a common metric used to understand selectivity, it can be misleading if the few kinases under 100-fold are equally potent or more potent than the target kinase. Alternatively, the partition index method can be used to quantify the fraction of the inhibitor that would be bound to the target of interest at thermodynamic equilibrium, with values closer to one indicating that the ligand is highly selective and binds only to the desired target.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Lead compound <b>28</b> is a highly selective JAK1 inhibitor demonstrating greater than 100-fold selectivity over 99% of the 265 kinases tested with a partition index of 0.94 (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>).</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Analysis of kinase selectivity profile of compounds <b>2</b>, <b>22</b>, and <b>28</b> against 265 kinases using a radar plot, percent of kinases at least 100-fold selectivity over JAK1 and partition index.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to gain greater clarity on the protein–ligand molecular interactions and the nature of the JAK isoform selectivity, crystallographic studies of <b>28</b> were examined. <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a> shows compound <b>28</b> binding to the active site of the JAK1 kinase domain.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The primary amide anchors the ligand by making hydrogen bonds to the backbone carbonyl oxygen of Glu957 and the backbone amide NH of Leu959 in the hinge region of the kinase. Additionally, the primary amide is involved in a water molecule (H<sub>2</sub>O-412 in PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WO4">5WO4</a>) mediated hydrogen bond interaction with the backbone carbonyl oxygen atom of Gly1020 in the back pocket. The para position of the aniline projects out to solvent, consistent with the flexible SAR observed in this region of the molecule. Furthermore, the cyano substituted tetrahydropyran ring forces an increased dihedral angle resulting in hydrophobic packing in two deep pockets. The tetrahydropyran oxygen is buried under the glycine rich loop (omitted for clarity in <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>); however, this interaction is poorly understood because simple van der Waals interactions do not satisfyingly explain the 10-fold decrease in potency when lipophilic cyclohexane is substituted for the tetrahydropyran. Furthermore, the twisted conformation of the tetrahydropyran projects the nitrile group into a small hydrophobic back-pocket created by Leu1010 and Gly1020 unique to JAK family kinases. The combination of these unique interactions in conjunction with the conserved water molecule H<sub>2</sub>O-412 mediated hydrogen bond confers the excellent JAK family kinase selectivity.</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Co-crystal structure of <b>28</b> in JAK1 kinase domain showing ligand–protein interactions (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WO4">5WO4</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To determine the nature of the JAK isoform selectivity, comparison of the X-ray crystal structures of <b>28</b> bound to human JAK1 and overlaid on a JAK2 crystal structure revealed a unique 3-methoxy group interaction with a single amino acid difference between JAK1 and JAK2.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In particular, the 3-methoxy group interacts with the longer side residue Glu966 in JAK1 through van der Waals interactions, whereas in JAK2 the equivalent residue (Asp939) is positioned further away from any direct interaction (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Interestingly, this finding is consistent with the observations of Kim et al. and Zak et al., which led to the elegant designs of selective JAK1 inhibitors.<a onclick="showRef(event, 'cit6d cit6f'); return false;" href="javascript:void(0);" class="ref cit6d cit6f">(6d, 6f)</a> Overall, our findings along with others suggest that exploiting the Glu966 residue in JAK1 is a general and consistent strategy to optimize for JAK1 selectivity over JAK2.</div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Comparison of <b>28</b> contacts with residues Glu966 in JAK1 and Asp939 in JAK2. In the crystal structure of <b>28</b> bound to JAK1, the dashed lines correspond to van der Waals contacts between the ligand and Glu966 identified with the ViewContacts software. No van der Waals interactions were identified when <b>28</b> was modeled into the active site of JAK2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LPB">3LPB</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of the favorable lead compound profile, in vivo properties, and kinase selectivity, compounds <b>22</b> and <b>28</b> were studied in a rat collagen induced arthritis model (CIA)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> using a therapeutic dosing paradigm (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Rats were immunized and boosted with collagen intradermally at the base of the tail on days one and seven. Animals were stratified into treatment groups with comparable levels of paw inflammation on day 16, and treatment with compounds <b>22</b> and <b>28</b> (po BID) and dexamethasone (po QD) was initiated on day 17. Both compounds exhibited dose dependent inhibition of inflammation. The maximum attenuation of paw swelling with compounds <b>22</b> and <b>28</b> was achieved with 10 and 30 mg/kg, respectively, which was comparable to dexamethasone treated CIA and nonarthritic control groups. Compound <b>28</b> demonstrated that selectively inhibiting the JAK1 pathway is sufficient to drive efficacy in a preclinical inflammation model and suggests that JAK1 selective compounds may offer an advantage by offsetting the potential anemia side effects of inhibiting JAK2.</div><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Compound <b>22</b> dosed PO BID at 0.1, 1, and 10 mg/kg and <b>28</b> PO BID at 0.3, 3, 10, and 30 mg/kg were efficacious in reducing paw swelling in a 30 day rat CIA model. Dexamethasone was included as a positive control. .*<i>p</i> < 0.005, statistically different from nonarthritic controls, <sup>∧</sup><i>p</i> < 0.005, statistically different from CIA vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13116" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13116" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, while the lead compound <b>2</b> in the cyclohexylamine series served as a useful tool to probe the effects of JAK1 selectivity, further progression of that chemotype was challenging due to hERG activity and high predicted human dose. To address these issues, we attempted to optimize and differentiate analogs in that series based on the parameters associated with predicted human dose including intrinsic potency, Cl<sub>int</sub>, bioavailability, and solubility. Multiparameter optimization on compound <b>2</b> proved to be a difficult endeavor due to opposing SAR between decreasing hERG and PK parameters. A shift in strategy toward a new core with the tetrahydropyran chemotype followed by LLE guided optimization produced an enriched cohort of analogs with reduced hERG signal and improved PK parameters. In conjunction with these advances, structural chemistry information provided key insights in guiding modifications to improve JAK1 selectivity, in particular revealing a key amino acid difference between JAK1 and JAK2. By exploiting selectivity advancements in combination with the improved tetrahydropyran core, a significant enrichment of JAK1 selective compounds with the desired drug-like properties and low predicted human dose was achieved. These efforts culminated in the discovery of JAK1 selective compound <b>28</b>, which has an excellent predicted human dose projection of 81 mg QD and is highly active in our CIA inflammation model. Furthermore, the pathway selectivity of <b>28</b> allowed for further pharmacological investigation into delineating an improved therapeutic index with a JAK1 selective compound. This data will be reported in a future communication.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70316" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70316" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> General Experimental Methods</h3><div class="NLM_p">Commercial reagents were obtained from reputable suppliers and used as received. All solvents were purchased in septum-sealed bottles stored under an inert atmosphere. All reactions were sealed with septa through which an argon atmosphere was introduced unless otherwise noted. Liquid reagents and solvents were transferred under a positive pressure of nitrogen via syringe. Reactions were conducted in microwave vials or round bottomed flasks containing Teflon-coated magnetic stir bars. Microwave reactions were performed with a Biotage Initiator Series Microwave (fixed hold time setting; reaction temperatures monitored by the internal infrared sensor). Reactions were monitored by thin layer chromatography (TLC) on pre-coated TLC glass plates (silica gel 60 F254, 250 μm thickness) or by LC/MS (30 mm × 2 mm, 2 μm column + guard; 2 μL injection; 3% to 98% MeCN/water +0.05% TFA gradient over 2.3 min; 0.9 mL/min flow; ESI; positive ion mode; UV detection at 254 nm). Visualization of the developed TLC chromatogram was performed by fluorescence quenching. Flash chromatography was performed on an automated purification system using pre-packed silica gel columns. <sup>1</sup>H NMR spectra were recorded on either a 500 or a 600 MHz Varian spectrometer; chemical shifts (δ) are reported relative to residual proton solvent signals. Data for NMR spectra are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, brs = broad singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, td = triplet of doublets, m = multiplet), coupling constant (Hz), integration. All final compounds possess a purity of at least 95% as determined by <sup>1</sup>H NMR, LCMS, HRMS.</div><div id="sec4-1-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i10" class="anchor-spacer"></div><h4 class="article-section__title" id="_i10"> 3,6-Dihydro-2<i>H</i>-pyran-4-carbonitrile (<b>9</b>)</h4><div class="NLM_p last">To the solution of trimethylsilyl cyanide (105 g, 1080 mmol) in DCM (370 mL) were added tetrahydro-4<i>H</i>-pyran-4-one (90 g, 900 mmol) and trimethylsilyl triflate (6 g, 27 mmol) at 0 °C. The resulting mixture was stirred at 0 °C for 1 h before the addition of pyridine (1120 mL) and phosphoryl chloride (413 g, 2700 mmol). The mixture was refluxed for 12 h and then poured into the mixture of 2 N hydrochloric acid aqueous solution (1.5 L) and extracted with EtOAc (3 × 2 L). All the organic solutions were washed with brine (2 × 1000 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. The crude residue was purified by column chromatography (eluted with PE/EtOAc = 10/1) to give 3,6-dihydro-2<i>H</i>-pyran-4-carbonitrile (59 g, 60.1%) as a yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 6.62–6.59 (m, 1H), 4.29–4.21 (m, 2H), 3.78 (t, <i>J</i> = 5.4 Hz, 2H), 2.34–2.30 (m, 2H).</div></div><div id="sec4-1-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> 3-Amino-1-((3<i>R</i>,4<i>S</i>)-4-cyanotetrahydro-2<i>H</i>-pyran-3-yl)-1<i>H</i>-pyrazole-4-carboxamide (<b>10</b>)</h4><div class="NLM_p last">The solution of 3-amino-1<i>H</i>-pyrazole-4-carboxamide (85 g, 671 mmol), 3,6-dihydro-2<i>H</i>-pyran-4-carbonitrile (205 g, 1.88 mol), and DBU (234 g, 1.54 mol) in ethanol (850 mL) was stirred at 70 °C overnight under nitrogen and then concentrated under vacuum. The crude residue was purified by silica gel flash column chromatography (eluted with DCM/Methanol = 30/1) to yield racemic compound <b>10</b> (47 g, 29.8%) as a yellow solid. The chiral separation of 380 g of the racemic compound was accomplished by dissolving in ACN/MeOH (1:1) to a concentration of 25 mg/mL. Injections of 16 mL were made on a Thar 350 preparative SFC (Column, ChiralPak IC-10 μM, 300 mm × 50 mm; mobile phase, 45% 2-propanol, 55% CO<sub>2</sub>; flow rate, 220 mL/min; column temperature, 38 °C). After separation, the fractions were dried by rotary evaporation to give 3-amino-1-((3<i>S</i>,4<i>R</i>)-4-cyanotetrahydro-2<i>H</i>-pyran-3-yl)-1<i>H</i>-pyrazole-4-carboxamide (174 g, 48.8%, 99.6% ee) from the first (faster eluting) peak and 3-amino-1-((3<i>R</i>,4<i>S</i>)-4-cyanotetrahydro-2<i>H</i>-pyran-3-yl)-1<i>H</i>-pyrazole-4-carboxamide (181 g, 47.6%, 99.6% ee) from the second (slower eluting) peak. The absolute configuration of stereochemistry was determined from X-ray crystallography of compound <b>28</b> with JAK1 protein. The second (slower eluting) peak was carried on to generate SAR. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.03 (s, 1H), 7.36 (brs, 1H), 6.80 (brs, 1H), 5.36 (s, 2H), 4.86–4.31 (td, <i>J</i> = 10.5, 4.5 Hz, 1H), 3.91–3.88 (dd, <i>J</i> = 11.5, 4.5 Hz 1H), 3.86–3.83 (m, 1H), 3.53–3.50 (m, 2H), 3.39–3.33 (td, <i>J</i> = 11.5, 2 Hz, 1H), 2.10–2.07 (m, 1H), 1.95–1.87 (m, 1H). <sup>13</sup>C NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.3, 157.2, 131.6, 120.2, 101.2, 69.8, 65.8, 57.8, 31.9, 28.5. LRMS (ESI) calcd for C<sub>10</sub>H<sub>14</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 236. Found: 236.</div></div><div id="sec4-1-3" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> 1-((3<i>R</i>,4<i>S</i>)-4-Cyanotetrahydro-2<i>H</i>-pyran-3-yl)-3-(phenylamino)-1<i>H</i>-pyrazole-4-carboxamide (<b>13</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 57% yield. LRMS (ESI) calcd for (C<sub>16</sub>H<sub>17</sub>N<sub>5</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 312.1, found 312.1. HRMS: calcd for (C<sub>16</sub>H<sub>17</sub>N<sub>5</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 312.1460, found 312.1451; difference 2.9 ppm. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 8.17 (s, 1H), 7.51–7.50 (d, <i>J</i> = 8.7 Hz, 2H). 7.26–7.23 (t, <i>J</i> = 16.1, 8.1 Hz, 2H), 6.87–6.84 (t, <i>J</i> = 14.5, 7.4 Hz, 1H), 4.44–4.39 (m, 1H), 4.12–4.08 (m, 1H), 4.01–3.97 (m, 1H), 3.90–3.86 (m, 1H), 3.72–3.66 (m, 1H), 3.60–3.55 (m, 1H), 2.23–2.18 (m, 1H), 2.09–2.01 (m, 1H). <sup>13</sup>C NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.4, 153.05, 141.7, 131.6, 129.4 (2C), 120.23, 120.03, 116.4 (2C), 101.3, 69.4, 65.8, 58.0, 31.9, 28.4. [α]<sub>D</sub><sup>20</sup> +145 (<i>c</i> 0.83, MeOH/DMSO 2:1).</div></div><div id="sec4-1-4" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> 3-((4-Chlorophenyl)amino)-1-((3<i>R</i>,4<i>S</i>)-4-cyanotetrahydro-2<i>H</i>-pyran-3-yl)-1<i>H</i>-pyrazole-4-carboxamide (<b>14</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 45% yield. LRMS (ESI) calcd for (C<sub>16</sub>H<sub>16</sub>ClN<sub>5</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 346.1, found 346.1. HRMS: calcd for (C<sub>16</sub>H<sub>16</sub>ClN<sub>5</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 346.1071, found 346.1063; difference 2.3 ppm. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.83 (s, 1H), 7.77 (s, 1H), 7.47–7.45 (d, <i>J</i> = 8.7 Hz, 2H), 7.25–7.23 (d, <i>J</i> = 9 Hz, 2H), 5.48 (brs, 2H), 4.25–4.21 (m, 1H), 4.19–4.15 (m, 1H), 4.06–4.02 (m, 2H), 3.68–3.64 (m, 1H), 3.60–3.56 (m, 1H), 2.17–2.14 (m, 1H), 2.07–1.99 (m, 1H).</div></div><div id="sec4-1-5" class="NLM_sec NLM_sec_level_3"><div id="ac_i14" class="anchor-spacer"></div><h4 class="article-section__title" id="_i14"> 1-((3<i>R</i>,4<i>S</i>)-4-Cyanotetrahydro-2<i>H</i>-pyran-3-yl)-3-((4-fluorophenyl)amino)-1<i>H</i>-pyrazole-4-carboxamide (<b>15</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 40% yield. LRMS (ESI) calcd for (C<sub>16</sub>H<sub>16</sub>FN<sub>5</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 330.1, found 330.1. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.10 (s, 1H), 8.25 (s, 1H), 7.67 (brs, 1H), 7.52–7.48 (m, 2H), 7.13 (brs, 1H), 7.06–7.03 (t, <i>J</i> = 8.9 Hz, 2H), 4.54–4.49 (m, 1H), 3.99–3.96 (m, 1H), 3.88–3.86 (m, 1H), 3.66–3.61 (m, 2H), 3.47–3.42 (m, 1H), 2.12–2.09 (m, 1H), 1.97–1.91 (m, 1H).</div></div><div id="sec4-1-6" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> 1-((3<i>R</i>,4<i>S</i>)-4-Cyanotetrahydro-2<i>H</i>-pyran-3-yl)-3-((3-cyclopropylphenyl)amino)-1<i>H</i>-pyrazole-4-carboxamide (<b>16</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 17% yield. LRMS (ESI) calcd for (C<sub>19</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 352.2, found 352.2. HRMS: calcd for (C<sub>19</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 352.1773, found 352.1767; difference 1.7 ppm. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ9.08 (s, 1H), 8.28 (s, 1H), 7.71 (brs, 1H), 7.33–7.32 (d, <i>J</i> = 7.8 Hz, 1H), 7.16 (brs, 1H), 7.13–7.10 (t, <i>J</i> = 7.8 Hz, 2H), 6.57–6.56 (d, <i>J</i> = 7.3 Hz, 1H), 4.57–4.53 (m, 1H), 4.05–4.02 (m, 1H), 3.92–3.90 (m, 1H), 3.68–3.61 (m, 2H), 3.48–3.43 (m, 1H), 2.17–2.15 (m, 1H), 2.01–1.95 (m, 1H), 1.91–1.86 (m, 1H), 0.93–0.92 (d, <i>J</i> = 7.44 Hz, 2H), 0.67 (brs, 2H).</div></div><div id="sec4-1-7" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 1-((3<i>R</i>,4<i>S</i>)-4-Cyanotetrahydro-2<i>H</i>-pyran-3-yl)-3-((4-(difluoromethoxy)phenyl)amino)-1<i>H</i>-pyrazole-4-carboxamide (<b>17</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 17% yield. LRMS (ESI) calcd for (C<sub>17</sub>H<sub>17</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub>) [M + H]<sup>+</sup> 378.2, found 378.2. HRMS: calcd for (C<sub>17</sub>H<sub>17</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub>) [M + H]<sup>+</sup> 378.1377, found 378.1379; difference −0.5 ppm. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.16 (s, 1H), 8.27 (s, 1H), 7.72 (brs, 1H), 7.56–7.54 (d, <i>J</i> = 7.8 Hz, 2H), 7.18 (brs, 1H), 7.22–6.92 (dd, <i>J</i> = 73, 6.8 Hz, 1H), 7.07–7.06 (d, <i>J</i> = 6.8 Hz, 2H), 4.57–4.52 (m, 1H), 4.02–3.99 (m, 1H), 3.90–3.88 (m, 1H), 3.69–3.63 (m, 2H), 3.49–3.44 (m, 1H), 2.14–2.12 (m, 1H), 2.00–1.92 (m, 1H).</div></div><div id="sec4-1-8" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 1-((3<i>R</i>,4<i>S</i>)-4-Cyanotetrahydro-2<i>H</i>-pyran-3-yl)-3-((4-(1-methyl-1<i>H</i>-pyrazol-4-yl)phenyl)amino)-1<i>H</i>-pyrazole-4-carboxamide (<b>18</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 10% yield. LRMS (ESI) calcd for (C<sub>20</sub>H<sub>21</sub>N<sub>7</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 392.2, found 392.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.55 (s, 1H), 8.94–8.93 (d, <i>J</i> = 2.6 Hz, 1H), 8.68–8.67 (d, <i>J</i> = 2.3 Hz, 1H), 8.30 (s, 1H), 7.95–7.93 (d, <i>J</i> = 8.8 Hz, 1H), 7.92–7.91 (d, <i>J</i> = 1.9 Hz, 1H), 7.76 (brs, 1H), 7.55–7.52 (dd, <i>J</i> = 8.7, 2.1 Hz, 1H), 7.26 (brs, 1H), 4.46–4.41 (m, 1H), 3.44 (s, 3H), 2.19–2.17 (m, 1H), 2.03–1.99 (m, 1H), 1.94–1.86 (m, 1H), 1.83–1.79 (m, 1H), 1.76–1.71 (m, 2H), 1.48–1.38 (m, 2H).</div></div><div id="sec4-1-9" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 3-((4-(1<i>H</i>-1,2,3-Triazol-1-yl)phenyl)amino)-1-((3<i>R</i>,4<i>S</i>)-4-cyanotetrahydro-2<i>H</i>-pyran-3-yl)-1<i>H</i>-pyrazole-4-carboxamide (<b>19</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 9% yield. LRMS (ESI) calcd for (C<sub>18</sub>H<sub>18</sub>N<sub>8</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 379.1, found 379.1. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.39 (s, 1H), 8.70 (d, <i>J</i> = 0.93 Hz, 1H), 8.31 (s, 1H), 7.91 (d, <i>J</i> = 0.93 Hz, 1H), 7.76 (brs, 1H), 7.77–7.75 (d, <i>J</i> = 9.1 Hz, 2H), 7.73–7.71 (d, <i>J</i> = 9.1 Hz, 2H), 7.24 (brs, 1H), 4.61–4.56 (m, 1H), 4.05–4.02 (m, 1H), 3.93–3.89 (m, 1H), 3.73–3.66 (m, 2H), 3.50–3.46 (m, 1H), 2.16–2.14 (m, 1H), 2.02–1.94 (m, 1H).</div></div><div id="sec4-1-10" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 1-((3<i>R</i>,4<i>S</i>)-4-Cyanotetrahydro-2<i>H</i>-pyran-3-yl)-3-((2-fluoropyridin-4-yl)amino)-1<i>H</i>-pyrazole-4-carboxamide (<b>20</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 51% yield. LRMS (ESI) calcd for (C<sub>15</sub>H<sub>16</sub>FN<sub>6</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 331, found 331. HRMS: calcd for (C<sub>15</sub>H<sub>16</sub>FN<sub>6</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 331.1319, found 331.1307; difference 3.6 ppm. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.74 (s, 1H), 8.35 (s, 1H), 7.93 (d, <i>J</i> = 6 Hz, 1H), 7.84 (s, 1H), 7.33 (m, 3H), 0.4.65–4.60 (td, <i>J</i> = 10.5, 4.5 Hz, 1H), 4.04–4.00 (dd, <i>J</i> = 11.5, 4.5, 1H), 3.90–3.88 (m, 1H), 3.73- 3.63 (m, 2H), 3.51–3.46 (td, <i>J</i> = 11.5, 2 Hz, 1H), 2.15–2,12 (m, 1H), 2.00–1.93 (m, 1H).</div></div><div id="sec4-1-11" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 1-((3<i>R</i>,4<i>S</i>)-4-Cyanotetrahydro-2<i>H</i>-pyran-3-yl)-3-((4-(2,2,2-trifluoro-1-hydroxyethyl)phenyl)amino)-1<i>H</i>-pyrazole-4-carboxamide (<b>21</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 49% yield. LRMS (ESI) calcd for (C<sub>18</sub>H<sub>18</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>) [M + H]<sup>+</sup> 410.1, found 410.1. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.24 (s, 1H), 8.30 (s, 1H), 7.74 (brs, 1H), 7.55–7.54 (d, <i>J</i> = 7.9 Hz, 2H), 7.38–7.36 (d, <i>J</i> = 7.9 Hz, 2H), 7.20 (brs, 1H), 6.66 (s, 1H), 5.04 (brs, 1H), 4.59–4.55 (m, 1H), 4.04–4.02 (m, 1H), 3.93–3.91 (m, 1H), 3.74–3.66 (m, 2H), 3.53–3.48 (m, 1H), 2.17–2.15 (m, 1H), 2.00–1.98 (m, 1H).</div></div><div id="sec4-1-12" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 3-((4-Cyanophenyl)amino)-1-((3<i>R</i>,4<i>S</i>)-4-cyanotetrahydro-2<i>H</i>-pyran-3-yl)-1<i>H</i>-pyrazole-4-carboxamide (<b>22</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 20% yield). LRMS (ESI) calcd for (C<sub>17</sub>H<sub>16</sub>N<sub>6</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 337.1, found 337.1. HRMS: calcd for (C<sub>17</sub>H<sub>16</sub>N<sub>6</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 337.1413, found 337.1388; difference 7.4 ppm. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.64 (s, 1H), 8.33 (s, 1H), 7.82 (brs, 1H), 7.66 (s, 4H), 7.29 (brs, 1H), 4.63–4.58 (m, 1H), 4.03–4.00 (m, 1H), 3.90–3.88 (m, 1H), 3.71–3.64 (m, 2H), 3.50–3.46 (m, 1H), 2.15–2.13 (m, 1H), 2.01–1.93 (m, 1H). <sup>13</sup>C NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.1, 151.9, 145.4, 133.9 (2C), 131.9, 120.25, 120.14, 116.8 (2C), 102.2, 101.2, 69.3, 65.4, 58.1, 31.8, 28.4. [α]<sub>D</sub><a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> + 144 (<i>c</i> 0.37, MeOH/DMSO 1:1).</div></div><div id="sec4-1-13" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 1-((3<i>R</i>,4<i>S</i>)-4-Cyanotetrahydro-2<i>H</i>-pyran-3-yl)-3-((2,3-dimethyl-1,1-dioxido-2,3-dihydrobenzo[d]isothiazol-5-yl)amino)-1<i>H</i>-pyrazole-4-carboxamide (<b>23</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 61% yield. LRMS (ESI) calcd for (C<sub>19</sub>H<sub>22</sub>N<sub>6</sub>O<sub>4</sub>S) [M + H]<sup>+</sup> 431.1, found 431.1. HRMS: calcd for (C<sub>19</sub>H<sub>22</sub>N<sub>6</sub>O<sub>4</sub>S) [M + H]<sup>+</sup> 431.1501, found 431.1498; difference 0.7 ppm. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.64 (s, 1H), 8.34 (s, 1H), 7.81 (brs, 1H), 7.75 (s, 1H), 7.72–7.70 (d, <i>J</i> = 8.7 Hz, 1H), 7.67–7.65 (d, <i>J</i> = 8.0 Hz, 1H), 7.30 (brs, 1H), 4.64–4.59 (m, 1H), 4.32–4.28 (m, 1H), 4.06–4.04 (m, 1H), 3.92–3.89 (m, 1H), 3.71–3.64 (m, 2H), 3.49–3.38 (m, 1H), 2.51–2.42 (m, 1H), 2.48 (s, 3H), 2.16–2.13 (m, 1H), 2.02–1.94 (m, 1H), 1.48–1.47 (d, <i>J</i> = 6.1 Hz, 3H).</div></div><div id="sec4-1-14" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 3-((4-Cyano-3-methoxyphenyl)amino)-1-((3<i>R</i>,4<i>S</i>)-4-cyanotetrahydro-2<i>H</i>-pyran-3-yl)-1<i>H</i>-pyrazole-4-carboxamide (<b>24</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 49% yield. LRMS (ESI) calcd for (C<sub>18</sub>H<sub>18</sub>N<sub>6</sub>O<sub>3</sub>) [M + H]<sup>+</sup> 467.1, found 467.1. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.62 (s, 1H), 8.34 (s, 1H), 7.82 (brs, 1H), 7.51–7.50 (d, <i>J</i> = 7.7 Hz, 1H), 7.51 (s, 1H), 7.30 (brs, 1H), 7.17–7.15 (d, <i>J</i> = 8.3 Hz, 1H), 4.65–4.60 (m, 1H), 4.05–3.99 (m, 2H), 3.92 (s, 3H), 3.69–3.62 (m, 2H), 3.44–3.40 (m, 1H), 2.15–2.13 (m, 1H), 2.01–1.93 (m, 1H).</div></div><div id="sec4-1-15" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 3-((4-Cyano-3-cyclopropylphenyl)amino)-1-((3<i>R</i>,4<i>S</i>)-4-cyanotetrahydro-2<i>H</i>-pyran-3-yl)-1<i>H</i>-pyrazole-4-carboxamide (<b>25</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 40% yield. LRMS (ESI) calcd for (C<sub>20</sub>H<sub>20</sub>N<sub>6</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 377, found 377. HRMS: calcd for (C<sub>20</sub>H<sub>20</sub>N<sub>6</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 377.1726, found 377.1701; difference 6.6 ppm. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.50 (s, 1H), 8.33 (s, 1H), 7.80 (brs, 1H), 7.58–7.56 (d, <i>J</i> = 8.5 Hz, 1H), 7.52–7.50 (d, <i>J</i> = 8.3 Hz, 1H), 7.28 (brs, 1H), 7.19 (s, 1H), 4.64–4.60 (m, 1H), 4.07–4.04 (m, 1H), 3.94–3.92 (m, 1H), 3.67–3.60 (m, 2H), 3.47–3.42 (m, 1H), 2.18–2.09 (m, 2H), 2.02–1.96 (m, 1H), 1.11–1.09 (d, <i>J</i> = 8.2 Hz, 2H), 0.88–0.81 (m, 2H).</div></div><div id="sec4-1-16" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 1-((3<i>R</i>,4<i>S</i>)-4-Cyanotetrahydro-2<i>H</i>-pyran-3-yl)-3-((3,4-dicyanophenyl)amino)-1<i>H</i>-pyrazole-4-carboxamide (<b>26</b>)</h4><div class="NLM_p last">Prepared in analogy to that described for <b>28</b> in 16% yield. LRMS (ESI) calcd for (C<sub>18</sub>H<sub>15</sub>N<sub>7</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 362, found 362. HRMS: calcd for (C<sub>18</sub>H<sub>15</sub>N<sub>7</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 362.1365, found 362.1352; difference 3.6 ppm. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ9.89 (s, 1H), 8.39 (s, 1H), 8.19 (s, 1H), 8.08–8.07 (d, <i>J</i> = 8.3 Hz, 1H), 7.94–7.93 (d, J = 8.8 Hz, 1H), 7.87 (brs, 1H), 7.37 (brs, 1H), 4.68–4.68 (m, 1H), 4.07–4.04 (m, 1H), 3.94–3.90 (m, 1H), 3.74–3.66 (m, 2H), 3.52–3.47 (m, 1H), 2.18–2.14 (m, 1H), 2.04–1.95 (m, 1H).</div></div><div id="sec4-1-17" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 3-((3-Chloro-4-cyanophenyl)amino)-1-((3<i>R</i>,4<i>S</i>)-4-cyanotetrahydro-2<i>H</i>-pyran-3-yl)-1<i>H</i>-pyrazole-4-carboxamide (<b>27</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 45% yield. LRMS (ESI) calcd for (C<sub>17</sub>H<sub>15</sub>ClN<sub>6</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 371.1, found 371.1. HRMS: calcd for (C<sub>17</sub>H<sub>15</sub>ClN<sub>6</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 371.1023, found 371.1003; difference 5.4 ppm. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.75 (s, 1H), 8.36 (s, 1H), 7.89 (s, 1H), 7.84 (brs, 1H), 7.76–7.74 (d, <i>J</i> = 8.6 Hz, 1H), 7.65–7.63 (d, <i>J</i> = 8.6 Hz, 1H), 7.33 (brs, 1H), 4.66–4.61 (m, 1H), 4.05–4.02 (m, 1H), 3.92–3.88 (m, 1H), 3.68–3.62 (m, 2H), 3.49–3.45 (m, 1H), 2.16–2.13 (m, 1H), 2.02–1.93 (m, 1H).</div></div><div id="sec4-1-18" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3<i>R</i>,4<i>S</i>)-4-cyanotetrahydro-2<i>H</i>-pyran-3-yl)-1<i>H</i>-pyrazole-4-carboxamide (<b>28</b>)</h4><div class="NLM_p">A 500 mL 3-neck flask was fitted with a reflux condenser and J-KEM thermocouple, then charged with 3-amino-1-((3<i>R</i>,4<i>S</i>)-4-cyanotetrahydro-2<i>H</i>-pyran-3-yl)-1<i>H</i>-pyrazole-4-carboxamide (10.0 g, 42.5 mmol), 5-bromo-2-chloroanisole (14.1 g, 63.7 mmol), potassium acetate (6.26 g, 63.8 mmol), and 2-propanol (150 mL). The reactions mixture was purged with nitrogen gas for 20 min; then Pd<sub>2</sub>(dba)<sub>3</sub> (1.95 g, 2.13 mmol) and 2-di-<i>tert</i>-butylphosphino-2′,4′,6′-triisopropylbiphenyl (2.00 g, 4.71 mmol) were added. The reaction mixture was then heated to 80 °C for 16.5 h. After cooling to 23 °C, acetone (150 mL) was added, and the mixture was stirred for 10 min, then filtered through Celite with acetone elution. The filtrate was concentrated onto silica gel in vacuo and purified via flash-column chromatography (ISCO 220 g cartridge, gradient elution with 3–6% methanol–dicholoromethane). The product-containing fractions were concentrated to afford 3-((4-chloro-3-methoxyphenyl)amino)-1-((3<i>R</i>,4<i>S</i>)-4-cyanotetrahydro-2<i>H</i>-pyran-3-yl)-1<i>H</i>-pyrazole-4-carboxamide (12.2 g, 30.7 mmol, 72.3% yield) as a bright yellow solid.</div><div class="NLM_p last">LRMS (ESI) calcd for C<sub>17</sub>H<sub>19</sub>ClN<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 376. Found: 376. HRMS: calcd mass for C<sub>17</sub>H<sub>19</sub>ClN<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 376.1176; found 376.1163; difference 3.5 ppm. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.24 (s, 1H), 8.31 (s, 1H), 7.75 (s, 1H), 7.48 (d, <i>J</i> = 2.3 Hz, 1H), 7.23–7.22 (m, 2H); 7.08 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 4.59 (td, <i>J</i> = 10.2, 4.4 Hz, 1H), 4.05 (dd, <i>J</i> = 11.3, 4.4 Hz, 1H), 3.94–3.87 (m, 4H), 3.68–3.64 (m, 2H), 3.44 (t, <i>J</i> = 11.7 Hz, 1H), 2.16 (d, <i>J</i> = 13.3 Hz, 1H), 1.98 (qd, <i>J</i> = 12.3, 4.3 Hz, 1H). <sup>13</sup>C NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 166.3, 155.2, 152.7, 141.9, 131.7, 130.2, 120.2, 111.4, 109.4, 101.54, 101.52, 69.5, 65.9, 58.0, 56.2, 32.0, 28.5. [α]<sub>D</sub><sup>20</sup> +136 (<i>c</i> 0.74, MeOH).</div></div><div id="sec4-1-19" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 1-((3<i>R</i>,4<i>S</i>)-4-Cyanotetrahydro-2<i>H</i>-pyran-3-yl)-3-((2-(dimethylamino)-6-fluoropyridin-4-yl)amino)-1<i>H</i>-pyrazole-4-carboxamide (<b>29</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 27% yield. LRMS (ESI) calcd for (C<sub>17</sub>H<sub>20</sub>FN<sub>7</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 374.1, found 374.1. HRMS: calcd for (C<sub>17</sub>H<sub>20</sub>FN<sub>7</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 374.1741, found 374.1756; difference −4.0 ppm. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.47 (s, 1H), 8.31 (s, 1H), 7.79 (brs, 1H), 7.27 (brs, 1H), 6.53 (s, 1H), 6.46 (s, 1H), 4.62–4.58 (m, 1H), 4.05–3.99 (m, 1H), 3.91–3.88 (m, 1H), 3.65–3.59 (m, 2H), 3.45–3.40 (m, 1H), 2.97 (s, 6H), 2.16–2.12 (m, 1H), 2.00–1.93 (m, 1H).</div></div><div id="sec4-1-20" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 1-((3<i>R</i>,4<i>S</i>)-4-Cyanotetrahydro-2<i>H</i>-pyran-3-yl)-3-((2-fluoro-6-methoxypyridin-4-yl)amino)-1<i>H</i>-pyrazole-4-carboxamide (<b>30</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 27% yield. LRMS (ESI) calcd for (C<sub>16</sub>H<sub>17</sub>FN<sub>6</sub>O<sub>3</sub>) [M + H]<sup>+</sup> 361.1, found 361.1. HRMS: calcd for (C<sub>16</sub>H<sub>17</sub>FN<sub>6</sub>O<sub>3</sub>) [M + H]<sup>+</sup> 361.1424, found 361.1394; difference 8.3 ppm. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ9.68 (s, 1H), 8.34 (s, 1H), 7.82 (brs, 1H), 7.31 (brs, 1H), 6.86 (s, 1H), 6.83 (s, 1H), 4.65–4.60 (m, 1H), 4.03–4.00 (m, 1H), 3.91–3.87 (m, 1H), 3.78 (s, 3H), 3.68–3.60 (m, 2H), 3.50–3.45 (m, 1H), 2.16–2.12 (m, 1H), 2.00–1.92 (m, 1H).</div></div><div id="sec4-1-21" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 1-((3<i>R</i>,4<i>S</i>)-4-Cyanotetrahydro-2<i>H</i>-pyran-3-yl)-3-((8-fluoro-4-methoxyquinolin-6-yl)amino)-1<i>H</i>-pyrazole-4-carboxamide (<b>31</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 23% yield. LRMS (ESI) calcd for (C<sub>20</sub>H<sub>19</sub>FN<sub>6</sub>O<sub>3</sub>) [M + H]<sup>+</sup> 411.1, found 411.1. HRMS: calcd for (C<sub>20</sub>H<sub>19</sub>FN<sub>6</sub>O<sub>3</sub>) [M + H]<sup>+</sup> 411.1581, found 411.1596; difference −3.6 ppm. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.54 (s, 1H), 8.55–8.54 (d, <i>J</i> = 4.3 Hz, 1H), 8.35 (s, 1H), 8.11 (s, 1H), 7.86–7.84 (d, <i>J</i> = 13.5 Hz, 1H), 7.80 (brs, 1H), 7.28 (brs, 1H), 7.02–7.01 (d, <i>J</i> = 4.5 Hz, 1H), 4.68–4.62 (m, 1H), 4.11–4.08 (m, 1H), 4.05 (s, 3H), 3.98–3.94 (m, 1H), 3.73–3.69 (m, 1H), 3.67–3.64 (m, 1H), 3.51–3.46 (m, 1H), 2.24–2.20 (m, 1H), 2.05–1.98 (m, 1H).</div></div><div id="sec4-1-22" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 3-((4-Chloro-8-fluoroquinolin-6-yl)amino)-1-((3<i>R</i>,4<i>S</i>)-4-cyanotetrahydro-2<i>H</i>-pyran-3-yl)-1<i>H</i>-pyrazole-4-carboxamide (<b>32</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b>, yield not determined. LRMS (ESI) calcd for (C<sub>19</sub>H<sub>16</sub>ClFN<sub>6</sub>O<sub>3</sub>) [M + H]<sup>+</sup> 415.1, found 415.1. HRMS: calcd for (C<sub>19</sub>H<sub>16</sub>ClFN<sub>6</sub>O<sub>3</sub>) [M + H]<sup>+</sup> 415.1085, found 415.1090; difference −1.2 ppm. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.66 (s, 1H), 8.61 (d, <i>J</i> = 3.6 Hz, 1H), 8.44 (s, 1H), 8.38 (s, 1H), 7.89–7.86 (d, <i>J</i> = 12.7 Hz, 1H), 7.85 (brs, 1H), 7.76 (d, <i>J</i> = 3.4 Hz, 1H), 7.31 (brs, 1H), 4.71–4.66 (m, 1H), 4.13–4.10 (m, 1H), 3.97–3.95 (m, 1H), 3.76–3.71 (m, 1H), 3.67–3.63 (m, 1H), 3.46–3.41 (m, 1H), 2.23–2.21 (m, 1H), 2.05–1.98 (m, 1H).</div></div><div id="sec4-1-23" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 1-((3<i>R</i>,4<i>S</i>)-4-Cyanotetrahydro-2<i>H</i>-pyran-3-yl)-3-((4-methylquinazolin-6-yl)amino)-1<i>H</i>-pyrazole-4-carboxamide (<b>33</b>)</h4><div class="NLM_p last">Prepared following similar procedure described for <b>28</b> in 38% yield. LRMS (ESI) calcd for (C<sub>19</sub>H<sub>19</sub>N<sub>7</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 378.1, found 378.1. HRMS: calcd for (C<sub>19</sub>H<sub>19</sub>N<sub>7</sub>O<sub>2</sub>) [M + H]<sup>+</sup> 378.1678, found 378.1673; difference 1.3 ppm. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.67 (s, 1H), 8.98 (s, 1H), 8.60–8.59 (d, <i>J</i> = 2.4 Hz, 1H), 8.38 (s, 1H), 8.06–8.04 (dd, <i>J</i> = 9.1, 2.4 Hz, 1H), 7.91–7.89 (d, <i>J</i> = 9.1 Hz, 1H), 7.85 (brs, 1H), 7.32 (brs, 1H), 4.71–4.66 (m, 1H), 4.14–4.10 (m, 1H), 3.98–3.94 (m, 1H), 3.78–3.72 (m, 2H), 3.48–3.44 (m, 1H), 2.94 (s, 3H), 2.21–2.17 (m, 1H), 2.06–1.98 (m, 1H).</div></div></div><div id="sec4-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Aromatic Building Block Synthesis</h3><div id="sec4-2-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Synthesis of 5-Bromo-2,3-dimethyl-2,3-dihydrobenzo[<i>d</i>]isothiazole 1,1-Dioxide</h4><div id="sec4-2-1-1" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> Step 1: 4-Bromo-2-ethylbenzenesulfonyl Azide</h5><div class="NLM_p last">A solution of 4-bromo-2-ethylbenzene-1-sulfonyl chloride (256 mg, 0.868 mmol) in water/acetone (1:1, 5.3 mL) was stirred in a 25 mL round-bottom flask and cooled to 0 °C. Sodium azide (85 mg, 1.30 mmol) was added to the sulfonyl chloride mixture and the reaction was warmed to room temperature overnight. The crude reaction mixture underwent rotary evaporation to remove most of the acetone. The product was extracted from the aqueous layer using dichloromethane (3 × 20 mL). The organic layers were combined, washed with brine, dried over sodium sulfate, and concentrated in vacuo. The resulting colorless oil was purified by flash chromatography (9:1 hexanes/EtOAc). The pure fractions were combined and concentrated to afford the desired product in 83% yield. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.91–7.88 (dd, <i>J</i> = 8.3, 3.5 Hz, 1H), 7.62 (s, 1H), 7.56–7.53 (m, 1H), 3.04–3.00 (m, 2H), 1.35–1.31 (m, 3H).</div></div><div id="sec4-2-1-2" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> Step 2: 5-Bromo-3-methyl-2,3-dihydrobenzo[<i>d</i>]isothiazole 1,1-Dioxide</h5><div class="NLM_p last">An oven-dried 2 mL vial with stir bar was evacuated and backfilled with argon (3×). Upon cooling to room temperature, 4-bromo-2-ethylbenzenesulfonyl azide (77 mg, 0.256 mmol) was added followed by chlorobenzene (1.3 mL) and 5 A MS. Co(II) <i>meso</i>-tetraphenylporphine (8.9 mg, 0.013 mmol) was then added, and the reaction mixture was heated to 80 °C overnight. The reaction mixture was cooled to room temperature and purified by silica gel flash chromatography on ISCO, 5% EtOAc in hexanes to 50% EtOAc in hexanes gradient. Isolated 80% yield (56 mg) of the desired product. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.65–7.64 (d, <i>J</i> = 8.3 Hz, 1H), 7.62–7.60 (d, <i>J</i> = 8.3 Hz, 1H), 7.54 (s, 1H), 4.77–4.73 (q, <i>J</i> = 6.6 Hz, 1H), 1.61–1.60 (d, <i>J</i> = 6.5 Hz, 3H).</div></div><div id="sec4-2-1-3" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> Step 3: 5-Bromo-2,3-dimethyl-2,3-dihydrobenzo[<i>d</i>]isothiazole 1,1-Dioxide</h5><div class="NLM_p last">To a solution of 5-bromo-3-methyl-2,3-dihydrobenzo[<i>d</i>]isothiazole 1,1-dioxide (56 mg, 0.214 mmol) in DMF (0.7 mL) at 0 °C, NaH (60%) (8.5 mg, 0.214 mmol) was added. The reaction mixture was stirred for 15 min followed by the addition of iodomethane (17 μL, 0.267 mmol). The reaction was slowly warmed to room temperature overnight. The reaction was quenched with 1:1 sat. NH<sub>4</sub>Cl/H<sub>2</sub>O and diluted with Et<sub>2</sub>O. The aqueous layer was extracted with Et<sub>2</sub>O (3 × 20 mL). The combined organics were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The reaction mixture was purified by silica gel flash purification using 0% EtOAc to 30% EtOAc gradient afforded the desired product in 75% yield (44 mg). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.67 (s, 2H), 7.56 (s, 1H), 4.32–4.28 (q, <i>J</i> = 6.5 Hz, 1H), 2.91 (s, 3H), 1.56–1.55 (d, <i>J</i> = 6.6 Hz, 3H).</div></div></div><div id="sec4-2-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 4-Bromo-6-fluoro-<i>N,N</i>-dimethylpyridin-2-amine</h4><div class="NLM_p last">Dimethylamine (2 M in THF) (147 μL, 0.294 mmol) was added to a solution of 4-bromo-2,6-difluoropyridine (57 mg, 0.294 mmol) in THF (1 mL) at room temperature. The reaction was stirred for 30 min until TLC showed full conversion. The crude reaction mixture was concentrated and carried on forward without further purification, 80% yield. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 6.44 (s, 1H), 6.29–6.28 (m, 1H), 3.06 (s, 6H).</div></div><div id="sec4-2-3" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 6-Bromo-8-fluoro-4-methoxyquinoline</h4><div class="NLM_p last">To a microwave vial was added 6-bromo-4-chloro-8-fluoroquinoline (0.2 g, 0.768 mmol) and sodium methoxide (0.5 M in MeOH) (3.84 mL, 1.92 mmol). The vial was sealed and heated to 80 °C for 2 h. The mixture was cooled to room temperature, diluted with water, and extracted with EtOAc. The organic layer was dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was purified using flash silica gel chromatography with eluent gradient 10–100% EtOAc/Hex. Desired fractions were identified, combined, and concentrated in vacuo to afford the desired product in 77% yield. LRMS (ESI) calcd for (C<sub>10</sub>H<sub>7</sub>BrFNO) [M + H]<sup>+</sup> 256, found 256. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ8.81–8.80 (d, <i>J</i> = 5.2, 1H), 8.16 (s, 1H), 7.54–7.52 (dd, <i>J</i> = 9.7, 2.0 Hz, 1H), 6.83–6.82 (d, <i>J</i> = 5.1 Hz, 1H), 4.07 (s, 3H).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01135">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62845" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62845" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01135" class="ext-link">10.1021/acs.jmedchem.7b01135</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Kinase selectivity profile of key compounds in panel of 265 kinases and kinase selectivity for compounds <b>2</b>, <b>22</b>, and <b>28</b>, JAK biochemical HTRF assay protocol, cell based assay protocol, human whole blood STAT phosphorylation assay protocol, crystallographic data collection and refinement statistics for the complex of JAK1 with compound <b>28</b>, rat collagen induced arthritis (CIA) model, experimental procedure for compounds <b>2</b>, <b>3</b>, <b>4</b>, and <b>5</b>, high-throughput (HT) HPLC log D (pH 7.0) determination, high-throughput (HT) FaSSIF solubility determination, hepatocyte intrinsic clearance method, and references (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01135/suppl_file/jm7b01135_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01135/suppl_file/jm7b01135_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01135/suppl_file/jm7b01135_si_001.pdf">jm7b01135_si_001.pdf (638.14 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01135/suppl_file/jm7b01135_si_002.csv">jm7b01135_si_002.csv (2.33 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WO4">5WO4</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b01135" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48475" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48475" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tony Siu</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5149-7457" title="Orcid link">http://orcid.org/0000-0001-5149-7457</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3f4b505146604c564a7f525a4d5c54115c5052"><span class="__cf_email__" data-cfemail="f98d969780a68a908cb9949c8b9a92d79a9694">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Brubaker</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Fuller</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luis Torres</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongbo Zeng</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joshua Close</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dawn M. Mampreian</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feng Shi</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Duan Liu</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xavier Fradera</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Johnson</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nathan Bays</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elma Kadic</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fang He</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Goldenblatt</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lynsey Shaffer</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sangita B. Patel</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charles A. Lesburg</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carla Alpert</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lauren Dorosh</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sujal V. Deshmukh</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hongshi Yu</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joel Klappenbach</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fiona Elwood</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher J. Dinsmore</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rafael Fernandez</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lily Moy</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathan R. Young</span> - <span class="hlFld-Affiliation affiliation">†Department
of Medicinal Chemistry, ‡Department of Discovery Process Chemistry, §Department of Modeling
& Informatics, ∥Department of In Vitro Pharmacology, ⊥Department of Structural Chemistry, #Department of Pharmacokinetics
Pharmacodynamics and Drug Metabolism, ∇Department of Discovery Pharmaceutical
Sciences, ○Department of Molecular Biomarkers, ¶Department of In Vivo Pharmacology, $Department of Respiratory
and Immunology, Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States</span>; 
    <span class="hlFld-Affiliation affiliation">◆Department of Chemistry and ◇Department of Biology, Pharmaron Beijing Co. Ltd, 6 Taihe Road BDA, Beijing 100176, P.R. China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i42">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70850" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70850" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">T.S. thanks Jongwon Lim and Jared Cumming for careful reading of this manuscript and Bruce Adams and Bridget Becker for NMR support.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i43" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i43"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i44" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i44"> Abbreviations Used</h2><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">DMARDS</td><td class="NLM_def"><p class="first last">disease modifying antirheumatic drugs</p></td></tr><tr><td class="NLM_term">IL-6</td><td class="NLM_def"><p class="first last">interleukin-6</p></td></tr><tr><td class="NLM_term">EPO</td><td class="NLM_def"><p class="first last">erythropoietin</p></td></tr><tr><td class="NLM_term">Cl<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">AUC<sub>u</sub></td><td class="NLM_def"><p class="first last">unbound area under the curve</p></td></tr><tr><td class="NLM_term"><i>f</i><sub>a</sub></td><td class="NLM_def"><p class="first last">fraction absorbed</p></td></tr><tr><td class="NLM_term"><i>f</i><sub>g</sub></td><td class="NLM_def"><p class="first last">fraction escaping gut metabolism</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">LBE</td><td class="NLM_def"><p class="first last">ligand binding efficiency</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">lipophilic ligand efficiency</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">FASSIF</td><td class="NLM_def"><p class="first last">fasted state stimulated intestinal fluid</p></td></tr><tr><td class="NLM_term">D<sub>0</sub></td><td class="NLM_def"><p class="first last">dose number</p></td></tr><tr><td class="NLM_term">Cl<sub>u</sub></td><td class="NLM_def"><p class="first last">unbound clearance</p></td></tr><tr><td class="NLM_term">IL-7</td><td class="NLM_def"><p class="first last">interleukin-7</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">quaque die/everyday</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">CIA</td><td class="NLM_def"><p class="first last">collagen induced arthritis</p></td></tr><tr><td class="NLM_term">PO</td><td class="NLM_def"><p class="first last">per os/by mouth</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">bis in die/twice a day.</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21521" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21521" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 30 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Shuai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span> </span><span class="NLM_article-title">Regulation of JAK-STAT signaling in the immune system</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">900</span><span class="NLM_x">–</span> <span class="NLM_lpage">910</span><span class="refDoi"> DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-910&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK-STAT+signaling+in+the+immune+system&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0lgBApe6_nZOjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK-STAT%2520signaling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D910%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">Therapeutic targeting of janus kinases</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">223</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span><span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00644.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1111%2Fj.1600-065X.2008.00644.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=18613833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2008&pages=132-142&author=M.+Pesuauthor=A.+Laurenceauthor=N.+Kishoreauthor=S.+H.+Zwillichauthor=G.+Chanauthor=J.+J.+O%E2%80%99Shea&title=Therapeutic+targeting+of+janus+kinases&doi=10.1111%2Fj.1600-065X.2008.00644.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of Janus kinases</span></div><div class="casAuthors">Pesu, Marko; Laurence, Arian; Kishore, Nandini; Zwillich, Samuel H.; Chan, Gary; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">223</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132-142</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines play pivotal roles in immunity and inflammation, and targeting cytokines and their receptors is an effective means of treating such disorders.  Type I and II cytokine receptors assoc. with Janus family kinases (JAKs) to effect intracellular signaling.  These structurally unique protein kinases play essential and specific roles in immune cell development and function.  One JAK, JAK3, has particularly selective functions.  Mutations of this kinase underlie severe combined immunodeficiency, indicative of its crit. role in the development and function of lymphocytes.  Because JAK3 appears not to have functions outside of hematopoietic cells, this kinase has been viewed as an excellent therapeutic target for the development of a new class of immunosuppressive drugs.  In fact, several companies are developing JAK3 inhibitors, and Phase II studies are underway.  Mutations of Tyk2 cause autosomal recessive hyperIgE syndrome, and in principle, Tyk2 inhibitors might also be useful as immunosuppressive drugs.  JAK2 gain-of-function mutations (V617F) underlie a subset of disorders collectively referred to as myeloproliferative diseases and phase 2 trials using JAK inhibitors are underway in this setting.  Thus, we are learning a great deal about the feasibility and effectiveness of targeting Janus kinases, and it appears likely that this will be a fruitful strategy in a variety of settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-VTmlwlhcv7Vg90H21EOLACvtfcHk0ljkIGIBW_8aAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D&md5=73dc15932d0eaa312bc2588bdbce404c</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00644.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00644.x%26sid%3Dliteratum%253Aachs%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DTherapeutic%2520targeting%2520of%2520janus%2520kinases%26jtitle%3DImmunol.%2520Rev.%26date%3D2008%26volume%3D223%26spage%3D132%26epage%3D142%26doi%3D10.1111%2Fj.1600-065X.2008.00644.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villarino, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInnes, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span> </span><span class="NLM_article-title">The JAK-STAT pathway: impact on human disease and therapeutic intervention</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span><span class="refDoi"> DOI: 10.1146/annurev-med-051113-024537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1146%2Fannurev-med-051113-024537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=25587654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFyhsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2015&pages=311-328&author=J.+J.+O%E2%80%99Sheaauthor=D.+M.+Schwartzauthor=A.+V.+Villarinoauthor=M.+Gadinaauthor=I.+B.+McInnesauthor=A.+Laurence&title=The+JAK-STAT+pathway%3A+impact+on+human+disease+and+therapeutic+intervention&doi=10.1146%2Fannurev-med-051113-024537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">The JAK-STAT pathway: impact on human disease and therapeutic intervention</span></div><div class="casAuthors">O'Shea, John J.; Schwartz, Daniella M.; Villarino, Alejandro V.; Gadina, Massimo; McInnes, Iain B.; Laurence, Arian</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">311-328</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)-signal transducer of activators of transcription (STAT) pathway is now recognized as an evolutionarily conserved signaling pathway employed by diverse cytokines, interferons, growth factors, and related mols.  This pathway provides an elegant and remarkably straightforward mechanism whereby extracellular factors control gene expression.  It thus serves as a fundamental paradigm for how cells sense environmental cues and interpret these signals to regulate cell growth and differentiation.  Genetic mutations and polymorphisms are functionally relevant to a variety of human diseases, esp. cancer and immune-related conditions.  The clin. relevance of the pathway has been confirmed by the emergence of a new class of therapeutics that targets JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMxvQCRiTbL7Vg90H21EOLACvtfcHk0ljkIGIBW_8aAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFyhsLY%253D&md5=19182154f1a046df039eb4a37b66bf78</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-051113-024537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-051113-024537%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DVillarino%26aufirst%3DA.%2BV.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DLaurence%26aufirst%3DA.%26atitle%3DThe%2520JAK-STAT%2520pathway%253A%2520impact%2520on%2520human%2520disease%2520and%2520therapeutic%2520intervention%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2015%26volume%3D66%26spage%3D311%26epage%3D328%26doi%3D10.1146%2Fannurev-med-051113-024537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Pisetsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, M. M.</span><span> </span><span class="NLM_article-title">Advances in the treatment of inflammatory arthritis</span> <span class="citation_source-journal">Best Pract. Res. Clin. Rheumatol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span><span class="refDoi"> DOI: 10.1016/j.berh.2012.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1016%2Fj.berh.2012.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=22794097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A280%3ADC%252BC38jpvVGqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=251-261&author=D.+S.+Pisetskyauthor=M.+M.+Ward&title=Advances+in+the+treatment+of+inflammatory+arthritis&doi=10.1016%2Fj.berh.2012.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the treatment of inflammatory arthritis</span></div><div class="casAuthors">Pisetsky David S; Ward Michael M</div><div class="citationInfo"><span class="NLM_cas:title">Best practice & research. Clinical rheumatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The inflammatory arthritides are a diverse group of conditions characterised by joint inflammation which can lead to pain, deformity and disability.  Of these diseases, rheumatoid arthritis (RA) and spondyloarthritis are two of the most common.  While the clinical and demographic features of these diseases differ, the central role of inflammation in their pathogenesis has allowed the development of highly effective treatment strategies with wide applicability.  These strategies include the use of biological agents which target the cytokine tumour necrosis factor (TNF), a key mediator of inflammation.  With the advent of effective agents, therapy has become more aggressive, reducing disease activity and allowing, at least in RA, remission in many patients.  While the array of available effective treatments is extensive, the use of objective measures of disease activity can guide treatment decisions (treat to target) and lead to improved outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkLVFtJ16x2xLDWw4HIq2sfW6udTcc2ebAzNYrzXwwn7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38jpvVGqsw%253D%253D&md5=f0b1278ba3590ce50c6527b719bfaa92</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.berh.2012.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.berh.2012.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DPisetsky%26aufirst%3DD.%2BS.%26aulast%3DWard%26aufirst%3DM.%2BM.%26atitle%3DAdvances%2520in%2520the%2520treatment%2520of%2520inflammatory%2520arthritis%26jtitle%3DBest%2520Pract.%2520Res.%2520Clin.%2520Rheumatol%26date%3D2012%26volume%3D26%26spage%3D251%26epage%3D261%26doi%3D10.1016%2Fj.berh.2012.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breedveld, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombs, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgos-Vargas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerbini, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1895</span><span class="NLM_x">–</span> <span class="NLM_lpage">1905</span><span class="refDoi"> DOI: 10.1002/art.24567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1002%2Fart.24567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=19565475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1895-1905&author=J.+M.+Kremerauthor=B.+J.+Bloomauthor=F.+C.+Breedveldauthor=J.+H.+Coombsauthor=M.+P.+Fletcherauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=R.+Burgos-Vargasauthor=B.+Wilkinsonauthor=C.+A.+Zerbiniauthor=S.+H.+Zwillich&title=The+safety+and+efficacy+of+a+JAK+inhibitor+in+patients+with+active+rheumatoid+arthritis%3A+results+of+a+double-blind%2C+placebo-controlled+phase+IIa+trial+of+three+dosage+levels+of+CP-690%2C550+versus+placebo&doi=10.1002%2Fart.24567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span></div><div class="casAuthors">Kremer, Joel M.; Bloom, Bradley J.; Breedveld, Ferdinand C.; Coombs, John H.; Fletcher, Mark P.; Gruben, David; Krishnaswami, Sriram; Burgos-Vargas, Ruben; Wilkinson, Bethanie; Zerbini, Cristiano A. F.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1895-1905</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To det. the efficacy, safety, and tolerability of 3 different dosages of CP-690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate or toxic response.  Patients (n = 264) were randomized equally to receive placebo, 5 mg of CP-690,550,15 mg of CP-690,550, or 30 mg of CP-690,550 twice daily for 6 wk, and were followed up for an addnl. 6 wk after treatment.  The primary efficacy end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at 6 wk.  By week 6, the ACR20 response rates were 70.5%, 81.2%, and 76.8% in the 5 mg, 15 mg, and 30 mg twice daily groups, resp., compared with 29.2% in the placebo group (P < 0.001).  Improvements in disease activity in CP-690,550-treated patients compared with placebo were seen in all treatment groups as early as week 1.  ACR50 and ACR70 response rates significantly improved in all treatment groups by week 4.  The most common adverse events reported were headache and nausea.  The infection rate in both the 15 mg twice daily group and the 30 mg twice daily group was 30.4% (vs. 26.2% in the placebo group).  No opportunistic infections or deaths occurred.  Increases in mean low-d. lipoprotein cholesterol and high-d. lipoprotein cholesterol levels, and increases in mean serum creatinine level (0.04-0.06 mg/dL) were seen in all CP-690,550 treatment arms.  Our findings indicate that CP-690,550 is efficacious in the treatment of RA, resulting in rapid, statistically significant, and clin. meaningful redns. in the signs and symptoms of RA.  Further studies of CP-690,550 in RA are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBhxBhh_mG7rVg90H21EOLACvtfcHk0liUv0PQDr_zOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D&md5=ab5fb34e43d8643871560c67bbbca07d</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1002%2Fart.24567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24567%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DCoombs%26aufirst%3DJ.%2BH.%26aulast%3DFletcher%26aufirst%3DM.%2BP.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZerbini%26aufirst%3DC.%2BA.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DThe%2520safety%2520and%2520efficacy%2520of%2520a%2520JAK%2520inhibitor%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%253A%2520results%2520of%2520a%2520double-blind%252C%2520placebo-controlled%2520phase%2520IIa%2520trial%2520of%2520three%2520dosage%2520levels%2520of%2520CP-690%252C550%2520versus%2520placebo%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D1895%26epage%3D1905%26doi%3D10.1002%2Fart.24567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang-Poa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8468</span><span class="NLM_x">–</span> <span class="NLM_lpage">8484</span><span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lj6-dQnQRremQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kaur, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaushal, S.</span><span> </span><span class="NLM_article-title">Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1074</span><span class="NLM_x">–</span> <span class="NLM_lpage">1086</span><span class="refDoi"> DOI: 10.1016/j.clinthera.2014.06.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1016%2Fj.clinthera.2014.06.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=25047498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtF2ksb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2014&pages=1074-1086&author=K.+Kaurauthor=S.+Kalraauthor=S.+Kaushal&title=Systematic+review+of+tofacitinib%3A+a+new+drug+for+the+management+of+rheumatoid+arthritis&doi=10.1016%2Fj.clinthera.2014.06.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Review of Tofacitinib: A New Drug for the Management of Rheumatoid Arthritis</span></div><div class="casAuthors">Kaur, Kirandeep; Kalra, Sonesh; Kaushal, Sandeep</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1074-1086</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The goal of this study was to review and summarize the efficacy and safety of use of tofacitinib for treating rheumatoid arthritis (RA).  A systematic literature review was conducted to identify English-language articles published through May 2013 within PubMed, ClinicalTrials.gov, and Cochrane Library reporting results from Phase II and Phase III tofacitinib randomized clin. trials.  Tofacitinib must have been used as monotherapy or in combination therapy with disease-modifying antirheumatic drugs (DMARDs) in the treatment of RA.  Study outcomes had to include at least 1 of the following: American College of Rheumatol. (ACR) 20%, 50%, or 70% response rates; tender/swollen joint count; health assessment questionnaire of disability; radiog. outcomes; and drug persistence.  Eight studies (4 Phase II and 4 Phase III trials) were included in the review.  Patients with active RA and who were nonresponders to a biol. agent or the nonbiol. DMARD methotrexate were included in these studies.  The results of the Phase II trials show that tofacitinib at doses ≥3 mg BID was efficacious among the nonresponders.  The results of the Phase III trials, comparing tofacitinib 5 and 10 mg with placebo, show that tofacitinib led to a significant improvement in ACR20 response (P < 0.0001), Health Assessment Questionnaire-Disability Index (P < 0.0001) scores, and ACR50 response (P < 0.0001) after 3 mo.  The efficacy of tofacitinib was numerically similar to adalimumab.  The most common adverse events were infections, infestations, increases in LDL-C and HDL-C levels, and a decrease in neutrophil counts.  Tofacitinib is an efficacious drug for the management of moderate to severe RA among patients with an inadequate response to methotrexate and tumor necrosis factor inhibitors.  Long-term studies can help in understanding the risk/benefit profile of tofacitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNhogMT16YO7Vg90H21EOLACvtfcHk0lj6-dQnQRremQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtF2ksb%252FI&md5=8ffd0a6e85f9b9880cc80462337ddc7f</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2014.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2014.06.018%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DK.%26aulast%3DKalra%26aufirst%3DS.%26aulast%3DKaushal%26aufirst%3DS.%26atitle%3DSystematic%2520review%2520of%2520tofacitinib%253A%2520a%2520new%2520drug%2520for%2520the%2520management%2520of%2520rheumatoid%2520arthritis%26jtitle%3DClin.%2520Ther.%26date%3D2014%26volume%3D36%26spage%3D1074%26epage%3D1086%26doi%3D10.1016%2Fj.clinthera.2014.06.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Bathon, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleischmann, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tesser, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keystone, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasko, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreland, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markenson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finck, B. K.</span><span> </span><span class="NLM_article-title">A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">1586</span><span class="NLM_x">–</span> <span class="NLM_lpage">1593</span><span class="refDoi"> DOI: 10.1056/NEJM200011303432201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1056%2FNEJM200011303432201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=11096165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovVeltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2000&pages=1586-1593&author=J.+M.+Bathonauthor=R.+W.+Martinauthor=R.+M.+Fleischmannauthor=J.+R.+Tesserauthor=M.+H.+Schiffauthor=E.+C.+Keystoneauthor=M.+C.+Genoveseauthor=M.+C.+Waskoauthor=L.+W.+Morelandauthor=A.+L.+Weaverauthor=J.+Markensonauthor=B.+K.+Finck&title=A+comparison+of+etanercept+and+methotrexate+in+patients+with+early+rheumatoid+arthritis&doi=10.1056%2FNEJM200011303432201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis</span></div><div class="casAuthors">Bathon, Joan M.; Martin, Richard W.; Fleischmann, Roy M.; Tesser, John R.; Schiff, Michael H.; Keystone, Edward C.; Genovese, Mark C.; Wasko, Mary Chester; Moreland, Larry W.; Weaver, Arthur L.; Markenson, Joseph; Finck, Barbara K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1586-1593</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Etanercept, which blocks the action of tumor necrosis factor, reduces disease activity in patients with long-standing rheumatoid arthritis.  Its efficacy in reducing disease activity and preventing joint damage in patients with active early rheumatoid arthritis is unknown.  We treated 632 patients with early rheumatoid arthritis with either twice-weekly s.c. etanercept (10 or 25 mg) or weekly oral methotrexate (mean, 19 mg per wk) for 12 mo.  Clin. response was defined as the percent improvement in disease activity according to the criteria of the American College of Rheumatol.  Bone erosion and joint-space narrowing were measured radiog. and scored with use of the Sharp scale.  On this scale, an increase of 1 point represents one new erosion or minimal narrowing.  As compared with patients who received methotrexate, patients who received the 25-mg dose of etanercept had a more rapid rate of improvement, with significantly more patients having 20 %, 50 %, and 70 % improvement in disease activity during the first six months (P<0.05).  The mean increase in the erosion score during the first 6 mo was 0.30 in the group assigned to receive 25 mg of etanercept and 0.68 in the methotrexate group (P=0.001), and the resp. increases during the first 12 mo were 0.47 and 1.03 (P=0.002).  Among patients who received the 25-mg dose of etanercept, 72 % had no increase in the erosion score, as compared with 60 % of patients in the methotrexate group (P=0.007).  This group of patients also had fewer adverse events (P=0.02) and fewer infections (P=0.006) than the group that was treated with methotrexate.  As compared with oral methotrexate, i.v. etanercept acted more rapidly to decrease symptoms and slow joint damage in patients with early active rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplt2B0J1plyLVg90H21EOLACvtfcHk0li1b0dPA_uOXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovVeltLg%253D&md5=691f3d8475d72dfa639ae244d84c44ce</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJM200011303432201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200011303432201%26sid%3Dliteratum%253Aachs%26aulast%3DBathon%26aufirst%3DJ.%2BM.%26aulast%3DMartin%26aufirst%3DR.%2BW.%26aulast%3DFleischmann%26aufirst%3DR.%2BM.%26aulast%3DTesser%26aufirst%3DJ.%2BR.%26aulast%3DSchiff%26aufirst%3DM.%2BH.%26aulast%3DKeystone%26aufirst%3DE.%2BC.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DWasko%26aufirst%3DM.%2BC.%26aulast%3DMoreland%26aufirst%3DL.%2BW.%26aulast%3DWeaver%26aufirst%3DA.%2BL.%26aulast%3DMarkenson%26aufirst%3DJ.%26aulast%3DFinck%26aufirst%3DB.%2BK.%26atitle%3DA%2520comparison%2520of%2520etanercept%2520and%2520methotrexate%2520in%2520patients%2520with%2520early%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2000%26volume%3D343%26spage%3D1586%26epage%3D1593%26doi%3D10.1056%2FNEJM200011303432201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="note"><p class="first last">For an excellent review see:</p></div><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Menet, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mammoliti, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Ramos, M.</span><span> </span><span class="NLM_article-title">Progress toward JAK1-selective inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">235</span><span class="refDoi"> DOI: 10.4155/fmc.14.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.4155%2Ffmc.14.149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=25686006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=203-235&author=C.+J.+Menetauthor=O.+Mammolitiauthor=M.+Lopez-Ramos&title=Progress+toward+JAK1-selective+inhibitors&doi=10.4155%2Ffmc.14.149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Progress toward JAK1-selective inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Mammoliti, Oscar; Lopez-Ramos, Miriam</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-235</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery of the JAK-STAT pathway was a landmark in cell biol.  The identification of these pathways has changed the landscape of treatment of rheumatoid arthritis and other autoimmune diseases.  The two first (unselective) JAK inhibitors have recently been approved by the US FDA for the treatment of myelofibrosis and rheumatoid arthritis and many other JAK inhibitors are currently in clin. development or at the discovery stage.  Research groups have demonstrated the different roles of JAK member and the therapeutic potential of targeting them selectively.  JAK1 plays a crit. and potentially dominant role in the transduction of γc cytokine (γc = common γ chain) and in IL-6 signaling.  In this review, we will discuss the state-of-the-art research that evokes JAK1 selective inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFBuFU-x0dWrVg90H21EOLACvtfcHk0li1b0dPA_uOXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D&md5=ef6cf011f0078aaa4f83560c98524d1c</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.149%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DMammoliti%26aufirst%3DO.%26aulast%3DLopez-Ramos%26aufirst%3DM.%26atitle%3DProgress%2520toward%2520JAK1-selective%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D203%26epage%3D235%26doi%3D10.4155%2Ffmc.14.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">For JAK1 Selective Inhibitors see:</p></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyke, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir Kohli, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxey, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narukulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waszkowycz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span> </span><span class="NLM_article-title">Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5901</span><span class="NLM_x">–</span> <span class="NLM_lpage">5921</span><span class="refDoi"> DOI: 10.1021/jm300438j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300438j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC38XntVOktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5901-5921&author=J.+J.+Kulagowskiauthor=W.+Blairauthor=R.+J.+Bullauthor=C.+Changauthor=G.+Deshmukhauthor=H.+J.+Dykeauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=T.+K.+Harrisonauthor=P.+R.+Hewittauthor=M.+Liimattaauthor=C.+A.+Hurleyauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=P.+B.+Bir+Kohliauthor=R.+J.+Maxeyauthor=R.+Mendoncaauthor=K.+Mortaraauthor=J.+Murrayauthor=R.+Narukullaauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=M.+Ultschauthor=A.+van+Abbemaauthor=S.+I.+Wardauthor=B.+Waszkowyczauthor=M.+Zak&title=Identification+of+imidazo-pyrrolopyridines+as+novel+and+potent+JAK1+inhibitors&doi=10.1021%2Fjm300438j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors</span></div><div class="casAuthors">Kulagowski, Janusz J.; Blair, Wade; Bull, Richard J.; Chang, Christine; Deshmukh, Gauri; Dyke, Hazel J.; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Harrison, Trevor K.; Hewitt, Peter R.; Liimatta, Marya; Hurley, Christopher A.; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Bir Kohli, Pawan; Maxey, Robert J.; Mendonca, Rohan; Mortara, Kyle; Murray, Jeremy; Narukulla, Raman; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; Ultsch, Mark; van Abbema, Anne; Ward, Stuart I.; Waszkowycz, Bohdan; Zak, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5901-5921</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), by specific targeting of the JAK1 pathway.  Examn. of the preferred binding conformation of clin. effective, pan-JAK inhibitor 1 led to identification of a novel, tricyclic hinge binding scaffold 3.  Exploration of SAR through a series of cycloamino and cycloalkylamino analogs demonstrated this template to be highly tolerant of substitution, with a predisposition to moderate selectivity for the JAK1 isoform over JAK2.  This study culminated in the identification of subnanomolar JAK1 inhibitors such as 22 and 49, having excellent cell potency, good rat pharmacokinetic characteristics, and excellent kinase selectivity.  Detn. of the binding modes of the series in JAK1 and JAK2 by X-ray crystallog. supported the design of analogs to enhance affinity and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpamrk0bG1MK7Vg90H21EOLACvtfcHk0lg0wpnYjX32Ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntVOktL0%253D&md5=d91bc0e24abf14adcf44caf61e3e879f</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1021%2Fjm300438j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300438j%26sid%3Dliteratum%253Aachs%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DBlair%26aufirst%3DW.%26aulast%3DBull%26aufirst%3DR.%2BJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDyke%26aufirst%3DH.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHarrison%26aufirst%3DT.%2BK.%26aulast%3DHewitt%26aufirst%3DP.%2BR.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DBir%2BKohli%26aufirst%3DP.%2BB.%26aulast%3DMaxey%26aufirst%3DR.%2BJ.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DZak%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520imidazo-pyrrolopyridines%2520as%2520novel%2520and%2520potent%2520JAK1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5901%26epage%3D5921%26doi%3D10.1021%2Fjm300438j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanan, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M. F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir Kohli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labadie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupardus, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxey, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span> </span><span class="NLM_article-title">Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavaliable JAK1 inhibitors with selectivity over JAK2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6176</span><span class="NLM_x">–</span> <span class="NLM_lpage">6193</span><span class="refDoi"> DOI: 10.1021/jm300628c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300628c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6176-6193&author=M.+Zakauthor=R.+Mendoncaauthor=M.+Balazsauthor=K.+Barrettauthor=P.+Bergeronauthor=W.+S.+Blairauthor=C.+Changauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=C.+Hammanauthor=E.+J.+Hananauthor=E.+Harstadauthor=P.+R.+Hewittauthor=C.+A.+Hurleyauthor=T.+Jinauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+T.+Koehlerauthor=P.+Bir+Kohliauthor=J.+J.+Kulagowskiauthor=S.+Labadieauthor=J.+Liaoauthor=M.+Liimattaauthor=Z.+Linauthor=P.+J.+Lupardusauthor=R.+J.+Maxeyauthor=J.+M.+Murrayauthor=R.+Pulkauthor=M.+Rodriguezauthor=S.+Savageauthor=S.+Shiaauthor=M.+Streffekauthor=S.+Ubhayakarauthor=M.+Ultschauthor=A.+van+Abbemaauthor=S.+I.+Wardauthor=L.+Xiaoauthor=Y.+Xiao&title=Discovery+and+optimization+of+C-2+methyl+imidazopyrrolopyridines+as+potent+and+orally+bioavaliable+JAK1+inhibitors+with+selectivity+over+JAK2&doi=10.1021%2Fjm300628c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1021%2Fjm300628c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300628c%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%2BR.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DJin%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%2BT.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DMaxey%26aufirst%3DR.%2BJ.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DStreffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DY.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520C-2%2520methyl%2520imidazopyrrolopyridines%2520as%2520potent%2520and%2520orally%2520bioavaliable%2520JAK1%2520inhibitors%2520with%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6176%26epage%3D6193%26doi%3D10.1021%2Fjm300628c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crackett, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwood, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaines, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M. F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir Kohli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labadie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narukulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeve, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avitabile-Woo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span> </span><span class="NLM_article-title">Identification of C-2 hydroyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4764</span><span class="NLM_x">–</span> <span class="NLM_lpage">4785</span><span class="refDoi"> DOI: 10.1021/jm4004895</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4004895" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4764-4785&author=M.+Zakauthor=C.+A.+Hurleyauthor=S.+I.+Wardauthor=P.+Bergeronauthor=K.+Barrettauthor=M.+Balazsauthor=W.+S.+Blairauthor=R.+Bullauthor=P.+Chakravartyauthor=C.+Changauthor=P.+Crackettauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=C.+Ellwoodauthor=S.+Gainesauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=P.+Griblingauthor=C.+Hammanauthor=E.+Harstadauthor=P.+Hewittauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+T.+Koehlerauthor=P.+Bir+Kohliauthor=S.+Labadieauthor=W.+P.+Leeauthor=J.+Liaoauthor=M.+Liimattaauthor=R.+Mendoncaauthor=R.+Narukullaauthor=R.+Pulkauthor=A.+Reeveauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=A.+van+Abbemaauthor=I.+Aliagasauthor=B.+Avitabile-Wooauthor=Y.+Xiaoauthor=J.+Yangauthor=J.+J.+Kulagowski&title=Identification+of+C-2+hydroyethyl+imidazopyrrolopyridines+as+potent+JAK1+inhibitors+with+favorable+physicochemical+properties+and+high+selectivity+over+JAK2&doi=10.1021%2Fjm4004895"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1021%2Fjm4004895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004895%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DCrackett%26aufirst%3DP.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEllwood%26aufirst%3DC.%26aulast%3DGaines%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%2BT.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DReeve%26aufirst%3DA.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DAvitabile-Woo%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520C-2%2520hydroyethyl%2520imidazopyrrolopyridines%2520as%2520potent%2520JAK1%2520inhibitors%2520with%2520favorable%2520physicochemical%2520properties%2520and%2520high%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4764%26epage%3D4785%26doi%3D10.1021%2Fjm4004895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Menet, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Lommen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanc, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smits, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouannigot, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deprez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Aar, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement-Lacroix, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepescheux, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galien, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vayssiere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelles, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christophe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brys, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhring, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciesielski, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Rompaey, L.</span><span> </span><span class="NLM_article-title">Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">9323</span><span class="NLM_x">–</span> <span class="NLM_lpage">9342</span><span class="refDoi"> DOI: 10.1021/jm501262q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501262q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9323-9342&author=C.+J.+Menetauthor=S.+R.+Fletcherauthor=G.+Van+Lommenauthor=R.+Geneyauthor=J.+Blancauthor=K.+Smitsauthor=N.+Jouannigotauthor=P.+Deprezauthor=E.+M.+van+der+Aarauthor=P.+Clement-Lacroixauthor=L.+Lepescheuxauthor=R.+Galienauthor=B.+Vayssiereauthor=L.+Nellesauthor=T.+Christopheauthor=R.+Brysauthor=M.+Uhringauthor=F.+Ciesielskiauthor=L.+Van+Rompaey&title=Triazolopyridines+as+selective+JAK1+inhibitors%3A+from+hit+identification+to+GLPG0634&doi=10.1021%2Fjm501262q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6eR"><div class="casContent"><span class="casTitleNuber">6e</span><div class="casTitle"><span class="NLM_cas:atitle">Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634</span></div><div class="casAuthors">Menet, Christel J.; Fletcher, Stephen R.; Van Lommen, Guy; Geney, Raphael; Blanc, Javier; Smits, Koen; Jouannigot, Nolwenn; Deprez, Pierre; van der Aar, Ellen M.; Clement-Lacroix, Philippe; Lepescheux, Lien; Galien, Rene; Vayssiere, Beatrice; Nelles, Luc; Christophe, Thierry; Brys, Reginald; Uhring, Muriel; Ciesielski, Fabrice; Van Rompaey, Luc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9323-9342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function.  Blockade of the JAK-STAT pathway with a small mol. has been shown to provide therapeutic immunomodulation.  Having identified JAK1 as a possible new target for arthritis at Galapagos, the compd. library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by I.  Optimization within this chem. series led to identification of II (GLPG0634, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohn's disease (CD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBHELw4zQ5QLVg90H21EOLACvtfcHk0lghNCgo_W0B3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nN&md5=756f687dc30e6fd34004deb672fe8b23</span></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1021%2Fjm501262q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501262q%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DS.%2BR.%26aulast%3DVan%2BLommen%26aufirst%3DG.%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DBlanc%26aufirst%3DJ.%26aulast%3DSmits%26aufirst%3DK.%26aulast%3DJouannigot%26aufirst%3DN.%26aulast%3DDeprez%26aufirst%3DP.%26aulast%3Dvan%2Bder%2BAar%26aufirst%3DE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3DUhring%26aufirst%3DM.%26aulast%3DCiesielski%26aufirst%3DF.%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26atitle%3DTriazolopyridines%2520as%2520selective%2520JAK1%2520inhibitors%253A%2520from%2520hit%2520identification%2520to%2520GLPG0634%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9323%26epage%3D9342%26doi%3D10.1021%2Fjm501262q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Kim, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, Y.</span><span> </span><span class="NLM_article-title">Benzoimdazole derivatives as potent JAK1 selective inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">7596</span><span class="NLM_x">–</span> <span class="NLM_lpage">7602</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7596-7602&author=M.+K.+Kimauthor=H.+Shinauthor=K.+Parkauthor=H.+Kimauthor=J.+Parkauthor=K.+Kimauthor=J.+Namauthor=H.+Chooauthor=Y.+Chong&title=Benzoimdazole+derivatives+as+potent+JAK1+selective+inhibitors&doi=10.1021%2Facs.jmedchem.5b01263"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01263%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DShin%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DNam%26aufirst%3DJ.%26aulast%3DChoo%26aufirst%3DH.%26aulast%3DChong%26aufirst%3DY.%26atitle%3DBenzoimdazole%2520derivatives%2520as%2520potent%2520JAK1%2520selective%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7596%26epage%3D7602%26doi%3D10.1021%2Facs.jmedchem.5b01263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Simov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elwood, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibeau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunaydin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraybill, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapointe, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J. R.</span><span> </span><span class="NLM_article-title">Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase Inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1803</span><span class="NLM_x">–</span> <span class="NLM_lpage">1808</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.02.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1016%2Fj.bmcl.2016.02.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=26927423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt12mtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1803-1808&author=V.+Simovauthor=S.+V.+Deshmukhauthor=C.+J.+Dinsmoreauthor=F.+Elwoodauthor=R.+B.+Fernandezauthor=Y.+Garciaauthor=C.+Gibeauauthor=H.+Gunaydinauthor=J.+Jungauthor=J.+D.+Katzauthor=B.+Kraybillauthor=B.+Lapointeauthor=S.+B.+Patelauthor=T.+Siuauthor=H.+Suauthor=J.+R.+Young&title=Structure-based+design+and+development+of+%28benz%29imidazole+pyridones+as+JAK1-selective+kinase+Inhibitors&doi=10.1016%2Fj.bmcl.2016.02.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6gR"><div class="casContent"><span class="casTitleNuber">6g</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors</span></div><div class="casAuthors">Simov, Vladimir; Deshmukh, Sujal V.; Dinsmore, Christopher J.; Elwood, Fiona; Fernandez, Rafael B.; Garcia, Yudith; Gibeau, Craig; Gunaydin, Hakan; Jung, Joon; Katz, Jason D.; Kraybill, Brian; Lapointe, Blair; Patel, Sangita B.; Siu, Tony; Su, Hua; Young, Jonathan R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1803-1808</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mammalian Janus Kinases (JAK1, JAK2, JAK3 and TYK2) are intracellular, nonreceptor tyrosine kinases whose activities have been assocd. in the literature and the clinic with a variety of hyperproliferative diseases and immunol. disorders.  At the onset of the program, it was hypothesized that a JAK1 selective compd. over JAK2 could lead to an improved therapeutic index relative to marketed nonselective JAK inhibitors by avoiding the clin. AEs, such as anemia, presumably assocd. with JAK2 inhibition.  During the course of the JAK1 program, a no. of diverse chem. scaffolds were identified from both uHTS campaigns and de novo scaffold design.  As part of this effort, a (benz)imidazole scaffold evolved via a scaffold-hopping exercise from a mature chem. series.  Concurrent crystallog.-driven exploration of the ribose pocket and the solvent front led to analogs with optimized kinome and JAK1 selectivities over the JAK2 isoform by targeting several residues unique to JAK1, such as Arg-879 and Glu-966.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeRwubYziKxrVg90H21EOLACvtfcHk0lg6v2v8nAltDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt12mtLo%253D&md5=f863ad973f0f86993bb7f796821b5059</span></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.02.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.02.035%26sid%3Dliteratum%253Aachs%26aulast%3DSimov%26aufirst%3DV.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DElwood%26aufirst%3DF.%26aulast%3DFernandez%26aufirst%3DR.%2BB.%26aulast%3DGarcia%26aufirst%3DY.%26aulast%3DGibeau%26aufirst%3DC.%26aulast%3DGunaydin%26aufirst%3DH.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26aulast%3DKraybill%26aufirst%3DB.%26aulast%3DLapointe%26aufirst%3DB.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DSiu%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DJ.%2BR.%26atitle%3DStructure-based%2520design%2520and%2520development%2520of%2520%2528benz%2529imidazole%2520pyridones%2520as%2520JAK1-selective%2520kinase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1803%26epage%3D1808%26doi%3D10.1016%2Fj.bmcl.2016.02.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6h"><span><span class="NLM_label">(h) </span><div class="note"><p class="first last">For a review of JAK inhibitors in the clinic, see:</p></div><span class="NLM_contrib-group">Roskoski, R.,  Jr</span><span> </span><span class="NLM_article-title">Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">784</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span><span class="refDoi"> DOI: 10.1016/j.phrs.2016.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1016%2Fj.phrs.2016.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=27473820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12jurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=784-803&author=R.+Roskoski&title=Janus+kinase+%28JAK%29+inhibitors+in+the+treatment+of+inflammatory+and+neoplastic+diseases&doi=10.1016%2Fj.phrs.2016.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6hR"><div class="casContent"><span class="casTitleNuber">6h</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases</span></div><div class="casAuthors">Roskoski, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">784-803</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinase (JAK) family of non-receptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (tyrosine kinase-2).  Each of these proteins contains a JAK homol. pseudokinase (JH2) domain that regulates the adjacent protein kinase domain (JH1).  JAK1/2 and TYK2 are ubiquitously expressed whereas JAK3 is found predominantly in hematopoietic cells.  The Janus kinase family is regulated by numerous cytokines including interleukins, interferons, and hormones such as erythropoietin, thrombopoietin, and growth hormone.  Ligand binding to cytokine and hormone receptors leads to the activation of assocd. Janus kinases, which then mediate the phosphorylation of the receptors.  The SH2 domain of STATs (signal transducers and activators of transcription) binds to the receptor phosphotyrosines thereby promoting STAT phosphorylation by the Janus kinases and consequent activation.  STAT dimers are translocated to the nucleus where they participate in the regulation of the expression of thousands of proteins.  JAK-STAT dysregulation results in autoimmune disorders such as rheumatoid arthritis, ulcerative colitis, and Crohn disease.  JAK-STAT dysregulation also plays a role in the pathogenesis of myelofibrosis, polycythemia vera, and other myeloproliferative illnesses.  An activating JAK2 V617F mutation occurs in 95% of people with polycythemia vera and in a lower percentage of people with other neoplasms.  JAK1/3 signaling participates in the pathogenesis of inflammatory afflictions while JAK1/2 signaling participates in the development of several malignancies including leukemias and lymphomas as well as myeloproliferative neoplasms.  Tofacitinib is a pan-JAK inhibitor that is approved by the FDA for the treatment of rheumatoid arthritis and ruxolitinib is a JAK1/2 inhibitor that is approved for the treatment of polycythemia vera and myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov32m4UjOrv7Vg90H21EOLACvtfcHk0ljEzsezpII7YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12jurzJ&md5=a45fba1bb110eff4d5c1b31b78c1b3ac</span></div><a href="/servlet/linkout?suffix=cit6h&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DJanus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520in%2520the%2520treatment%2520of%2520inflammatory%2520and%2520neoplastic%2520diseases%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D784%26epage%3D803%26doi%3D10.1016%2Fj.phrs.2016.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Brubaker, J.</span><span> </span><span class="NLM_article-title">Discovery of an orally bioavailable JAK1 inhibitor for validation of JAK1-selective hypothesis</span>. Presented at Applied Pharmaceutical Chemistry Conference; Boston, MA, March 4,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=J.+Brubaker&title=Discovery+of+an+orally+bioavailable+JAK1+inhibitor+for+validation+of+JAK1-selective+hypothesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBrubaker%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520an%2520orally%2520bioavailable%2520JAK1%2520inhibitor%2520for%2520validation%2520of%2520JAK1-selective%2520hypothesis%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Moy, L.; Chiu, C-S.; Faltus, R.; Zielstorff, M.; Chakravarthy, K.; Deshmukh, S.; Kariv, I.; Klappenbach, J.; Brubaker, J.; Liu, D.; Siu, T.; Young, J.; Yu, H.; Elwood, F.; Cicmil, M.</span><span> </span><span class="NLM_article-title">Efficacy of a novel orally bioavailable JAK1 selective compound in a preclinical rat collagen-induced arthritis model</span>. Presented at ACR/ARHP Annual Meeting; Boston, MA, November 14–19,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=L.+Moy&author=C-S.+Chiu&author=R.+Faltus&author=M.+Zielstorff&author=K.+Chakravarthy&author=S.+Deshmukh&author=I.+Kariv&author=J.+Klappenbach&author=J.+Brubaker&author=D.+Liu&author=T.+Siu&author=J.+Young&author=H.+Yu&author=F.+Elwood&author=M.+Cicmil&title=Efficacy+of+a+novel+orally+bioavailable+JAK1+selective+compound+in+a+preclinical+rat+collagen-induced+arthritis+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DMoy%26aufirst%3DL.%26atitle%3DEfficacy%2520of%2520a%2520novel%2520orally%2520bioavailable%2520JAK1%2520selective%2520compound%2520in%2520a%2520preclinical%2520rat%2520collagen-induced%2520arthritis%2520model%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="note"><p class="first last">Human dose predication was based achieving exposure needed to achieve 15% pit improvements in ACR50 over 10 mg BID tofacitinib. PK/PD modeling for the required exposure will be disclosed in a future publication.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dack, K.</span> <span class="citation_source-book">Reducing Attrition Risk: Evolution of an in silico “compound safety evaluator” designing safer medicines in discovery</span>. <span class="NLM_publisher-name">SCI</span>: <span class="NLM_publisher-loc">London</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=K.+Dack&title=Reducing+Attrition+Risk%3A+Evolution+of+an+in+silico+%E2%80%9Ccompound+safety+evaluator%E2%80%9D+designing+safer+medicines+in+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDack%26aufirst%3DK.%26btitle%3DReducing%2520Attrition%2520Risk%253A%2520Evolution%2520of%2520an%2520in%2520silico%2520%25E2%2580%259Ccompound%2520safety%2520evaluator%25E2%2580%259D%2520designing%2520safer%2520medicines%2520in%2520discovery%26pub%3DSCI%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Uetrecht, J.</span><span> </span><span class="NLM_article-title">Idiosyncratic drug reactions: current understanding</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">539</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.47.120505.105150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1146%2Fannurev.pharmtox.47.120505.105150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=16879083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1altb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=513-539&author=J.+Uetrecht&title=Idiosyncratic+drug+reactions%3A+current+understanding&doi=10.1146%2Fannurev.pharmtox.47.120505.105150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Idiosyncratic drug reactions: current understanding</span></div><div class="casAuthors">Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">513-539</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Clin. characteristics and circumstantial evidence suggest that idiosyncratic drug reactions are caused by reactive metabolites and are immune-mediated; however, there are few definitive data and there are likely exceptions.  There are three principal hypotheses for how reactive metabolites might induce an immune-mediated idiosyncratic reaction: the hapten hypothesis, the danger hypothesis, and the PI hypothesis.  It has been proposed that some idiosyncratic reactions, esp. those involving the liver, represent metabolic idiosyncrasy; however, there are even less data to support this hypothesis.  The unpredictable nature of these reactions makes mechanistic studies difficult.  There is a very strong assocn. with specific human leukocyte antigen (HLA) genes for certain reactions, but this has only been demonstrated for very few drugs.  Animal models represent a very powerful tool for mechanistic studies, but the no. of valid models is also limited.  There may be biomarkers of risk; however, much more work needs to be done.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwjyupTxgQMrVg90H21EOLACvtfcHk0ljEzsezpII7YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1altb0%253D&md5=587b03e88f3b881c87d383818bea7f47</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.47.120505.105150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.47.120505.105150%26sid%3Dliteratum%253Aachs%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DIdiosyncratic%2520drug%2520reactions%253A%2520current%2520understanding%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2007%26volume%3D47%26spage%3D513%26epage%3D539%26doi%3D10.1146%2Fannurev.pharmtox.47.120505.105150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Chalasani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjornsson, E.</span><span> </span><span class="NLM_article-title">Risk factors for idiosyncratic drug-induced liver injury</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">2246</span><span class="NLM_x">–</span> <span class="NLM_lpage">2259</span><span class="refDoi"> DOI: 10.1053/j.gastro.2010.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1053%2Fj.gastro.2010.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=20394749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnslaku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2010&pages=2246-2259&author=N.+Chalasaniauthor=E.+Bjornsson&title=Risk+factors+for+idiosyncratic+drug-induced+liver+injury&doi=10.1053%2Fj.gastro.2010.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Risk factors for idiosyncratic drug-induced liver injury</span></div><div class="casAuthors">Chalasani, Naga; Bjornsson, Einar</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2246-2259</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Idiosyncratic drug-induced liver injury (DILI) is a rare disorder that is not related directly to dosage and little is known about individuals who are at increased risk.  There are no suitable preclin. models for the study of idiosyncratic DILI and its pathogenesis is poorly understood.  It is likely to arise from complex interactions among genetic, nongenetic host susceptibility, and environmental factors.  Nongenetic risk factors include age, sex, and other diseases (eg, chronic liver disease or human immunodeficiency virus infection).  Compd.-specific risk factors include daily dose, metab. characteristics, and propensity for drug interactions.  Alc. consumption has been proposed as a risk factor for DILI from medications, but there is insufficient evidence to support this.  Many studies have explored genetic defects that might be involved in pathogenesis and focused on genes involved in drug metab. and the immune response.  Multicenter databases of patients with DILI (the United States Drug Induced Liver Injury Network, DILIGEN, and the Spanish DILI registry) are important tools for clin. and genetic research.  A genome-wide assocn. study of flucloxacillin hepatotoxicity has yielded groundbreaking results and many similar studies are underway.  Nonetheless, DILI is challenging to investigate because of its rarity, the lack of exptl. models, the no. of medications that might cause it, and challenges to diagnosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8ybOkEsO25rVg90H21EOLACvtfcHk0lieL9NxfuNB8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnslaku7c%253D&md5=ed4fc7b289b9ffadeca654a26f4f2d5d</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2010.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2010.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DBjornsson%26aufirst%3DE.%26atitle%3DRisk%2520factors%2520for%2520idiosyncratic%2520drug-induced%2520liver%2520injury%26jtitle%3DGastroenterology%26date%3D2010%26volume%3D138%26spage%3D2246%26epage%3D2259%26doi%3D10.1053%2Fj.gastro.2010.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Tujios, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, R. J.</span><span> </span><span class="NLM_article-title">Mechanisms of drug-induced liver injury from bedside to bench</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span><span class="refDoi"> DOI: 10.1038/nrgastro.2011.22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1038%2Fnrgastro.2011.22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=21386809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFKntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=202-211&author=S.+Tujiosauthor=R.+J.+Fontana&title=Mechanisms+of+drug-induced+liver+injury+from+bedside+to+bench&doi=10.1038%2Fnrgastro.2011.22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10dR"><div class="casContent"><span class="casTitleNuber">10d</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of drug-induced liver injury: from bedside to bench</span></div><div class="casAuthors">Tujios, Shannan; Fontana, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">202-211</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The mechanisms of drug-induced liver injury (DILI) are not well understood.  In this Review, the authors propose that a bedside to bench approach involving the study of clinicopathol. features of patients with DILI can provide insight into the mechanisms underlying this condition.  The authors also discuss the potential role of several factors, including mitochondrial toxicity and the host immune system, in the etiopathogenesis of DILI.  The low incidence of idiosyncratic drug-induced liver injury (DILI), together with the lack of a reliable diagnostic biomarker and robust preclin. and in vitro toxicol. test systems for the condition have limited our ability to define the mechanisms of DILI.  A notable exception is acetaminophen hepatotoxicity, which is assocd. with the formation of a well-characterized and highly reactive intermediate metabolite, N-acetyl-p-benzoquinone imine.  However, studies have also suggested a role for the host immune response and variation in the expression of the lymphocyte CD44 gene in the pathogenesis of acetaminophen hepatotoxicity.  A careful review of the lab., clin. and histol. phenotype of patients with DILI can provide potential clues to the mechanisms of disease pathogenesis, as obsd. with fialuridine and valproate hepatotoxicity.  In addn., the use of transcriptomic and genomic approaches in patients with well-characterized DILI has provided important insights into the involvement of the host immune response in the pathogenesis of hepatotoxicity assocd. with the administration of flucloxacillin, lumiracoxib or ximelagatran.  This Review highlights new developments regarding the potential role of reactive metabolites, mitochondrial toxicity, host immune-response pathways and biliary transporters in the etiopathogenesis of DILI.  Going forward, a bedside-to-bench approach could improve our understanding of the mechanisms and risk factors for DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKmG8kDlaH5bVg90H21EOLACvtfcHk0lieL9NxfuNB8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFKntro%253D&md5=cd55bdf561cea3f34c62f998ebed98fc</span></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2011.22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2011.22%26sid%3Dliteratum%253Aachs%26aulast%3DTujios%26aufirst%3DS.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26atitle%3DMechanisms%2520of%2520drug-induced%2520liver%2520injury%2520from%2520bedside%2520to%2520bench%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2011%26volume%3D8%26spage%3D202%26epage%3D211%26doi%3D10.1038%2Fnrgastro.2011.22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Oh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curl, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amidon, G. L.</span><span> </span><span class="NLM_article-title">Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1023/A:1018947113238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1023%2FA%3A1018947113238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=8456075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADyaK3sXhs1SmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1993&pages=264-270&author=D.+Ohauthor=R.+L.+Curlauthor=G.+L.+Amidon&title=Estimating+the+fraction+dose+absorbed+from+suspensions+of+poorly+soluble+compounds+in+humans%3A+a+mathematical+model&doi=10.1023%2FA%3A1018947113238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model</span></div><div class="casAuthors">Oh, Doo Man; Curl, Rane L.; Amidon, Gordon L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">264-70</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">A microscopic mass balance approach has been developed to predict the fraction dose absorbed of suspensions of poorly sol. compds.  The math. model includes four fundamental dimensionless parameters to est. the fraction dose absorbed: initial satn. (Is), absorption no. (An), dose no. (Do), and dissoln. no. (Dn).  The fraction dose absorbed (F) increases with increasing Is, An, and Dn and with decreasing Do.  At higher Dn and lower Do, the fraction dose absorbed reaches the maximal F, which depends only on An.  The dissoln. no. limit on F can appear at both lower Do and lower Dn.  It is shown that the extent fo drug absorption is expected to be highly variable when Dn and Do are approx. one.  Furthermore, by calcg. these dimensionless groups for a given compd., a formulation scientists can est. not only the extent of drug absorption but also the effect, if any, of particle size redn. on the extent of drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopaxhSvKyLwrVg90H21EOLACvtfcHk0liBXTB4R8jodQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhs1SmsLw%253D&md5=a83a50cd018fc09bd4b3142305199fa9</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1023%2FA%3A1018947113238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1018947113238%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DD.%26aulast%3DCurl%26aufirst%3DR.%2BL.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26atitle%3DEstimating%2520the%2520fraction%2520dose%2520absorbed%2520from%2520suspensions%2520of%2520poorly%2520soluble%2520compounds%2520in%2520humans%253A%2520a%2520mathematical%2520model%26jtitle%3DPharm.%2520Res.%26date%3D1993%26volume%3D10%26spage%3D264%26epage%3D270%26doi%3D10.1023%2FA%3A1018947113238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dahan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amidon, G. L.</span><span> </span><span class="NLM_article-title">Prediction of solubility and permeability class membership: provisional BCS classification of the world top oral drugs</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">740</span><span class="NLM_x">–</span> <span class="NLM_lpage">746</span><span class="refDoi"> DOI: 10.1208/s12248-009-9144-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1208%2Fs12248-009-9144-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=740-746&author=A.+Dahanauthor=J.+M.+Millerauthor=G.+L.+Amidon&title=Prediction+of+solubility+and+permeability+class+membership%3A+provisional+BCS+classification+of+the+world+top+oral+drugs&doi=10.1208%2Fs12248-009-9144-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1208%2Fs12248-009-9144-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-009-9144-x%26sid%3Dliteratum%253Aachs%26aulast%3DDahan%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DJ.%2BM.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26atitle%3DPrediction%2520of%2520solubility%2520and%2520permeability%2520class%2520membership%253A%2520provisional%2520BCS%2520classification%2520of%2520the%2520world%2520top%2520oral%2520drugs%26jtitle%3DAAPS%2520J.%26date%3D2009%26volume%3D11%26spage%3D740%26epage%3D746%26doi%3D10.1208%2Fs12248-009-9144-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Kerns, E. H.; Di, Li.</span> <span class="citation_source-book">Drug-Like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization</span>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>p  <span class="NLM_fpage">223</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=223&author=E.+H.+Kerns&author=Li.+Di&title=Drug-Like+Properties%3A+Concepts%2C+Structure+Design+and+Methods%3A+From+ADME+to+Toxicity+Optimization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKerns%26aufirst%3DE.%2BH.%26btitle%3DDrug-Like%2520Properties%253A%2520Concepts%252C%2520Structure%2520Design%2520and%2520Methods%253A%2520From%2520ADME%2520to%2520Toxicity%2520Optimization%26pub%3DAcademic%2520Press%26date%3D2008%26spage%3D223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><div class="note"><p class="first last">The MK499 IC<sub>50</sub> values were acquired by radio ligand binding competition experiments using membrane preparations from human embryonic kidney cells that express hERG. IC<sub>50</sub> values are reported as the averages of at least two independent determinations; standard deviations are within ±25–50% of IC<sub>50</sub> values. For assay detail, see</p></div><span class="NLM_contrib-group">Bell, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallicchio, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beshore, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buser, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culberson, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davide, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis-Hutchings, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbrook, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homnick, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassahun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koblan, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohl, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobell, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. J.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omer, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. M.</span><span> </span><span class="NLM_article-title">Design and biological activity of (S)-4-{[1-(3-chlorobenzyl-2-oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethylbenzonitrile, a 3-Aminopyrrolidine farnesyltransferase inhibitor with excellent cell potency</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">2933</span><span class="NLM_x">–</span> <span class="NLM_lpage">2949</span><div class="note"><p class="first last">and references therein</p></div><span class="refDoi"> DOI: 10.1021/jm010156p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010156p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=2933-2949&author=I.+M.+Bellauthor=S.+N.+Gallicchioauthor=M.+Abramsauthor=D.+C.+Beshoreauthor=C.+A.+Buserauthor=J.+C.+Culbersonauthor=J.+Davideauthor=M.+Ellis-Hutchingsauthor=C.+Fernandesauthor=J.+B.+Gibbsauthor=S.+L.+Grahamauthor=G.+D.+Hartmanauthor=D.+C.+Heimbrookauthor=C.+F.+Homnickauthor=J.+R.+Huffauthor=K.+Kassahunauthor=K.+S.+Koblanauthor=N.+E.+Kohlauthor=R.+B.+Lobellauthor=J.+J.+Lynchauthor=P.+A.+Millerauthor=C.+A.+Omerauthor=A.+D.+Rodriguesauthor=E.+S.+Walshauthor=T.+M.+Williams&title=Design+and+biological+activity+of+%28S%29-4-%7B%5B1-%283-chlorobenzyl-2-oxopyrrolidin-3-ylamino%5Dmethyl%7Dimidazol-1-ylmethylbenzonitrile%2C+a+3-Aminopyrrolidine+farnesyltransferase+inhibitor+with+excellent+cell+potency&doi=10.1021%2Fjm010156p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm010156p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010156p%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DI.%2BM.%26aulast%3DGallicchio%26aufirst%3DS.%2BN.%26aulast%3DAbrams%26aufirst%3DM.%26aulast%3DBeshore%26aufirst%3DD.%2BC.%26aulast%3DBuser%26aufirst%3DC.%2BA.%26aulast%3DCulberson%26aufirst%3DJ.%2BC.%26aulast%3DDavide%26aufirst%3DJ.%26aulast%3DEllis-Hutchings%26aufirst%3DM.%26aulast%3DFernandes%26aufirst%3DC.%26aulast%3DGibbs%26aufirst%3DJ.%2BB.%26aulast%3DGraham%26aufirst%3DS.%2BL.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DHeimbrook%26aufirst%3DD.%2BC.%26aulast%3DHomnick%26aufirst%3DC.%2BF.%26aulast%3DHuff%26aufirst%3DJ.%2BR.%26aulast%3DKassahun%26aufirst%3DK.%26aulast%3DKoblan%26aufirst%3DK.%2BS.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DLobell%26aufirst%3DR.%2BB.%26aulast%3DLynch%26aufirst%3DJ.%2BJ.%26aulast%3DMiller%26aufirst%3DP.%2BA.%26aulast%3DOmer%26aufirst%3DC.%2BA.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DWalsh%26aufirst%3DE.%2BS.%26aulast%3DWilliams%26aufirst%3DT.%2BM.%26atitle%3DDesign%2520and%2520biological%2520activity%2520of%2520%2528S%2529-4-%257B%255B1-%25283-chlorobenzyl-2-oxopyrrolidin-3-ylamino%255Dmethyl%257Dimidazol-1-ylmethylbenzonitrile%252C%2520a%25203-Aminopyrrolidine%2520farnesyltransferase%2520inhibitor%2520with%2520excellent%2520cell%2520potency%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D2933%26epage%3D2949%26doi%3D10.1021%2Fjm010156p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Redfern, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palethorpe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegl, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strang, I</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallis, R.</span><span> </span><span class="NLM_article-title">Relationship between preclinical cardiac electrophysiology, clinical QT interval prolongation and Torsade de Pontes for a broad range of drugs: evidence for provisional safety margin in drug development</span> <span class="citation_source-journal">Cardiovasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span><span class="refDoi"> DOI: 10.1016/S0008-6363(02)00846-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1016%2FS0008-6363%2802%2900846-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=32-45&author=W.+S.+Redfernauthor=L.+Carlssonauthor=A.+S.+Davisauthor=W.+G.+Lynchauthor=I.+MacKenzieauthor=S.+Palethorpeauthor=P.+Sieglauthor=I+Strangauthor=A.+Sullivanauthor=R.+Wallis&title=Relationship+between+preclinical+cardiac+electrophysiology%2C+clinical+QT+interval+prolongation+and+Torsade+de+Pontes+for+a+broad+range+of+drugs%3A+evidence+for+provisional+safety+margin+in+drug+development&doi=10.1016%2FS0008-6363%2802%2900846-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1016%2FS0008-6363%2802%2900846-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6363%252802%252900846-5%26sid%3Dliteratum%253Aachs%26aulast%3DRedfern%26aufirst%3DW.%2BS.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DA.%2BS.%26aulast%3DLynch%26aufirst%3DW.%2BG.%26aulast%3DMacKenzie%26aufirst%3DI.%26aulast%3DPalethorpe%26aufirst%3DS.%26aulast%3DSiegl%26aufirst%3DP.%26aulast%3DStrang%26aufirst%3DI%26aulast%3DSullivan%26aufirst%3DA.%26aulast%3DWallis%26aufirst%3DR.%26atitle%3DRelationship%2520between%2520preclinical%2520cardiac%2520electrophysiology%252C%2520clinical%2520QT%2520interval%2520prolongation%2520and%2520Torsade%2520de%2520Pontes%2520for%2520a%2520broad%2520range%2520of%2520drugs%253A%2520evidence%2520for%2520provisional%2520safety%2520margin%2520in%2520drug%2520development%26jtitle%3DCardiovasc.%2520Res.%26date%3D2003%26volume%3D58%26spage%3D32%26epage%3D45%26doi%3D10.1016%2FS0008-6363%2802%2900846-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Trepakova, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malik, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imredy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penniman, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dech, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salata, J. J.</span><span> </span><span class="NLM_article-title">Application of PatchXpress planar patch clamp technology to the screening of new drug candidates for cardiac KCNQ1/KCNE1 (I Ks) activity</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">627</span><span class="refDoi"> DOI: 10.1089/adt.2007.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1089%2Fadt.2007.091" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=617-627&author=E.+S.+Trepakovaauthor=M.+G.+Malikauthor=J.+P.+Imredyauthor=J.+R.+Pennimanauthor=S.+J.+Dechauthor=J.+J.+Salata&title=Application+of+PatchXpress+planar+patch+clamp+technology+to+the+screening+of+new+drug+candidates+for+cardiac+KCNQ1%2FKCNE1+%28I+Ks%29+activity&doi=10.1089%2Fadt.2007.091"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1089%2Fadt.2007.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2007.091%26sid%3Dliteratum%253Aachs%26aulast%3DTrepakova%26aufirst%3DE.%2BS.%26aulast%3DMalik%26aufirst%3DM.%2BG.%26aulast%3DImredy%26aufirst%3DJ.%2BP.%26aulast%3DPenniman%26aufirst%3DJ.%2BR.%26aulast%3DDech%26aufirst%3DS.%2BJ.%26aulast%3DSalata%26aufirst%3DJ.%2BJ.%26atitle%3DApplication%2520of%2520PatchXpress%2520planar%2520patch%2520clamp%2520technology%2520to%2520the%2520screening%2520of%2520new%2520drug%2520candidates%2520for%2520cardiac%2520KCNQ1%252FKCNE1%2520%2528I%2520Ks%2529%2520activity%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2007%26volume%3D5%26spage%3D617%26epage%3D627%26doi%3D10.1089%2Fadt.2007.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Morissette, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepakova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imredy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagrutta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaves, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoagland, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoe, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zrada, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travis, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zingaro, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerenser, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedrichs, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salata, J. J.</span><span> </span><span class="NLM_article-title">The anesthetized guinea pig: an effective early cardiovascular derisking and lead optimization model</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">149</span><span class="refDoi"> DOI: 10.1016/j.vascn.2013.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1016%2Fj.vascn.2013.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=23649000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFKkt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=137-149&author=P.+Morissetteauthor=M.+Nishidaauthor=E.+Trepakovaauthor=J.+Imredyauthor=A.+Lagruttaauthor=A.+Chavesauthor=K.+Hoaglandauthor=C.+L.+Hoeauthor=M.+M.+Zradaauthor=J.+J.+Travisauthor=G.+J.+Zingaroauthor=P.+Gerenserauthor=G.+Friedrichsauthor=J.+J.+Salata&title=The+anesthetized+guinea+pig%3A+an+effective+early+cardiovascular+derisking+and+lead+optimization+model&doi=10.1016%2Fj.vascn.2013.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">The anesthetized guinea pig: An effective early cardiovascular derisking and lead optimization model</span></div><div class="casAuthors">Morissette, Pierre; Nishida, Masahiro; Trepakova, Elena; Imredy, John; Lagrutta, Armando; Chaves, Alysia; Hoagland, Kimberly; Hoe, Chao-Min Lei; Zrada, Matthew M.; Travis, Jeffrey J.; Zingaro, Gloria J.; Gerenser, Pamela; Friedrichs, Greg; Salata, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-149</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In recent years, the anesthetized guinea pig was used increasingly to evaluate the cardiovascular effects of drug-candidate mols. during lead optimization prior to conducting longer, more resource intensive safety pharmacol. and toxicol. studies.  The aim of these studies was to evaluate the correlations between pharmacol.-induced ECG changes in the anesthetized cardiovascular guinea pig (CVGP) with ECG changes in conscious non-rodent telemetry models, human clin. studies, and effects on key cardiac ion channels.  We compared the effects of 38 agents on ion channel inhibition to their ECG effects in the CVGP.  26 Of these agents were also evaluated in non-rodent telemetry and compared to the results in the CVGP.  The CVGP was highly sensitive for detecting QTc, PR, and QRS interval prolongation mediated by inhibition of hERG, hCav1.2 and hNav1.5, resp.  There were robust correlations between ion channel inhibitory potencies and the free blood plasma concns. (Cu) producing prolongation of the QTc, PR, or QRS interval.  Further evaluation showed that ECG changes in the CVGP were predictive of their effects on the QTc, PR, and QRS intervals in non-rodent telemetry models with 92%, 92%, and 100% accuracy, resp.  The CVGP proved to be 100% specific and 88%, 75%, and 100% sensitive for QTc, PR, and QRS interval prolongation, resp.  Similarly, the Cu that prolonged the QTc, PR, and QRS in CVGP and humans correlated well.  The CVGP is a sensitive model for assessing QTc, PR, and QRS prolongation elicited by effects on hERG, hCav1.2, and hNav1.5, resp.  ECG changes in the CVGP are predictive of changes in non-rodent telemetry models and in humans (QTc).  ECG parameters can be reliably evaluated with the CVGP model which increases the efficiency of CV derisking.  Importantly, the design and implementation of this model is consistent with the "3Rs" for animal research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk3tOc0LoFCbVg90H21EOLACvtfcHk0ljSiRtEMIt5QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFKkt74%253D&md5=ad6704867172f645536eca06fbe40080</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2013.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2013.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DMorissette%26aufirst%3DP.%26aulast%3DNishida%26aufirst%3DM.%26aulast%3DTrepakova%26aufirst%3DE.%26aulast%3DImredy%26aufirst%3DJ.%26aulast%3DLagrutta%26aufirst%3DA.%26aulast%3DChaves%26aufirst%3DA.%26aulast%3DHoagland%26aufirst%3DK.%26aulast%3DHoe%26aufirst%3DC.%2BL.%26aulast%3DZrada%26aufirst%3DM.%2BM.%26aulast%3DTravis%26aufirst%3DJ.%2BJ.%26aulast%3DZingaro%26aufirst%3DG.%2BJ.%26aulast%3DGerenser%26aufirst%3DP.%26aulast%3DFriedrichs%26aufirst%3DG.%26aulast%3DSalata%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520anesthetized%2520guinea%2520pig%253A%2520an%2520effective%2520early%2520cardiovascular%2520derisking%2520and%2520lead%2520optimization%2520model%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2013%26volume%3D68%26spage%3D137%26epage%3D149%26doi%3D10.1016%2Fj.vascn.2013.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fermini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossa, A. A.</span><span> </span><span class="NLM_article-title">The impact of drug-induced QT interval prolongation on drug discovery and development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span><span class="refDoi"> DOI: 10.1038/nrd1108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1038%2Fnrd1108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=439-447&author=B.+Ferminiauthor=A.+A.+Fossa&title=The+impact+of+drug-induced+QT+interval+prolongation+on+drug+discovery+and+development&doi=10.1038%2Fnrd1108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1038%2Fnrd1108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1108%26sid%3Dliteratum%253Aachs%26aulast%3DFermini%26aufirst%3DB.%26aulast%3DFossa%26aufirst%3DA.%2BA.%26atitle%3DThe%2520impact%2520of%2520drug-induced%2520QT%2520interval%2520prolongation%2520on%2520drug%2520discovery%2520and%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D439%26epage%3D447%26doi%3D10.1038%2Fnrd1108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Roden, D. M.</span><span> </span><span class="NLM_article-title">Drug-induced prolongation of the QT interval</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">1013</span><span class="NLM_x">–</span> <span class="NLM_lpage">1022</span><span class="refDoi"> DOI: 10.1056/NEJMra032426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1056%2FNEJMra032426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=14999113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFGjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=1013-1022&author=D.+M.+Roden&title=Drug-induced+prolongation+of+the+QT+interval&doi=10.1056%2FNEJMra032426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced prolongation of the QT interval</span></div><div class="casAuthors">Roden, Dan M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1013-1022</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA8PoMXlMg57Vg90H21EOLACvtfcHk0ljSiRtEMIt5QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFGjs7Y%253D&md5=a020a545700649d9914ed8dc61910244</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1056%2FNEJMra032426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra032426%26sid%3Dliteratum%253Aachs%26aulast%3DRoden%26aufirst%3DD.%2BM.%26atitle%3DDrug-induced%2520prolongation%2520of%2520the%2520QT%2520interval%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D1013%26epage%3D1022%26doi%3D10.1056%2FNEJMra032426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poluzzi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span> </span><span class="NLM_article-title">Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3844</span><span class="NLM_x">–</span> <span class="NLM_lpage">3853</span><span class="refDoi"> DOI: 10.1021/jm0208875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0208875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFalsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3844-3853&author=A.+Cavalliauthor=E.+Poluzziauthor=F.+De+Pontiauthor=M.+Recanatini&title=Toward+a+pharmacophore+for+drugs+inducing+the+long+QT+syndrome%3A+insights+from+a+CoMFA+study+of+HERG+K%2B+channel+blockers&doi=10.1021%2Fjm0208875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers</span></div><div class="casAuthors">Cavalli, Andrea; Poluzzi, Elisabetta; De Ponti, Fabrizio; Recanatini, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3844-3853</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we present a pharmacophore for QT-prolonging drugs, along with a 3D QSAR (CoMFA) study for a series of very structurally variegate HERG K+ channel blockers.  The blockade of HERG K+ channels is one of the most important mol. mechanisms through which QT-prolonging drugs increase cardiac action potential duration.  Since QT prolongation is one of the most undesirable side effects of drugs, we first tried to identify the min. set of mol. features responsible for this action and then we attempted to develop a quant. model correlating the 3D stereoelectronic characteristics of the mols. with their HERG blocking potency.  Having considered an initial set of 31 QT-prolonging drugs for which the HERG K+ channel blocking activity was measured on mammalian transfected cells, we started the construction of a theor. screening tool able to predict whether a new mol. can interact with the HERG channel and eventually induce the long QT syndrome.  This in silico tool might be useful in the design of new drug candidates devoid of the physicochem. features likely to cause the above-mentioned side effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7WFt3kf6ZVLVg90H21EOLACvtfcHk0lj6vURIptfJtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFalsrk%253D&md5=5e980476ccc9a8a6244aaab230eeb701</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1021%2Fjm0208875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0208875%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26aulast%3DRecanatini%26aufirst%3DM.%26atitle%3DToward%2520a%2520pharmacophore%2520for%2520drugs%2520inducing%2520the%2520long%2520QT%2520syndrome%253A%2520insights%2520from%2520a%2520CoMFA%2520study%2520of%2520HERG%2520K%252B%2520channel%2520blockers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3844%26epage%3D3853%26doi%3D10.1021%2Fjm0208875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Jamieson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moir, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G.</span><span> </span><span class="NLM_article-title">Medicinal Chemistry of hERG optimizations: highlights and hang-ups</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5029</span><span class="NLM_x">–</span> <span class="NLM_lpage">5046</span><span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+Chemistry+of+hERG+optimizations%3A+highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lj6vURIptfJtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520Chemistry%2520of%2520hERG%2520optimizations%253A%2520highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groom, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alex, A.</span><span> </span><span class="NLM_article-title">Ligand efficiency: A useful metric for lead selection</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">430</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1016/S1359-6446(04)03069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+efficiency%3A+A+useful+metric+for+lead+selection&doi=10.1016%2FS1359-6446%2804%2903069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2eZTJUrY5w99B7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520efficiency%253A%2520A%2520useful%2520metric%2520for%2520lead%2520selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D430%26epage%3D431%26doi%3D10.1016%2FS1359-6446%2804%2903069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Abad-Zapatero, C.</span><span> </span><span class="NLM_article-title">Ligand efficiency indices for effective drug discovery</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">488</span><span class="refDoi"> DOI: 10.1517/17460441.2.4.469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1517%2F17460441.2.4.469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=23484756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVCqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=469-488&author=C.+Abad-Zapatero&title=Ligand+efficiency+indices+for+effective+drug+discovery&doi=10.1517%2F17460441.2.4.469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency indices for effective drug discovery</span></div><div class="casAuthors">Abad-Zapatero, Cele</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-488</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Successful drug discovery requires the optimization of a large no. of variables ranging from strictly physicochem. parameters such as mol. wt. to more complex parameters related to toxicity and bioavailability.  Presently, structure-based methodologies influence many aspects of the drug discovery process from lead discovery to the final preclin. characterization.  However, crit. biol. issues along the path to the market have diminished the impact and power of this methodol.  The physicochem. properties of the novel chem. entities designed and guided by structural methods have become the subject of intense scrutiny from lead discovery to drug candidate.  The idea of ligand efficiency (binding energy/non-hydrogen atoms) has recently emerged as a useful guide to optimize fragment and lead selection in the discovery process.  More generalized concepts of ligand efficiency, related to efficiency per dalton and per unit of polar surface area, have also been introduced and will be discussed in the broader context.  Preliminary results and trends obtained using ligand efficiencies as guides are reviewed and their future application to guide drug discovery will be discussed, as well as their integration into the structure-based drug design methods to make them more effective and numerically robust.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmKduo41JcS7Vg90H21EOLACvtfcHk0lg3hb2nQ98qsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVCqsL4%253D&md5=a1682fbc4545d8eab3a44417c0e88869</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1517%2F17460441.2.4.469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2.4.469%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26atitle%3DLigand%2520efficiency%2520indices%2520for%2520effective%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26spage%3D469%26epage%3D488%26doi%3D10.1517%2F17460441.2.4.469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1420</span><span class="NLM_x">–</span> <span class="NLM_lpage">1456</span><span class="refDoi"> DOI: 10.1021/tx200211v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200211v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlCitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1420-1456&author=N.+A.+Meanwell&title=Improving+drug+candidates+by+design%3A+a+focus+on+physicochemical+properties+as+a+means+of+improving+compound+disposition+and+safety&doi=10.1021%2Ftx200211v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1420-1456</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of small mol. drug candidates from the discovery phase to a marketed product continues to be a challenging enterprise with very low success rates that have fostered the perception of poor productivity by the pharmaceutical industry.  Although there have been significant advances in preclin. profiling that have improved compd. triaging and altered the underlying reasons for compd. attrition, the failure rates have not appreciably changed.  As part of an effort to more deeply understand the reasons for candidate failure, there has been considerable interest in analyzing the physicochem. properties of marketed drugs for the purpose of comparing with drugs in discovery and development as a means capturing recent trends in drug design.  The scenario that has emerged is one in which contemporary drug discovery is thought to be focused too heavily on advancing candidates with profiles that are most easily satisfied by mols. with increased mol. wt. and higher overall lipophilicity.  The preponderance of mols. expressing these properties is frequently a function of increased arom. ring count when compared with that of the drugs launched in the latter half of the 20th century and may reflect a preoccupation with maximizing target affinity rather than taking a more holistic approach to drug design.  These attributes not only present challenges for formulation and absorption but also may influence the manifestation of toxicity during development.  By providing some definition around the optimal physicochem. properties assocd. with marketed drugs, guidelines for drug design have been developed that are based largely on calcd. parameters and which may readily be applied by medicinal chemists as an aid to understanding candidate quality.  The physicochem. properties of a mol. that are consistent with the potential for good oral absorption were initially defined by Lipinski, with addnl. insights allowing further refinement, while deeper analyses have explored the correlation with metabolic stability and toxicity.  These insights have been augmented by careful analyses of physicochem. aspects of drug-target interactions, with thermodn. profiling indicating that the signature of best-in-class drugs is a dependence on enthalpy to drive binding energetics rather than entropy, which is dependent on lipophilicity.  Optimization of the entropic contribution to the binding energy of a ligand to its target is generally much easier than refining the enthalpic element.  Consequently, in the absence of a fundamental understanding of the thermodn. complexion of an interaction, the design of mols. with increased lipophilicity becomes almost inevitable.  The application of ligand efficiency, a measure of affinity per heavy atom, group efficiency, which assesses affinity in the context of structural changes, and lipophilic ligand efficiency, which relates potency to lipophilicity, offer less sophisticated but practically useful anal. algorithms to assess the quality of drug-target interactions.  These parameters are readily calcd. and can be applied to lead optimization programs in a fashion that helps to maximize potency while minimizing the kind of lipophilic burden that has been dubbed "mol. obesity".  Several recently described lead optimization campaigns provide illustrative, informative, and productive examples of the effect of paying close attention to carefully controlling physicochem. properties by monitoring ligand efficiency and lipophilic ligand efficiency.  However, to be successful during the lead optimization phase, drug candidate identification programs will need to adopt a holistic approach that integrates multiple parameters, many of which will have unique dependencies on both the drug target and the specific chemotype under prosecution.  Nevertheless, there are many important drug targets that necessitate working in space beyond that which has been defined by the retrospective analyses of marketed drugs and which will require adaptation of some of the guideposts that are useful in directing lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQrUfIwZiIR7Vg90H21EOLACvtfcHk0lg3hb2nQ98qsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlCitLs%253D&md5=9ddcf6dc81bf8ab0441df5037979ff4e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Ftx200211v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200211v%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DImproving%2520drug%2520candidates%2520by%2520design%253A%2520a%2520focus%2520on%2520physicochemical%2520properties%2520as%2520a%2520means%2520of%2520improving%2520compound%2520disposition%2520and%2520safety%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1420%26epage%3D1456%26doi%3D10.1021%2Ftx200211v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span><span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision+making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision%2520making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span> </span><span class="NLM_article-title">Role of physicochemical properties and ligand lipophilicity in addressing drug safety risks</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span><span class="refDoi"> DOI: 10.1016/S0065-7743(10)45023-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1016%2FS0065-7743%2810%2945023-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=381-391&author=M.+P.+Edwardsauthor=D.+A.+Price&title=Role+of+physicochemical+properties+and+ligand+lipophilicity+in+addressing+drug+safety+risks&doi=10.1016%2FS0065-7743%2810%2945023-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2810%2945023-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252810%252945023-X%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DRole%2520of%2520physicochemical%2520properties%2520and%2520ligand%2520lipophilicity%2520in%2520addressing%2520drug%2520safety%2520risks%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D381%26epage%3D391%26doi%3D10.1016%2FS0065-7743%2810%2945023-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tarcsay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyiri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keseru, G. M.</span><span> </span><span class="NLM_article-title">Impact of lipophilic efficiency on compound quality</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1252</span><span class="NLM_x">–</span> <span class="NLM_lpage">1260</span><span class="refDoi"> DOI: 10.1021/jm201388p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201388p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVKjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1252-1260&author=A.+Tarcsayauthor=K.+Nyiriauthor=G.+M.+Keseru&title=Impact+of+lipophilic+efficiency+on+compound+quality&doi=10.1021%2Fjm201388p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19cR"><div class="casContent"><span class="casTitleNuber">19c</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Lipophilic Efficiency on Compound Quality</span></div><div class="casAuthors">Tarcsay, Akos; Nyiri, Kinga; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1252-1260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lipophilic efficiency indexes such as LLE and LELP were suggested to support balanced optimization of potency and ADMET profile.  Here we investigated the performance of LLE and LELP on multiple data sets representing different stages of drug discovery including fragment and HTS hits and leads, development candidates, phase II compds., and launched drugs.  Analyzing their impact on ADME and safety properties and binding thermodn., we found that both LLE and LELP help identifying better quality compds.  LLE is sensible for the development stages but does not prefer fragment-type hits, while LELP has an advantage for this class of compds. and discriminates preferred starting points effectively.  Both LLE and LELP have significant impact on ADME and safety profiles; however, LELP outperforms LLE in risk assessment at least on the present data set.  On the basis of the results reported here, monitoring lipophilic efficiency metrics could contribute significantly to compd. quality and might improve the output of medicinal chem. programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxB8xs6-5DL7Vg90H21EOLACvtfcHk0lhe8Y20hERMvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVKjsQ%253D%253D&md5=2536abef781f52806013016971c78bcb</span></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1021%2Fjm201388p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201388p%26sid%3Dliteratum%253Aachs%26aulast%3DTarcsay%26aufirst%3DA.%26aulast%3DNyiri%26aufirst%3DK.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26atitle%3DImpact%2520of%2520lipophilic%2520efficiency%2520on%2520compound%2520quality%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1252%26epage%3D1260%26doi%3D10.1021%2Fjm201388p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Anderson, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tundel, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Monodentate phosphines provide highly active catalysts for Pd-catalyzed C-N bond-forming reactions of heteroaromatic halides/amines and (H)N-heterocycles</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">6523</span><span class="NLM_x">–</span> <span class="NLM_lpage">6527</span><span class="refDoi"> DOI: 10.1002/anie.200601612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1002%2Fanie.200601612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWgsrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=6523-6527&author=K.+W.+Andersonauthor=R.+E.+Tundelauthor=T.+Ikawaauthor=R.+A.+Altmanauthor=S.+L.+Buchwald&title=Monodentate+phosphines+provide+highly+active+catalysts+for+Pd-catalyzed+C-N+bond-forming+reactions+of+heteroaromatic+halides%2Famines+and+%28H%29N-heterocycles&doi=10.1002%2Fanie.200601612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Monodentate phosphines provide highly active catalysts for Pd-catalyzed C-N bond-forming reactions of heteroaromatic halides/amines and (H)N-heterocycles</span></div><div class="casAuthors">Anderson, Kevin W.; Tundel, Rachel E.; Ikawa, Takashi; Altman, Ryan A.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">6523-6527</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Highly reactive catalysts based on palladium and dialkylbiarylphosphino ligands provide unprecedented reactivity and selectivity in C-N bond-forming processes.  The bulky monophosphine catalyst system Pd2(dba)3/I is effective for the reaction of aryl/heteroaryl halides bearing primary amides and 2-aminoheterocycles, thus showing that monodentate phosphines are viable alternatives to, and sometimes superior to, chelating ligands.  E.g., amination of 3-chlorobenzamide by morpholine gave 81% II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwitHXua7pPbVg90H21EOLACvtfcHk0lhe8Y20hERMvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWgsrnP&md5=5958e76b262517af3527cea57573210a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fanie.200601612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200601612%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DK.%2BW.%26aulast%3DTundel%26aufirst%3DR.%2BE.%26aulast%3DIkawa%26aufirst%3DT.%26aulast%3DAltman%26aufirst%3DR.%2BA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DMonodentate%2520phosphines%2520provide%2520highly%2520active%2520catalysts%2520for%2520Pd-catalyzed%2520C-N%2520bond-forming%2520reactions%2520of%2520heteroaromatic%2520halides%252Famines%2520and%2520%2528H%2529N-heterocycles%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2006%26volume%3D45%26spage%3D6523%26epage%3D6527%26doi%3D10.1002%2Fanie.200601612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="note"><p class="first last"><a class="ref internalNav" href="#fig6" aria-label="Figures 6">Figures 6</a> and <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a> were generated using</p></div><div class="NLM_citation" id="cit21"><span>Tibco Spotfire 7.0.1, <a href="http://spotfire.tibco.com" class="extLink">spotfire.tibco.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Tibco+Spotfire+7.0.1%2C+spotfire.tibco.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">van de Waterbeemd, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. K.</span><span> </span><span class="NLM_article-title">Property-based design: optimization of drug absorption and pharmacokinetics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1313</span><span class="NLM_x">–</span> <span class="NLM_lpage">1333</span><span class="refDoi"> DOI: 10.1021/jm000407e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000407e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD3MXit1Whu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=1313-1333&author=H.+van+de+Waterbeemdauthor=D.+A.+Smithauthor=K.+Beaumontauthor=D.+K.+Walker&title=Property-based+design%3A+optimization+of+drug+absorption+and+pharmacokinetics&doi=10.1021%2Fjm000407e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Property-based design: optimization of drug absorption and pharmacokinetics</span></div><div class="casAuthors">van de Waterbeemd, Han; Smith, Dennis A.; Beaumont, Kevin; Walker, Don K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1313-1333</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 223 refs.  The authors discuss some aspects of the properties of biol. barriers.  In different sections the estn. of drug absorption via important barriers including gastrointestinal tract, blood-brain barrier, and skin are reviewed.  Various approaches for the measurement and computation of physicochem. and mol. properties currently used in the optimization of absorption as well as the use of physicochem. properties in the design of optimal pharmacokinetic profiles are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaQwsmoX0-mbVg90H21EOLACvtfcHk0lhy_xi66KcozA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXit1Whu7c%253D&md5=3183baedca70020f4ce27f306ba0997e</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1021%2Fjm000407e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000407e%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bde%2BWaterbeemd%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DD.%2BK.%26atitle%3DProperty-based%2520design%253A%2520optimization%2520of%2520drug%2520absorption%2520and%2520pharmacokinetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D1313%26epage%3D1333%26doi%3D10.1021%2Fjm000407e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">van de Waterbeemd, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B. C.</span><span> </span><span class="NLM_article-title">Lipophilicity in pk design: methyl, ethyl, futile</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span><span class="refDoi"> DOI: 10.1023/A:1008192010023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1023%2FA%3A1008192010023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2001&pages=273-286&author=H.+van+de+Waterbeemdauthor=D.+A.+Smithauthor=B.+C.+Jones&title=Lipophilicity+in+pk+design%3A+methyl%2C+ethyl%2C+futile&doi=10.1023%2FA%3A1008192010023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1023%2FA%3A1008192010023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1008192010023%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bde%2BWaterbeemd%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DJones%26aufirst%3DB.%2BC.%26atitle%3DLipophilicity%2520in%2520pk%2520design%253A%2520methyl%252C%2520ethyl%252C%2520futile%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2001%26volume%3D15%26spage%3D273%26epage%3D286%26doi%3D10.1023%2FA%3A1008192010023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. M.</span><span> </span><span class="NLM_article-title">Time-related differences in the physical property profiles of oral drugs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6338</span><span class="NLM_x">–</span> <span class="NLM_lpage">6348</span><span class="refDoi"> DOI: 10.1021/jm049717d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049717d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpt1Sksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6338-6348&author=P.+D.+Leesonauthor=A.+M.+Davis&title=Time-related+differences+in+the+physical+property+profiles+of+oral+drugs&doi=10.1021%2Fjm049717d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22cR"><div class="casContent"><span class="casTitleNuber">22c</span><div class="casTitle"><span class="NLM_cas:atitle">Time-Related Differences in the Physical Property Profiles of Oral Drugs</span></div><div class="casAuthors">Leeson, Paul D.; Davis, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">6338-6348</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Comparisons of the calcd. physicochem. properties of oral drugs launched prior to 1983 (864 drugs) and between 1983 and 2002 (329 drugs) show that mean values of lipophilicity, percent polar surface area and H-bond donor count are the same, suggesting that these are the most important oral drug-like phys. properties.  In contrast, mean values of mol. wt. and the nos. of O + N atoms, H-bond acceptors, and rotatable bonds and rings have increased in 1983-2002 drugs (by 13-29%).  Anal. of the 1983-2002 oral drugs by therapy area shows that anti-infectives and nervous system drugs have the most extreme phys. property profiles.  Cardiovascular drugs show increasing mol. wt. with year of publication, primarily a consequence of focusing on clin. proven mechanisms, with limited chem. diversity.  Drug classes other than anti-infectives show comparable distributions of lipophilicity, suggesting that this property in oral drugs is important irresp. of the drug's target.  The results suggest that the balance between polar and nonpolar drug properties is an important, unchanging feature of oral drug mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtNkiWH6Bl6bVg90H21EOLACvtfcHk0lhy_xi66KcozA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpt1Sksbg%253D&md5=edd5cceab1ccfe3542cb4df180e3c160</span></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1021%2Fjm049717d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049717d%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DDavis%26aufirst%3DA.%2BM.%26atitle%3DTime-related%2520differences%2520in%2520the%2520physical%2520property%2520profiles%2520of%2520oral%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6338%26epage%3D6348%26doi%3D10.1021%2Fjm049717d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit22d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Lazerwith, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahador, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canales, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerffler, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matles, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mertzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morganelli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickley, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tessler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirunagari, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, W. J.</span><span> </span><span class="NLM_article-title">Optimization of pharmacokinetics through manipulation of physicochemical properties in a series of HCV inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">715</span><span class="NLM_x">–</span> <span class="NLM_lpage">719</span><span class="refDoi"> DOI: 10.1021/ml200163b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200163b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVyhu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=715-719&author=S.+E.+Lazerwithauthor=G.+Bahadorauthor=E.+Canalesauthor=G.+Chengauthor=L.+Chongauthor=M.+O.+Clarkeauthor=E.+Doerfflerauthor=E.+J.+Eisenbergauthor=J.+Hayesauthor=B.+Luauthor=Q.+Liuauthor=M.+Matlesauthor=M.+Mertzmanauthor=M.+L.+Mitchellauthor=P.+Morganelliauthor=B.+P.+Murrayauthor=M.+Robinsonauthor=R.+G.+Strickleyauthor=M.+Tesslerauthor=N.+Tirunagariauthor=J.+Wangauthor=Y.+Wangauthor=J.+R.+Zhangauthor=X.+Zhengauthor=W.+Zhongauthor=W.+J.+Watkins&title=Optimization+of+pharmacokinetics+through+manipulation+of+physicochemical+properties+in+a+series+of+HCV+inhibitors&doi=10.1021%2Fml200163b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22dR"><div class="casContent"><span class="casTitleNuber">22d</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors</span></div><div class="casAuthors">Lazerwith, Scott E.; Bahador, Gina; Canales, Eda; Cheng, Guo-Feng; Chong, Lee; Clarke, Michael O.; Doerffler, Edward; Eisenberg, Eugene J.; Hayes, Jaclyn; Lu, Bing; Liu, Qi; Matles, Mike; Mertzman, Michael; Mitchell, Michael L.; Morganelli, Philip; Murray, Bernard P.; Robinson, Margaret; Strickley, Robert G.; Tessler, Megan; Tirunagari, Neeraj; Wang, Jian-Hong; Wang, Yu-Jin; Zhang, Jennifer R.; Zheng, Xu-Bin; Zhong, Wei-Dong; Watkins, William J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">715-719</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of HCV replication inhibitors based on a pyrido[3,2-d]pyrimidine core were optimized for pharmacokinetics (PK) in rats.  Several assocns. between physicochem. properties and PK were identified and exploited to guide the design of compds.  In addn., a simple new metric that may aid in the prediction of bioavailability for compds. with higher polar surface area is described (3*HBD-cLogP).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9QmQ7Imm6ALVg90H21EOLACvtfcHk0lgJZhFR_sd_vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVyhu7w%253D&md5=a9aee94fa770dc39e9180c79e1cd1ef8</span></div><a href="/servlet/linkout?suffix=cit22d&amp;dbid=16384&amp;doi=10.1021%2Fml200163b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200163b%26sid%3Dliteratum%253Aachs%26aulast%3DLazerwith%26aufirst%3DS.%2BE.%26aulast%3DBahador%26aufirst%3DG.%26aulast%3DCanales%26aufirst%3DE.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DChong%26aufirst%3DL.%26aulast%3DClarke%26aufirst%3DM.%2BO.%26aulast%3DDoerffler%26aufirst%3DE.%26aulast%3DEisenberg%26aufirst%3DE.%2BJ.%26aulast%3DHayes%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMatles%26aufirst%3DM.%26aulast%3DMertzman%26aufirst%3DM.%26aulast%3DMitchell%26aufirst%3DM.%2BL.%26aulast%3DMorganelli%26aufirst%3DP.%26aulast%3DMurray%26aufirst%3DB.%2BP.%26aulast%3DRobinson%26aufirst%3DM.%26aulast%3DStrickley%26aufirst%3DR.%2BG.%26aulast%3DTessler%26aufirst%3DM.%26aulast%3DTirunagari%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%2BR.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DW.%26aulast%3DWatkins%26aufirst%3DW.%2BJ.%26atitle%3DOptimization%2520of%2520pharmacokinetics%2520through%2520manipulation%2520of%2520physicochemical%2520properties%2520in%2520a%2520series%2520of%2520HCV%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D715%26epage%3D719%26doi%3D10.1021%2Fml200163b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Fleming, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravikumar, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shook, B. C.</span><span> </span><span class="NLM_article-title">Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7902</span><span class="NLM_x">–</span> <span class="NLM_lpage">7917</span><span class="refDoi"> DOI: 10.1021/jm100762r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100762r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2kurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7902-7917&author=F.+F.+Flemingauthor=L.+Yaoauthor=P.+C.+Ravikumarauthor=L.+Funkauthor=B.+C.+Shook&title=Nitrile-containing+pharmaceuticals%3A+efficacious+roles+of+the+nitrile+pharmacophore&doi=10.1021%2Fjm100762r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore</span></div><div class="casAuthors">Fleming, Fraser F.; Yao, Lihua; Ravikumar, P. C.; Funk, Lee; Shook, Brian C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7902-7917</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review is structured according to the nature of the nitrile-bearing substituent.  As the no. of nitrile-contg. drug leads is vast, the review has focused on launched nitrile-contg. pharmaceuticals and currently active clin. candidates.  Most nitrile-contg. pharmaceuticals are aroms. with aliph.-, alkene-, and nitrogen-bearing nitriles being progressively less frequent.  Within each class, the bioactive nitriles are collated according to common structural elements and mode of action.  The hope is that this survey will allow greater deployment of this versatile functionality within drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR6kPPdWVuvLVg90H21EOLACvtfcHk0lgJZhFR_sd_vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2kurvP&md5=040bbaebd9e8c9999d195b9a22221fea</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm100762r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100762r%26sid%3Dliteratum%253Aachs%26aulast%3DFleming%26aufirst%3DF.%2BF.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DRavikumar%26aufirst%3DP.%2BC.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DShook%26aufirst%3DB.%2BC.%26atitle%3DNitrile-containing%2520pharmaceuticals%253A%2520efficacious%2520roles%2520of%2520the%2520nitrile%2520pharmacophore%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7902%26epage%3D7917%26doi%3D10.1021%2Fjm100762r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="note"><p class="first last">Selectivity folds were calculated based on estimated IC<sub>50</sub>’s from 3 point titrations (1, 100, and 1000 nM) and the internal JAK1 potencies; 265 kinases were screened at a Invitrogen at their respective <i>K</i><sub>M</sub>. For the full list of kinases, see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01135/suppl_file/jm7b01135_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Cheng, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eksterowicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geuns-Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span> </span><span class="NLM_article-title">Analysis of kinase inhibitor selectivity using a thermodynamics-based partition index</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4502</span><span class="NLM_x">–</span> <span class="NLM_lpage">4510</span><span class="refDoi"> DOI: 10.1021/jm100301x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100301x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvVOisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4502-4510&author=A.+C.+Chengauthor=J.+Eksterowiczauthor=S.+Geuns-Meyerauthor=Y.+Sun&title=Analysis+of+kinase+inhibitor+selectivity+using+a+thermodynamics-based+partition+index&doi=10.1021%2Fjm100301x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Kinase Inhibitor Selectivity using a Thermodynamics-Based Partition Index</span></div><div class="casAuthors">Cheng, Alan C.; Eksterowicz, John; Geuns-Meyer, Stephanie; Sun, Yaxiong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4502-4510</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the quest for safe, efficacious kinase inhibitors as drugs, selectivity is often assessed early using kinase profiling panels.  Here we present a selectivity index based on thermodn. principles that can help in anal. of the resulting data.  The "partition" selectivity index is easy to calc. and is applicable in certain situations where other widely used indexes are not.  It is uniquely useful in anal. of small, focused selectivity panel data frequently encountered in medicinal chem. hit-to-lead and lead optimization.  For larger "kinome" panels, the partition index allows assessment of selectivity relative to a kinase or multiple kinases of interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFHFduiUmbgbVg90H21EOLACvtfcHk0lgIvTY2n1OJBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvVOisrk%253D&md5=d50d74d4224ccba3c3ea7bbe72fd22d1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm100301x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100301x%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGeuns-Meyer%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DAnalysis%2520of%2520kinase%2520inhibitor%2520selectivity%2520using%2520a%2520thermodynamics-based%2520partition%2520index%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4502%26epage%3D4510%26doi%3D10.1021%2Fjm100301x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="note"><p class="first last">JAK1 kinase domain at 20 mg/mL was incubated with 1.6 mM adenosine and 3.2 mM DTT for 60 min then crystallized at 4 °C using vapor diffusion. Equal volumes of protein and reservoir were mixed and suspended over a 1 mL reservoir containing 30% w/v poly(ethylene glycol) 6000 and 100 mM MES buffer at pH 6.3. After streak-seeding, crystals appeared within 3 days. Crystals were soaked with 4 mM <b>28</b> for 5 days prior to flash cooling. Synchrotron data were collected at the Canadian Light Source</p></div><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Grochulski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fodje, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labiuk, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, R.</span><span> </span><span class="NLM_article-title">Beamline 08ID-1, the prime beamline of the Canadian Macromolecular Crystallography Facility</span> <span class="citation_source-journal">J. Synchrotron Radiat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">681</span><span class="NLM_x">–</span> <span class="NLM_lpage">684</span><span class="refDoi"> DOI: 10.1107/S0909049511019431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1107%2FS0909049511019431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=21685687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnslOqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=681-684&author=P.+Grochulskiauthor=M.+N.+Fodjeauthor=J.+Gorinauthor=S.+L.+Labiukauthor=R.+Berg&title=Beamline+08ID-1%2C+the+prime+beamline+of+the+Canadian+Macromolecular+Crystallography+Facility&doi=10.1107%2FS0909049511019431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Beamline 08ID-1, the prime beamline of the Canadian Macromolecular Crystallography Facility</span></div><div class="casAuthors">Grochulski, Pawel; Fodje, Michel N.; Gorin, James; Labiuk, Shaunivan L.; Berg, Russ</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Synchrotron Radiation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">681-684</span>CODEN:
                <span class="NLM_cas:coden">JSYRES</span>;
        ISSN:<span class="NLM_cas:issn">0909-0495</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Beamline 08ID-1 is the prime macromol. crystallog. beamline at the Canadian Light Source.  Based on a small-gap in-vacuum undulator, it is designed for challenging projects like small crystals and crystals with large cell dimensions.  Beamline 08ID-1, together with a second bending-magnet beamline, constitute the Canadian Macromol. Crystallog. Facility (CMCF).  This paper presents an overall description of the 08ID-1 beamline, including its specifications, beamline software and recent scientific highlights.  The end-station of the beamline is equipped with a CCD X-ray detector, on-axis crystal visualization system, a single-axis goniometer and a sample automounter allowing remote access to the beamline.  The general user program is guaranteed up to 55% of the useful beam time and is run under a peer-review proposal system.  The CMCF staff provide 'Mail-in' crystallog. service to the users with the highest-scored proposals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmQwWQ_1HgJrVg90H21EOLACvtfcHk0lgIvTY2n1OJBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnslOqurg%253D&md5=cba3bb23196a3b32d03179324a72bf0a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1107%2FS0909049511019431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0909049511019431%26sid%3Dliteratum%253Aachs%26aulast%3DGrochulski%26aufirst%3DP.%26aulast%3DFodje%26aufirst%3DM.%2BN.%26aulast%3DGorin%26aufirst%3DJ.%26aulast%3DLabiuk%26aufirst%3DS.%2BL.%26aulast%3DBerg%26aufirst%3DR.%26atitle%3DBeamline%252008ID-1%252C%2520the%2520prime%2520beamline%2520of%2520the%2520Canadian%2520Macromolecular%2520Crystallography%2520Facility%26jtitle%3DJ.%2520Synchrotron%2520Radiat.%26date%3D2011%26volume%3D18%26spage%3D681%26epage%3D684%26doi%3D10.1107%2FS0909049511019431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">Data collection and refinement details are found in <a href="/doi/suppl/10.1021/acs.jmedchem.7b01135/suppl_file/jm7b01135_si_001.pdf" class="ext-link">Table S2</a>. Coordinates have been deposited with PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WO4">5WO4</a>. <a class="ref internalNav" href="#fig9" aria-label="Figures 9">Figures 9</a> and <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a> were generated using PyMOL (The PyMOL Molecular Graphics System, Schrödinger, LLC).</p></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="note"><p class="first last">JAK2 PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LPB">3LPB</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span>View Contacts, version 2.24, <span class="NLM_publisher-name">Desert Scientific Software</span>, <span class="NLM_publisher-loc">Norwest, Australia</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=View+Contacts%2C+version+2.24%2C+Desert+Scientific+Software%2C+Norwest%2C+Australia."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DView%2520Contacts%26pub%3DDesert%2520Scientific%2520Software" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Courtenay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayan, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosedale, B.</span><span> </span><span class="NLM_article-title">Immunization against heterologous type II collagen induces arthritis in mice. <i>Nature</i></span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">666</span><span class="NLM_x">–</span> <span class="NLM_lpage">668</span><span class="refDoi"> DOI: 10.1038/283666a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1038%2F283666a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1980&pages=666-668&author=J.+S.+Courtenayauthor=M.+J.+Dallmanauthor=A.+D.+Dayanauthor=A.+Martinauthor=B.+Mosedale&title=Immunization+against+heterologous+type+II+collagen+induces+arthritis+in+mice.+Nature&doi=10.1038%2F283666a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2F283666a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F283666a0%26sid%3Dliteratum%253Aachs%26aulast%3DCourtenay%26aufirst%3DJ.%2BS.%26aulast%3DDallman%26aufirst%3DM.%2BJ.%26aulast%3DDayan%26aufirst%3DA.%2BD.%26aulast%3DMartin%26aufirst%3DA.%26aulast%3DMosedale%26aufirst%3DB.%26atitle%3DImmunization%2520against%2520heterologous%2520type%2520II%2520collagen%2520induces%2520arthritis%2520in%2520mice.%2520Nature%26jtitle%3DNature%26date%3D1980%26volume%3D283%26spage%3D666%26epage%3D668%26doi%3D10.1038%2F283666a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="note"><p class="first last"><a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a> was generated using</p></div><div class="NLM_citation" id="cit30"><span>Prism 7, <a href="https://www.graphpad.com/scientific-software/prism/" class="extLink">https://www.graphpad.com/scientific-software/prism/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Prism+7%2C+https%3A%2F%2Fwww.graphpad.com%2Fscientific-software%2Fprism%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b'],'ref3':['cit3'],'ref4':['cit4a','cit4b','cit4c'],'ref5':['cit5'],'ref6':['cit6a','cit6b','cit6c','cit6d','cit6e','cit6f','cit6g','cit6h'],'ref7':['cit7'],'ref8':['cit8'],'ref9':[],'ref10':['cit10a','cit10b','cit10c','cit10d'],'ref11':['cit11a','cit11b'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14a','cit14b','cit14c'],'ref15':['cit15a','cit15b'],'ref16':['cit16a','cit16b'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19a','cit19b','cit19c'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22a','cit22b','cit22c','cit22d'],'ref23':['cit23'],'ref24':[],'ref25':['cit25'],'ref26':['cit26'],'ref27':[],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 8 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Minjian Yang, Bingzhong Tao, Chengjuan Chen, Wenqiang Jia, Shaolei Sun, Tiantai Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Xiaojian Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Machine Learning Models Based on Molecular Fingerprints and an Extreme Gradient Boosting Method Lead to the Discovery of JAK2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (12)
                                     , 5002-5012. <a href="https://doi.org/10.1021/acs.jcim.9b00798" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00798</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00798%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DMachine%252BLearning%252BModels%252BBased%252Bon%252BMolecular%252BFingerprints%252Band%252Ban%252BExtreme%252BGradient%252BBoosting%252BMethod%252BLead%252Bto%252Bthe%252BDiscovery%252Bof%252BJAK2%252BInhibitors%26aulast%3DYang%26aufirst%3DMinjian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15092019%26date%3D04122019%26date%3D20112019%26volume%3D59%26issue%3D12%26spage%3D5002%26epage%3D5012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robert J. Young, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Leeson</span>. </span><span class="cited-content_cbyCitation_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6421-6467. <a href="https://doi.org/10.1021/acs.jmedchem.8b00180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMapping%252Bthe%252BEfficiency%252Band%252BPhysicochemical%252BTrajectories%252Bof%252BSuccessful%252BOptimizations%26aulast%3DYoung%26aufirst%3DRobert%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03022018%26date%3D25042018%26date%3D05042018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Edita  Sarukhanyan</span>, <span class="hlFld-ContribAuthor ">Sergey  Shityakov</span>, <span class="hlFld-ContribAuthor ">Thomas  Dandekar</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Drug Design of Axl Tyrosine Kinase Type I Inhibitors as Promising Candidates Against Cancer. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2020,</strong> <em>7 </em><a href="https://doi.org/10.3389/fchem.2019.00920" title="DOI URL">https://doi.org/10.3389/fchem.2019.00920</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2019.00920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2019.00920%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DRational%252BDrug%252BDesign%252Bof%252BAxl%252BTyrosine%252BKinase%252BType%252BI%252BInhibitors%252Bas%252BPromising%252BCandidates%252BAgainst%252BCancer%26aulast%3DSarukhanyan%26aufirst%3DEdita%26date%3D2020%26date%3D2020%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria Maddalena  Cavalluzzi</span>, <span class="hlFld-ContribAuthor ">Paola  Imbrici</span>, <span class="hlFld-ContribAuthor ">Roberta  Gualdani</span>, <span class="hlFld-ContribAuthor ">Angela  Stefanachi</span>, <span class="hlFld-ContribAuthor ">Giuseppe Felice  Mangiatordi</span>, <span class="hlFld-ContribAuthor ">Giovanni  Lentini</span>, <span class="hlFld-ContribAuthor ">Orazio  Nicolotti</span>. </span><span class="cited-content_cbyCitation_article-title">Human ether-à-go-go-related potassium channel: exploring SAR to improve drug design. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (2)
                                     , 344-366. <a href="https://doi.org/10.1016/j.drudis.2019.11.005" title="DOI URL">https://doi.org/10.1016/j.drudis.2019.11.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2019.11.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2019.11.005%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DHuman%252Bether-%2525C3%2525A0-go-go-related%252Bpotassium%252Bchannel%25253A%252Bexploring%252BSAR%252Bto%252Bimprove%252Bdrug%252Bdesign%26aulast%3DCavalluzzi%26aufirst%3DMaria%2BMaddalena%26date%3D2020%26volume%3D25%26issue%3D2%26spage%3D344%26epage%3D366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Hu</span>, <span class="hlFld-ContribAuthor ">Chengbo  Xu</span>, <span class="hlFld-ContribAuthor ">Chao  Yang</span>, <span class="hlFld-ContribAuthor ">Hongli  Zuo</span>, <span class="hlFld-ContribAuthor ">Chengjuan  Chen</span>, <span class="hlFld-ContribAuthor ">Dan  Zhang</span>, <span class="hlFld-ContribAuthor ">Gaona  Shi</span>, <span class="hlFld-ContribAuthor ">Wenjie  Wang</span>, <span class="hlFld-ContribAuthor ">Jiangong  Shi</span>, <span class="hlFld-ContribAuthor ">Tiantai  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms. </span><span class="cited-content_cbyCitation_journal-name">Journal of Experimental & Clinical Cancer Research</span><span> <strong>2019,</strong> <em>38 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13046-019-1062-x" title="DOI URL">https://doi.org/10.1186/s13046-019-1062-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13046-019-1062-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13046-019-1062-x%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Experimental%2520%2526%2520Clinical%2520Cancer%2520Research%26atitle%3DDiscovery%252Band%252Bevaluation%252Bof%252BZT55%25252C%252Ba%252Bnovel%252Bhighly-selective%252Btyrosine%252Bkinase%252Binhibitor%252Bof%252BJAK2V617F%252Bagainst%252Bmyeloproliferative%252Bneoplasms%26aulast%3DHu%26aufirst%3DMin%26date%3D2019%26date%3D2019%26volume%3D38%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rong-Hong  Hsiao</span>, <span class="hlFld-ContribAuthor ">Ching-Chun  Tseng</span>, <span class="hlFld-ContribAuthor ">Jia-Jun  Xie</span>, <span class="hlFld-ContribAuthor ">Shuo-En  Tsai</span>, <span class="hlFld-ContribAuthor ">Naoto  Uramaru</span>, <span class="hlFld-ContribAuthor ">Ching-Ya  Lin</span>, <span class="hlFld-ContribAuthor ">Ching-Yuh  Chern</span>, <span class="hlFld-ContribAuthor ">Fung Fuh  Wong</span>. </span><span class="cited-content_cbyCitation_article-title">Selective synthesis of functionalized pyrazoles from 5-amino-1H-pyrazole-4-carbaldehydes with sodium nitrite: 5-Amino-4-nitrosopyrazoles and pyrazole-4-carbaldehydes. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2019,</strong> <em>75 </em>
                                    (33)
                                     , 4561-4569. <a href="https://doi.org/10.1016/j.tet.2019.06.048" title="DOI URL">https://doi.org/10.1016/j.tet.2019.06.048</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2019.06.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2019.06.048%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DSelective%252Bsynthesis%252Bof%252Bfunctionalized%252Bpyrazoles%252Bfrom%252B5-amino-1H-pyrazole-4-carbaldehydes%252Bwith%252Bsodium%252Bnitrite%25253A%252B5-Amino-4-nitrosopyrazoles%252Band%252Bpyrazole-4-carbaldehydes%26aulast%3DHsiao%26aufirst%3DRong-Hong%26date%3D2019%26volume%3D75%26issue%3D33%26spage%3D4561%26epage%3D4569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James S.  Scott</span>, <span class="hlFld-ContribAuthor ">Michael J.  Waring</span>. </span><span class="cited-content_cbyCitation_article-title">Practical application of ligand efficiency metrics in lead optimisation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (11)
                                     , 3006-3015. <a href="https://doi.org/10.1016/j.bmc.2018.04.004" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.04.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.04.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DPractical%252Bapplication%252Bof%252Bligand%252Befficiency%252Bmetrics%252Bin%252Blead%252Boptimisation%26aulast%3DScott%26aufirst%3DJames%2BS.%26date%3D2018%26volume%3D26%26issue%3D11%26spage%3D3006%26epage%3D3015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chieyeon  Chough</span>, <span class="hlFld-ContribAuthor ">Misuk  Joung</span>, <span class="hlFld-ContribAuthor ">Sunmin  Lee</span>, <span class="hlFld-ContribAuthor ">Jaemin  Lee</span>, <span class="hlFld-ContribAuthor ">Jong Hoon  Kim</span>, <span class="hlFld-ContribAuthor ">B. Moon  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (8)
                                     , 1495-1510. <a href="https://doi.org/10.1016/j.bmc.2018.01.021" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.01.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.01.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.01.021%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252Bselective%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Brheumatoid%252Barthritis%25253A%252B%252528R%252529-3-%2525283-%252528Methyl%2525287H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-yl%252529amino%252529pyrrolidin-1-yl%252529-3-oxopropanenitrile%252Bas%252Ba%252BJAK1-selective%252Binhibitor%26aulast%3DChough%26aufirst%3DChieyeon%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D1495%26epage%3D1510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selectivity profile for tofacitinib (<b>1</b>) and <b>2</b>. For entries marked with “a” values were determined by the HTRF assay; for those marked with “b” values were determined by GeneBLAzer assay; all values are the mean of <i>n</i> = 2 experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Characterization and liabilities of compound <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Parameters that affect human dose calculation for AUC driven protein target. AUC unbound (AUC<sub>u</sub>), intrinsic clearance (Cl<sub>int</sub>), fraction absorbed (<i>f</i><sub>a</sub>), fraction escape from gut metabolism (<i>f</i><sub>g</sub>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Strategies to address hERG binding negatively impacted dose-related parameters.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Minimal pharmacophore has high LBE and LLE.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Tetrahydropyran Pyrazole Analogs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) TMS-CN, TMS-OTf, 0 °C; (ii) POCl<sub>3</sub>, pyridine, 0 °C, CH<sub>2</sub>Cl<sub>2</sub>, 60% (two steps); (b) (i) 3-amino-4-pyrazole carboxamide, DBU, 70 °C, EtOH; (ii) chiral SFC separation of active enantiomer 14% (two steps); (c) t-Bu XPhos, KOAc, Pd<sub>2</sub>(dba)<sub>3</sub>, 60 °C, iPrOH, 30–80%. Abbreviations: trimethylsilyl cyanide (TMS-CN), Trimethyl silyl trifluoromethansulfonate (TMS-OTf), Phosphoryl chloride (POCl<sub>3</sub>), 1,8-Diazabicycloundec-7-ene (DBU), 2-Di-tert-butylphosphino-2′,4′,6′-triisoporopylbiphenyl (t-Bu XPhos).</p></p></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Binned analysis comparing LLE, MK499 IC<sub>50</sub> distribution, human hepatocyte Cl<sub>int</sub>, and F% between tetrahydropyran and cyclohexylamine chemotypes. Filter settings: JAK1 Enzyme IC<sub>50</sub> < 100 nM, Cell IL6 IC<sub>50</sub> < 1000 nM, 897 samples for LLE and MK499, 350 samples for human hepatocyte Cl<sub>int</sub>, 88 samples for F%.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Analysis of %F and Cl<sub>int</sub> frequency plotted against HPLC Log D. HPLC Log D between 1.50 and 2.50 is the optimal range. Filter settings: JAK1 Enzyme IC<sub>50</sub> < 100 nM, Cell IL6 IC<sub>50</sub> < 1000 nM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Analysis of kinase selectivity profile of compounds <b>2</b>, <b>22</b>, and <b>28</b> against 265 kinases using a radar plot, percent of kinases at least 100-fold selectivity over JAK1 and partition index.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Co-crystal structure of <b>28</b> in JAK1 kinase domain showing ligand–protein interactions (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WO4">5WO4</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Comparison of <b>28</b> contacts with residues Glu966 in JAK1 and Asp939 in JAK2. In the crystal structure of <b>28</b> bound to JAK1, the dashed lines correspond to van der Waals contacts between the ligand and Glu966 identified with the ViewContacts software. No van der Waals interactions were identified when <b>28</b> was modeled into the active site of JAK2 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LPB">3LPB</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/medium/jm-2017-01135b_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Compound <b>22</b> dosed PO BID at 0.1, 1, and 10 mg/kg and <b>28</b> PO BID at 0.3, 3, 10, and 30 mg/kg were efficacious in reducing paw swelling in a 30 day rat CIA model. Dexamethasone was included as a positive control. .*<i>p</i> < 0.005, statistically different from nonarthritic controls, <sup>∧</sup><i>p</i> < 0.005, statistically different from CIA vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-23/acs.jmedchem.7b01135/20171215/images/large/jm-2017-01135b_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01135&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i45">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82451" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82451" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 30 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Shuai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span> </span><span class="NLM_article-title">Regulation of JAK-STAT signaling in the immune system</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">900</span><span class="NLM_x">–</span> <span class="NLM_lpage">910</span><span class="refDoi"> DOI: 10.1038/nri1226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1038%2Fnri1226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=14668806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=900-910&author=K.+Shuaiauthor=B.+Liu&title=Regulation+of+JAK-STAT+signaling+in+the+immune+system&doi=10.1038%2Fnri1226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of JAK-STAT signalling in the immune system</span></div><div class="casAuthors">Shuai, Ke; Liu, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">900-911</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has an important role in the control of immune responses.  Dysregulation of JAK-STAT signalling is assocd. with various immune disorders.  The signalling strength kinetics and specificity of the JAK-STAT pathway are modulated at many levels by distinct regulatory proteins.  Here, we review recent studies on the regulation of the JAK-STAT pathway that will enhance our ability to design rational therapeutic strategies for immune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDG-MzyqAi4bVg90H21EOLACvtfcHk0lh142bjIZKMEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFCltbc%253D&md5=cb04239e0d430052a975e930c656e31d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnri1226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1226%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DB.%26atitle%3DRegulation%2520of%2520JAK-STAT%2520signaling%2520in%2520the%2520immune%2520system%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2003%26volume%3D3%26spage%3D900%26epage%3D910%26doi%3D10.1038%2Fnri1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">Therapeutic targeting of janus kinases</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">223</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span><span class="refDoi"> DOI: 10.1111/j.1600-065X.2008.00644.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1111%2Fj.1600-065X.2008.00644.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=18613833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2008&pages=132-142&author=M.+Pesuauthor=A.+Laurenceauthor=N.+Kishoreauthor=S.+H.+Zwillichauthor=G.+Chanauthor=J.+J.+O%E2%80%99Shea&title=Therapeutic+targeting+of+janus+kinases&doi=10.1111%2Fj.1600-065X.2008.00644.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of Janus kinases</span></div><div class="casAuthors">Pesu, Marko; Laurence, Arian; Kishore, Nandini; Zwillich, Samuel H.; Chan, Gary; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">223</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132-142</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines play pivotal roles in immunity and inflammation, and targeting cytokines and their receptors is an effective means of treating such disorders.  Type I and II cytokine receptors assoc. with Janus family kinases (JAKs) to effect intracellular signaling.  These structurally unique protein kinases play essential and specific roles in immune cell development and function.  One JAK, JAK3, has particularly selective functions.  Mutations of this kinase underlie severe combined immunodeficiency, indicative of its crit. role in the development and function of lymphocytes.  Because JAK3 appears not to have functions outside of hematopoietic cells, this kinase has been viewed as an excellent therapeutic target for the development of a new class of immunosuppressive drugs.  In fact, several companies are developing JAK3 inhibitors, and Phase II studies are underway.  Mutations of Tyk2 cause autosomal recessive hyperIgE syndrome, and in principle, Tyk2 inhibitors might also be useful as immunosuppressive drugs.  JAK2 gain-of-function mutations (V617F) underlie a subset of disorders collectively referred to as myeloproliferative diseases and phase 2 trials using JAK inhibitors are underway in this setting.  Thus, we are learning a great deal about the feasibility and effectiveness of targeting Janus kinases, and it appears likely that this will be a fruitful strategy in a variety of settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-VTmlwlhcv7Vg90H21EOLACvtfcHk0lh142bjIZKMEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D&md5=73dc15932d0eaa312bc2588bdbce404c</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00644.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00644.x%26sid%3Dliteratum%253Aachs%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DTherapeutic%2520targeting%2520of%2520janus%2520kinases%26jtitle%3DImmunol.%2520Rev.%26date%3D2008%26volume%3D223%26spage%3D132%26epage%3D142%26doi%3D10.1111%2Fj.1600-065X.2008.00644.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villarino, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInnes, I. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span> </span><span class="NLM_article-title">The JAK-STAT pathway: impact on human disease and therapeutic intervention</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">328</span><span class="refDoi"> DOI: 10.1146/annurev-med-051113-024537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1146%2Fannurev-med-051113-024537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=25587654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFyhsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2015&pages=311-328&author=J.+J.+O%E2%80%99Sheaauthor=D.+M.+Schwartzauthor=A.+V.+Villarinoauthor=M.+Gadinaauthor=I.+B.+McInnesauthor=A.+Laurence&title=The+JAK-STAT+pathway%3A+impact+on+human+disease+and+therapeutic+intervention&doi=10.1146%2Fannurev-med-051113-024537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">The JAK-STAT pathway: impact on human disease and therapeutic intervention</span></div><div class="casAuthors">O'Shea, John J.; Schwartz, Daniella M.; Villarino, Alejandro V.; Gadina, Massimo; McInnes, Iain B.; Laurence, Arian</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">311-328</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  The Janus kinase (JAK)-signal transducer of activators of transcription (STAT) pathway is now recognized as an evolutionarily conserved signaling pathway employed by diverse cytokines, interferons, growth factors, and related mols.  This pathway provides an elegant and remarkably straightforward mechanism whereby extracellular factors control gene expression.  It thus serves as a fundamental paradigm for how cells sense environmental cues and interpret these signals to regulate cell growth and differentiation.  Genetic mutations and polymorphisms are functionally relevant to a variety of human diseases, esp. cancer and immune-related conditions.  The clin. relevance of the pathway has been confirmed by the emergence of a new class of therapeutics that targets JAKs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMxvQCRiTbL7Vg90H21EOLACvtfcHk0liQilTqpie3pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFyhsLY%253D&md5=19182154f1a046df039eb4a37b66bf78</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1146%2Fannurev-med-051113-024537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-med-051113-024537%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DSchwartz%26aufirst%3DD.%2BM.%26aulast%3DVillarino%26aufirst%3DA.%2BV.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DMcInnes%26aufirst%3DI.%2BB.%26aulast%3DLaurence%26aufirst%3DA.%26atitle%3DThe%2520JAK-STAT%2520pathway%253A%2520impact%2520on%2520human%2520disease%2520and%2520therapeutic%2520intervention%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2015%26volume%3D66%26spage%3D311%26epage%3D328%26doi%3D10.1146%2Fannurev-med-051113-024537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Pisetsky, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, M. M.</span><span> </span><span class="NLM_article-title">Advances in the treatment of inflammatory arthritis</span> <span class="citation_source-journal">Best Pract. Res. Clin. Rheumatol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span><span class="refDoi"> DOI: 10.1016/j.berh.2012.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1016%2Fj.berh.2012.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=22794097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A280%3ADC%252BC38jpvVGqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=251-261&author=D.+S.+Pisetskyauthor=M.+M.+Ward&title=Advances+in+the+treatment+of+inflammatory+arthritis&doi=10.1016%2Fj.berh.2012.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the treatment of inflammatory arthritis</span></div><div class="casAuthors">Pisetsky David S; Ward Michael M</div><div class="citationInfo"><span class="NLM_cas:title">Best practice & research. Clinical rheumatology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-61</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The inflammatory arthritides are a diverse group of conditions characterised by joint inflammation which can lead to pain, deformity and disability.  Of these diseases, rheumatoid arthritis (RA) and spondyloarthritis are two of the most common.  While the clinical and demographic features of these diseases differ, the central role of inflammation in their pathogenesis has allowed the development of highly effective treatment strategies with wide applicability.  These strategies include the use of biological agents which target the cytokine tumour necrosis factor (TNF), a key mediator of inflammation.  With the advent of effective agents, therapy has become more aggressive, reducing disease activity and allowing, at least in RA, remission in many patients.  While the array of available effective treatments is extensive, the use of objective measures of disease activity can guide treatment decisions (treat to target) and lead to improved outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkLVFtJ16x2xLDWw4HIq2sfW6udTcc2eYyrRggYAULNLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38jpvVGqsw%253D%253D&md5=f0b1278ba3590ce50c6527b719bfaa92</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.berh.2012.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.berh.2012.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DPisetsky%26aufirst%3DD.%2BS.%26aulast%3DWard%26aufirst%3DM.%2BM.%26atitle%3DAdvances%2520in%2520the%2520treatment%2520of%2520inflammatory%2520arthritis%26jtitle%3DBest%2520Pract.%2520Res.%2520Clin.%2520Rheumatol%26date%3D2012%26volume%3D26%26spage%3D251%26epage%3D261%26doi%3D10.1016%2Fj.berh.2012.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breedveld, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombs, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgos-Vargas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerbini, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">1895</span><span class="NLM_x">–</span> <span class="NLM_lpage">1905</span><span class="refDoi"> DOI: 10.1002/art.24567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1002%2Fart.24567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=19565475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=1895-1905&author=J.+M.+Kremerauthor=B.+J.+Bloomauthor=F.+C.+Breedveldauthor=J.+H.+Coombsauthor=M.+P.+Fletcherauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=R.+Burgos-Vargasauthor=B.+Wilkinsonauthor=C.+A.+Zerbiniauthor=S.+H.+Zwillich&title=The+safety+and+efficacy+of+a+JAK+inhibitor+in+patients+with+active+rheumatoid+arthritis%3A+results+of+a+double-blind%2C+placebo-controlled+phase+IIa+trial+of+three+dosage+levels+of+CP-690%2C550+versus+placebo&doi=10.1002%2Fart.24567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo</span></div><div class="casAuthors">Kremer, Joel M.; Bloom, Bradley J.; Breedveld, Ferdinand C.; Coombs, John H.; Fletcher, Mark P.; Gruben, David; Krishnaswami, Sriram; Burgos-Vargas, Ruben; Wilkinson, Bethanie; Zerbini, Cristiano A. F.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1895-1905</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To det. the efficacy, safety, and tolerability of 3 different dosages of CP-690,550, a potent, orally active JAK inhibitor, in patients with active rheumatoid arthritis (RA) in whom methotrexate, etanercept, infliximab, or adalimumab caused an inadequate or toxic response.  Patients (n = 264) were randomized equally to receive placebo, 5 mg of CP-690,550,15 mg of CP-690,550, or 30 mg of CP-690,550 twice daily for 6 wk, and were followed up for an addnl. 6 wk after treatment.  The primary efficacy end point was the American College of Rheumatol. 20% improvement criteria (ACR20) response rate at 6 wk.  By week 6, the ACR20 response rates were 70.5%, 81.2%, and 76.8% in the 5 mg, 15 mg, and 30 mg twice daily groups, resp., compared with 29.2% in the placebo group (P < 0.001).  Improvements in disease activity in CP-690,550-treated patients compared with placebo were seen in all treatment groups as early as week 1.  ACR50 and ACR70 response rates significantly improved in all treatment groups by week 4.  The most common adverse events reported were headache and nausea.  The infection rate in both the 15 mg twice daily group and the 30 mg twice daily group was 30.4% (vs. 26.2% in the placebo group).  No opportunistic infections or deaths occurred.  Increases in mean low-d. lipoprotein cholesterol and high-d. lipoprotein cholesterol levels, and increases in mean serum creatinine level (0.04-0.06 mg/dL) were seen in all CP-690,550 treatment arms.  Our findings indicate that CP-690,550 is efficacious in the treatment of RA, resulting in rapid, statistically significant, and clin. meaningful redns. in the signs and symptoms of RA.  Further studies of CP-690,550 in RA are warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBhxBhh_mG7rVg90H21EOLACvtfcHk0lgDKj4nNNAemQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKktLg%253D&md5=ab5fb34e43d8643871560c67bbbca07d</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1002%2Fart.24567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24567%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DBloom%26aufirst%3DB.%2BJ.%26aulast%3DBreedveld%26aufirst%3DF.%2BC.%26aulast%3DCoombs%26aufirst%3DJ.%2BH.%26aulast%3DFletcher%26aufirst%3DM.%2BP.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DWilkinson%26aufirst%3DB.%26aulast%3DZerbini%26aufirst%3DC.%2BA.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DThe%2520safety%2520and%2520efficacy%2520of%2520a%2520JAK%2520inhibitor%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%253A%2520results%2520of%2520a%2520double-blind%252C%2520placebo-controlled%2520phase%2520IIa%2520trial%2520of%2520three%2520dosage%2520levels%2520of%2520CP-690%252C550%2520versus%2520placebo%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D1895%26epage%3D1905%26doi%3D10.1002%2Fart.24567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang-Poa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8468</span><span class="NLM_x">–</span> <span class="NLM_lpage">8484</span><span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lgDKj4nNNAemQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Kaur, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalra, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaushal, S.</span><span> </span><span class="NLM_article-title">Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis</span> <span class="citation_source-journal">Clin. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1074</span><span class="NLM_x">–</span> <span class="NLM_lpage">1086</span><span class="refDoi"> DOI: 10.1016/j.clinthera.2014.06.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1016%2Fj.clinthera.2014.06.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=25047498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtF2ksb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2014&pages=1074-1086&author=K.+Kaurauthor=S.+Kalraauthor=S.+Kaushal&title=Systematic+review+of+tofacitinib%3A+a+new+drug+for+the+management+of+rheumatoid+arthritis&doi=10.1016%2Fj.clinthera.2014.06.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic Review of Tofacitinib: A New Drug for the Management of Rheumatoid Arthritis</span></div><div class="casAuthors">Kaur, Kirandeep; Kalra, Sonesh; Kaushal, Sandeep</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1074-1086</span>CODEN:
                <span class="NLM_cas:coden">CLTHDG</span>;
        ISSN:<span class="NLM_cas:issn">0149-2918</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The goal of this study was to review and summarize the efficacy and safety of use of tofacitinib for treating rheumatoid arthritis (RA).  A systematic literature review was conducted to identify English-language articles published through May 2013 within PubMed, ClinicalTrials.gov, and Cochrane Library reporting results from Phase II and Phase III tofacitinib randomized clin. trials.  Tofacitinib must have been used as monotherapy or in combination therapy with disease-modifying antirheumatic drugs (DMARDs) in the treatment of RA.  Study outcomes had to include at least 1 of the following: American College of Rheumatol. (ACR) 20%, 50%, or 70% response rates; tender/swollen joint count; health assessment questionnaire of disability; radiog. outcomes; and drug persistence.  Eight studies (4 Phase II and 4 Phase III trials) were included in the review.  Patients with active RA and who were nonresponders to a biol. agent or the nonbiol. DMARD methotrexate were included in these studies.  The results of the Phase II trials show that tofacitinib at doses ≥3 mg BID was efficacious among the nonresponders.  The results of the Phase III trials, comparing tofacitinib 5 and 10 mg with placebo, show that tofacitinib led to a significant improvement in ACR20 response (P < 0.0001), Health Assessment Questionnaire-Disability Index (P < 0.0001) scores, and ACR50 response (P < 0.0001) after 3 mo.  The efficacy of tofacitinib was numerically similar to adalimumab.  The most common adverse events were infections, infestations, increases in LDL-C and HDL-C levels, and a decrease in neutrophil counts.  Tofacitinib is an efficacious drug for the management of moderate to severe RA among patients with an inadequate response to methotrexate and tumor necrosis factor inhibitors.  Long-term studies can help in understanding the risk/benefit profile of tofacitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNhogMT16YO7Vg90H21EOLACvtfcHk0lhDNd6HdLM_uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtF2ksb%252FI&md5=8ffd0a6e85f9b9880cc80462337ddc7f</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1016%2Fj.clinthera.2014.06.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinthera.2014.06.018%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DK.%26aulast%3DKalra%26aufirst%3DS.%26aulast%3DKaushal%26aufirst%3DS.%26atitle%3DSystematic%2520review%2520of%2520tofacitinib%253A%2520a%2520new%2520drug%2520for%2520the%2520management%2520of%2520rheumatoid%2520arthritis%26jtitle%3DClin.%2520Ther.%26date%3D2014%26volume%3D36%26spage%3D1074%26epage%3D1086%26doi%3D10.1016%2Fj.clinthera.2014.06.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Bathon, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleischmann, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tesser, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiff, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keystone, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wasko, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreland, L. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markenson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finck, B. K.</span><span> </span><span class="NLM_article-title">A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">1586</span><span class="NLM_x">–</span> <span class="NLM_lpage">1593</span><span class="refDoi"> DOI: 10.1056/NEJM200011303432201</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1056%2FNEJM200011303432201" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=11096165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD3cXovVeltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2000&pages=1586-1593&author=J.+M.+Bathonauthor=R.+W.+Martinauthor=R.+M.+Fleischmannauthor=J.+R.+Tesserauthor=M.+H.+Schiffauthor=E.+C.+Keystoneauthor=M.+C.+Genoveseauthor=M.+C.+Waskoauthor=L.+W.+Morelandauthor=A.+L.+Weaverauthor=J.+Markensonauthor=B.+K.+Finck&title=A+comparison+of+etanercept+and+methotrexate+in+patients+with+early+rheumatoid+arthritis&doi=10.1056%2FNEJM200011303432201"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis</span></div><div class="casAuthors">Bathon, Joan M.; Martin, Richard W.; Fleischmann, Roy M.; Tesser, John R.; Schiff, Michael H.; Keystone, Edward C.; Genovese, Mark C.; Wasko, Mary Chester; Moreland, Larry W.; Weaver, Arthur L.; Markenson, Joseph; Finck, Barbara K.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">1586-1593</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Etanercept, which blocks the action of tumor necrosis factor, reduces disease activity in patients with long-standing rheumatoid arthritis.  Its efficacy in reducing disease activity and preventing joint damage in patients with active early rheumatoid arthritis is unknown.  We treated 632 patients with early rheumatoid arthritis with either twice-weekly s.c. etanercept (10 or 25 mg) or weekly oral methotrexate (mean, 19 mg per wk) for 12 mo.  Clin. response was defined as the percent improvement in disease activity according to the criteria of the American College of Rheumatol.  Bone erosion and joint-space narrowing were measured radiog. and scored with use of the Sharp scale.  On this scale, an increase of 1 point represents one new erosion or minimal narrowing.  As compared with patients who received methotrexate, patients who received the 25-mg dose of etanercept had a more rapid rate of improvement, with significantly more patients having 20 %, 50 %, and 70 % improvement in disease activity during the first six months (P<0.05).  The mean increase in the erosion score during the first 6 mo was 0.30 in the group assigned to receive 25 mg of etanercept and 0.68 in the methotrexate group (P=0.001), and the resp. increases during the first 12 mo were 0.47 and 1.03 (P=0.002).  Among patients who received the 25-mg dose of etanercept, 72 % had no increase in the erosion score, as compared with 60 % of patients in the methotrexate group (P=0.007).  This group of patients also had fewer adverse events (P=0.02) and fewer infections (P=0.006) than the group that was treated with methotrexate.  As compared with oral methotrexate, i.v. etanercept acted more rapidly to decrease symptoms and slow joint damage in patients with early active rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplt2B0J1plyLVg90H21EOLACvtfcHk0lgkB5hLEncwNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXovVeltLg%253D&md5=691f3d8475d72dfa639ae244d84c44ce</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJM200011303432201&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200011303432201%26sid%3Dliteratum%253Aachs%26aulast%3DBathon%26aufirst%3DJ.%2BM.%26aulast%3DMartin%26aufirst%3DR.%2BW.%26aulast%3DFleischmann%26aufirst%3DR.%2BM.%26aulast%3DTesser%26aufirst%3DJ.%2BR.%26aulast%3DSchiff%26aufirst%3DM.%2BH.%26aulast%3DKeystone%26aufirst%3DE.%2BC.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DWasko%26aufirst%3DM.%2BC.%26aulast%3DMoreland%26aufirst%3DL.%2BW.%26aulast%3DWeaver%26aufirst%3DA.%2BL.%26aulast%3DMarkenson%26aufirst%3DJ.%26aulast%3DFinck%26aufirst%3DB.%2BK.%26atitle%3DA%2520comparison%2520of%2520etanercept%2520and%2520methotrexate%2520in%2520patients%2520with%2520early%2520rheumatoid%2520arthritis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2000%26volume%3D343%26spage%3D1586%26epage%3D1593%26doi%3D10.1056%2FNEJM200011303432201" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="note"><p class="first last">For an excellent review see:</p></div><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Menet, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mammoliti, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez-Ramos, M.</span><span> </span><span class="NLM_article-title">Progress toward JAK1-selective inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">235</span><span class="refDoi"> DOI: 10.4155/fmc.14.149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.4155%2Ffmc.14.149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=25686006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=203-235&author=C.+J.+Menetauthor=O.+Mammolitiauthor=M.+Lopez-Ramos&title=Progress+toward+JAK1-selective+inhibitors&doi=10.4155%2Ffmc.14.149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Progress toward JAK1-selective inhibitors</span></div><div class="casAuthors">Menet, Christel J.; Mammoliti, Oscar; Lopez-Ramos, Miriam</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-235</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  The discovery of the JAK-STAT pathway was a landmark in cell biol.  The identification of these pathways has changed the landscape of treatment of rheumatoid arthritis and other autoimmune diseases.  The two first (unselective) JAK inhibitors have recently been approved by the US FDA for the treatment of myelofibrosis and rheumatoid arthritis and many other JAK inhibitors are currently in clin. development or at the discovery stage.  Research groups have demonstrated the different roles of JAK member and the therapeutic potential of targeting them selectively.  JAK1 plays a crit. and potentially dominant role in the transduction of γc cytokine (γc = common γ chain) and in IL-6 signaling.  In this review, we will discuss the state-of-the-art research that evokes JAK1 selective inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFBuFU-x0dWrVg90H21EOLACvtfcHk0lgkB5hLEncwNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVensrs%253D&md5=ef6cf011f0078aaa4f83560c98524d1c</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.4155%2Ffmc.14.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.14.149%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DMammoliti%26aufirst%3DO.%26aulast%3DLopez-Ramos%26aufirst%3DM.%26atitle%3DProgress%2520toward%2520JAK1-selective%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D203%26epage%3D235%26doi%3D10.4155%2Ffmc.14.149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">For JAK1 Selective Inhibitors see:</p></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyke, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harrison, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir Kohli, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxey, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narukulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waszkowycz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span> </span><span class="NLM_article-title">Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5901</span><span class="NLM_x">–</span> <span class="NLM_lpage">5921</span><span class="refDoi"> DOI: 10.1021/jm300438j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300438j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC38XntVOktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5901-5921&author=J.+J.+Kulagowskiauthor=W.+Blairauthor=R.+J.+Bullauthor=C.+Changauthor=G.+Deshmukhauthor=H.+J.+Dykeauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=T.+K.+Harrisonauthor=P.+R.+Hewittauthor=M.+Liimattaauthor=C.+A.+Hurleyauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=P.+B.+Bir+Kohliauthor=R.+J.+Maxeyauthor=R.+Mendoncaauthor=K.+Mortaraauthor=J.+Murrayauthor=R.+Narukullaauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=M.+Ultschauthor=A.+van+Abbemaauthor=S.+I.+Wardauthor=B.+Waszkowyczauthor=M.+Zak&title=Identification+of+imidazo-pyrrolopyridines+as+novel+and+potent+JAK1+inhibitors&doi=10.1021%2Fjm300438j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors</span></div><div class="casAuthors">Kulagowski, Janusz J.; Blair, Wade; Bull, Richard J.; Chang, Christine; Deshmukh, Gauri; Dyke, Hazel J.; Eigenbrot, Charles; Ghilardi, Nico; Gibbons, Paul; Harrison, Trevor K.; Hewitt, Peter R.; Liimatta, Marya; Hurley, Christopher A.; Johnson, Adam; Johnson, Tony; Kenny, Jane R.; Bir Kohli, Pawan; Maxey, Robert J.; Mendonca, Rohan; Mortara, Kyle; Murray, Jeremy; Narukulla, Raman; Shia, Steven; Steffek, Micah; Ubhayakar, Savita; Ultsch, Mark; van Abbema, Anne; Ward, Stuart I.; Waszkowycz, Bohdan; Zak, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5901-5921</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as rheumatoid arthritis (RA), by specific targeting of the JAK1 pathway.  Examn. of the preferred binding conformation of clin. effective, pan-JAK inhibitor 1 led to identification of a novel, tricyclic hinge binding scaffold 3.  Exploration of SAR through a series of cycloamino and cycloalkylamino analogs demonstrated this template to be highly tolerant of substitution, with a predisposition to moderate selectivity for the JAK1 isoform over JAK2.  This study culminated in the identification of subnanomolar JAK1 inhibitors such as 22 and 49, having excellent cell potency, good rat pharmacokinetic characteristics, and excellent kinase selectivity.  Detn. of the binding modes of the series in JAK1 and JAK2 by X-ray crystallog. supported the design of analogs to enhance affinity and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpamrk0bG1MK7Vg90H21EOLACvtfcHk0lgts3H3OYnQTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntVOktL0%253D&md5=d91bc0e24abf14adcf44caf61e3e879f</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1021%2Fjm300438j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300438j%26sid%3Dliteratum%253Aachs%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DBlair%26aufirst%3DW.%26aulast%3DBull%26aufirst%3DR.%2BJ.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDyke%26aufirst%3DH.%2BJ.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DHarrison%26aufirst%3DT.%2BK.%26aulast%3DHewitt%26aufirst%3DP.%2BR.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DBir%2BKohli%26aufirst%3DP.%2BB.%26aulast%3DMaxey%26aufirst%3DR.%2BJ.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DWaszkowycz%26aufirst%3DB.%26aulast%3DZak%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520imidazo-pyrrolopyridines%2520as%2520novel%2520and%2520potent%2520JAK1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5901%26epage%3D5921%26doi%3D10.1021%2Fjm300438j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanan, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M. F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir Kohli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labadie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupardus, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxey, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Streffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span> </span><span class="NLM_article-title">Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavaliable JAK1 inhibitors with selectivity over JAK2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6176</span><span class="NLM_x">–</span> <span class="NLM_lpage">6193</span><span class="refDoi"> DOI: 10.1021/jm300628c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300628c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6176-6193&author=M.+Zakauthor=R.+Mendoncaauthor=M.+Balazsauthor=K.+Barrettauthor=P.+Bergeronauthor=W.+S.+Blairauthor=C.+Changauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=C.+Hammanauthor=E.+J.+Hananauthor=E.+Harstadauthor=P.+R.+Hewittauthor=C.+A.+Hurleyauthor=T.+Jinauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+T.+Koehlerauthor=P.+Bir+Kohliauthor=J.+J.+Kulagowskiauthor=S.+Labadieauthor=J.+Liaoauthor=M.+Liimattaauthor=Z.+Linauthor=P.+J.+Lupardusauthor=R.+J.+Maxeyauthor=J.+M.+Murrayauthor=R.+Pulkauthor=M.+Rodriguezauthor=S.+Savageauthor=S.+Shiaauthor=M.+Streffekauthor=S.+Ubhayakarauthor=M.+Ultschauthor=A.+van+Abbemaauthor=S.+I.+Wardauthor=L.+Xiaoauthor=Y.+Xiao&title=Discovery+and+optimization+of+C-2+methyl+imidazopyrrolopyridines+as+potent+and+orally+bioavaliable+JAK1+inhibitors+with+selectivity+over+JAK2&doi=10.1021%2Fjm300628c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1021%2Fjm300628c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300628c%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHanan%26aufirst%3DE.%2BJ.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%2BR.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DJin%26aufirst%3DT.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%2BT.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DMaxey%26aufirst%3DR.%2BJ.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DStreffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DXiao%26aufirst%3DY.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520C-2%2520methyl%2520imidazopyrrolopyridines%2520as%2520potent%2520and%2520orally%2520bioavaliable%2520JAK1%2520inhibitors%2520with%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6176%26epage%3D6193%26doi%3D10.1021%2Fjm300628c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergeron, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blair, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bull, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chakravarty, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crackett, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeVoss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dragovich, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellwood, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaines, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghilardi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gradl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, M. F. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bir Kohli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labadie, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liimatta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narukulla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pulk, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeve, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savage, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Abbema, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avitabile-Woo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kulagowski, J. J.</span><span> </span><span class="NLM_article-title">Identification of C-2 hydroyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">4764</span><span class="NLM_x">–</span> <span class="NLM_lpage">4785</span><span class="refDoi"> DOI: 10.1021/jm4004895</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4004895" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=4764-4785&author=M.+Zakauthor=C.+A.+Hurleyauthor=S.+I.+Wardauthor=P.+Bergeronauthor=K.+Barrettauthor=M.+Balazsauthor=W.+S.+Blairauthor=R.+Bullauthor=P.+Chakravartyauthor=C.+Changauthor=P.+Crackettauthor=G.+Deshmukhauthor=J.+DeVossauthor=P.+S.+Dragovichauthor=C.+Eigenbrotauthor=C.+Ellwoodauthor=S.+Gainesauthor=N.+Ghilardiauthor=P.+Gibbonsauthor=S.+Gradlauthor=P.+Griblingauthor=C.+Hammanauthor=E.+Harstadauthor=P.+Hewittauthor=A.+Johnsonauthor=T.+Johnsonauthor=J.+R.+Kennyauthor=M.+F.+T.+Koehlerauthor=P.+Bir+Kohliauthor=S.+Labadieauthor=W.+P.+Leeauthor=J.+Liaoauthor=M.+Liimattaauthor=R.+Mendoncaauthor=R.+Narukullaauthor=R.+Pulkauthor=A.+Reeveauthor=S.+Savageauthor=S.+Shiaauthor=M.+Steffekauthor=S.+Ubhayakarauthor=A.+van+Abbemaauthor=I.+Aliagasauthor=B.+Avitabile-Wooauthor=Y.+Xiaoauthor=J.+Yangauthor=J.+J.+Kulagowski&title=Identification+of+C-2+hydroyethyl+imidazopyrrolopyridines+as+potent+JAK1+inhibitors+with+favorable+physicochemical+properties+and+high+selectivity+over+JAK2&doi=10.1021%2Fjm4004895"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1021%2Fjm4004895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4004895%26sid%3Dliteratum%253Aachs%26aulast%3DZak%26aufirst%3DM.%26aulast%3DHurley%26aufirst%3DC.%2BA.%26aulast%3DWard%26aufirst%3DS.%2BI.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBarrett%26aufirst%3DK.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBlair%26aufirst%3DW.%2BS.%26aulast%3DBull%26aufirst%3DR.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DCrackett%26aufirst%3DP.%26aulast%3DDeshmukh%26aufirst%3DG.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDragovich%26aufirst%3DP.%2BS.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DEllwood%26aufirst%3DC.%26aulast%3DGaines%26aufirst%3DS.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DGibbons%26aufirst%3DP.%26aulast%3DGradl%26aufirst%3DS.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHamman%26aufirst%3DC.%26aulast%3DHarstad%26aufirst%3DE.%26aulast%3DHewitt%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DKenny%26aufirst%3DJ.%2BR.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%2BT.%26aulast%3DBir%2BKohli%26aufirst%3DP.%26aulast%3DLabadie%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DLiao%26aufirst%3DJ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DMendonca%26aufirst%3DR.%26aulast%3DNarukulla%26aufirst%3DR.%26aulast%3DPulk%26aufirst%3DR.%26aulast%3DReeve%26aufirst%3DA.%26aulast%3DSavage%26aufirst%3DS.%26aulast%3DShia%26aufirst%3DS.%26aulast%3DSteffek%26aufirst%3DM.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3Dvan%2BAbbema%26aufirst%3DA.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DAvitabile-Woo%26aufirst%3DB.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520C-2%2520hydroyethyl%2520imidazopyrrolopyridines%2520as%2520potent%2520JAK1%2520inhibitors%2520with%2520favorable%2520physicochemical%2520properties%2520and%2520high%2520selectivity%2520over%2520JAK2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D4764%26epage%3D4785%26doi%3D10.1021%2Fjm4004895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Menet, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Lommen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geney, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanc, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smits, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouannigot, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deprez, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Aar, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clement-Lacroix, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lepescheux, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galien, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vayssiere, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelles, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christophe, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brys, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhring, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciesielski, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Rompaey, L.</span><span> </span><span class="NLM_article-title">Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">9323</span><span class="NLM_x">–</span> <span class="NLM_lpage">9342</span><span class="refDoi"> DOI: 10.1021/jm501262q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501262q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9323-9342&author=C.+J.+Menetauthor=S.+R.+Fletcherauthor=G.+Van+Lommenauthor=R.+Geneyauthor=J.+Blancauthor=K.+Smitsauthor=N.+Jouannigotauthor=P.+Deprezauthor=E.+M.+van+der+Aarauthor=P.+Clement-Lacroixauthor=L.+Lepescheuxauthor=R.+Galienauthor=B.+Vayssiereauthor=L.+Nellesauthor=T.+Christopheauthor=R.+Brysauthor=M.+Uhringauthor=F.+Ciesielskiauthor=L.+Van+Rompaey&title=Triazolopyridines+as+selective+JAK1+inhibitors%3A+from+hit+identification+to+GLPG0634&doi=10.1021%2Fjm501262q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6eR"><div class="casContent"><span class="casTitleNuber">6e</span><div class="casTitle"><span class="NLM_cas:atitle">Triazolopyridines as Selective JAK1 Inhibitors: From Hit Identification to GLPG0634</span></div><div class="casAuthors">Menet, Christel J.; Fletcher, Stephen R.; Van Lommen, Guy; Geney, Raphael; Blanc, Javier; Smits, Koen; Jouannigot, Nolwenn; Deprez, Pierre; van der Aar, Ellen M.; Clement-Lacroix, Philippe; Lepescheux, Lien; Galien, Rene; Vayssiere, Beatrice; Nelles, Luc; Christophe, Thierry; Brys, Reginald; Uhring, Muriel; Ciesielski, Fabrice; Van Rompaey, Luc</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9323-9342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Janus kinases (JAK1, JAK2, JAK3, and TYK2) are involved in the signaling of multiple cytokines important in cellular function.  Blockade of the JAK-STAT pathway with a small mol. has been shown to provide therapeutic immunomodulation.  Having identified JAK1 as a possible new target for arthritis at Galapagos, the compd. library was screened against JAK1, resulting in the identification of a triazolopyridine-based series of inhibitors represented by I.  Optimization within this chem. series led to identification of II (GLPG0634, filgotinib), a selective JAK1 inhibitor currently in phase 2B development for RA and phase 2A development for Crohn's disease (CD).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBHELw4zQ5QLVg90H21EOLACvtfcHk0ljr42hmYI7KaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7nN&md5=756f687dc30e6fd34004deb672fe8b23</span></div><a href="/servlet/linkout?suffix=cit6e&amp;dbid=16384&amp;doi=10.1021%2Fjm501262q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501262q%26sid%3Dliteratum%253Aachs%26aulast%3DMenet%26aufirst%3DC.%2BJ.%26aulast%3DFletcher%26aufirst%3DS.%2BR.%26aulast%3DVan%2BLommen%26aufirst%3DG.%26aulast%3DGeney%26aufirst%3DR.%26aulast%3DBlanc%26aufirst%3DJ.%26aulast%3DSmits%26aufirst%3DK.%26aulast%3DJouannigot%26aufirst%3DN.%26aulast%3DDeprez%26aufirst%3DP.%26aulast%3Dvan%2Bder%2BAar%26aufirst%3DE.%2BM.%26aulast%3DClement-Lacroix%26aufirst%3DP.%26aulast%3DLepescheux%26aufirst%3DL.%26aulast%3DGalien%26aufirst%3DR.%26aulast%3DVayssiere%26aufirst%3DB.%26aulast%3DNelles%26aufirst%3DL.%26aulast%3DChristophe%26aufirst%3DT.%26aulast%3DBrys%26aufirst%3DR.%26aulast%3DUhring%26aufirst%3DM.%26aulast%3DCiesielski%26aufirst%3DF.%26aulast%3DVan%2BRompaey%26aufirst%3DL.%26atitle%3DTriazolopyridines%2520as%2520selective%2520JAK1%2520inhibitors%253A%2520from%2520hit%2520identification%2520to%2520GLPG0634%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9323%26epage%3D9342%26doi%3D10.1021%2Fjm501262q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Kim, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nam, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, Y.</span><span> </span><span class="NLM_article-title">Benzoimdazole derivatives as potent JAK1 selective inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">7596</span><span class="NLM_x">–</span> <span class="NLM_lpage">7602</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01263</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01263" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7596-7602&author=M.+K.+Kimauthor=H.+Shinauthor=K.+Parkauthor=H.+Kimauthor=J.+Parkauthor=K.+Kimauthor=J.+Namauthor=H.+Chooauthor=Y.+Chong&title=Benzoimdazole+derivatives+as+potent+JAK1+selective+inhibitors&doi=10.1021%2Facs.jmedchem.5b01263"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6f&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01263%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DM.%2BK.%26aulast%3DShin%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DNam%26aufirst%3DJ.%26aulast%3DChoo%26aufirst%3DH.%26aulast%3DChong%26aufirst%3DY.%26atitle%3DBenzoimdazole%2520derivatives%2520as%2520potent%2520JAK1%2520selective%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7596%26epage%3D7602%26doi%3D10.1021%2Facs.jmedchem.5b01263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Simov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elwood, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandez, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibeau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunaydin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraybill, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lapointe, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J. R.</span><span> </span><span class="NLM_article-title">Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase Inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">1803</span><span class="NLM_x">–</span> <span class="NLM_lpage">1808</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2016.02.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1016%2Fj.bmcl.2016.02.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=26927423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6g&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt12mtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=1803-1808&author=V.+Simovauthor=S.+V.+Deshmukhauthor=C.+J.+Dinsmoreauthor=F.+Elwoodauthor=R.+B.+Fernandezauthor=Y.+Garciaauthor=C.+Gibeauauthor=H.+Gunaydinauthor=J.+Jungauthor=J.+D.+Katzauthor=B.+Kraybillauthor=B.+Lapointeauthor=S.+B.+Patelauthor=T.+Siuauthor=H.+Suauthor=J.+R.+Young&title=Structure-based+design+and+development+of+%28benz%29imidazole+pyridones+as+JAK1-selective+kinase+Inhibitors&doi=10.1016%2Fj.bmcl.2016.02.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6gR"><div class="casContent"><span class="casTitleNuber">6g</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors</span></div><div class="casAuthors">Simov, Vladimir; Deshmukh, Sujal V.; Dinsmore, Christopher J.; Elwood, Fiona; Fernandez, Rafael B.; Garcia, Yudith; Gibeau, Craig; Gunaydin, Hakan; Jung, Joon; Katz, Jason D.; Kraybill, Brian; Lapointe, Blair; Patel, Sangita B.; Siu, Tony; Su, Hua; Young, Jonathan R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1803-1808</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mammalian Janus Kinases (JAK1, JAK2, JAK3 and TYK2) are intracellular, nonreceptor tyrosine kinases whose activities have been assocd. in the literature and the clinic with a variety of hyperproliferative diseases and immunol. disorders.  At the onset of the program, it was hypothesized that a JAK1 selective compd. over JAK2 could lead to an improved therapeutic index relative to marketed nonselective JAK inhibitors by avoiding the clin. AEs, such as anemia, presumably assocd. with JAK2 inhibition.  During the course of the JAK1 program, a no. of diverse chem. scaffolds were identified from both uHTS campaigns and de novo scaffold design.  As part of this effort, a (benz)imidazole scaffold evolved via a scaffold-hopping exercise from a mature chem. series.  Concurrent crystallog.-driven exploration of the ribose pocket and the solvent front led to analogs with optimized kinome and JAK1 selectivities over the JAK2 isoform by targeting several residues unique to JAK1, such as Arg-879 and Glu-966.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeRwubYziKxrVg90H21EOLACvtfcHk0liXanaBoydi5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt12mtLo%253D&md5=f863ad973f0f86993bb7f796821b5059</span></div><a href="/servlet/linkout?suffix=cit6g&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.02.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.02.035%26sid%3Dliteratum%253Aachs%26aulast%3DSimov%26aufirst%3DV.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DElwood%26aufirst%3DF.%26aulast%3DFernandez%26aufirst%3DR.%2BB.%26aulast%3DGarcia%26aufirst%3DY.%26aulast%3DGibeau%26aufirst%3DC.%26aulast%3DGunaydin%26aufirst%3DH.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26aulast%3DKraybill%26aufirst%3DB.%26aulast%3DLapointe%26aufirst%3DB.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DSiu%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DJ.%2BR.%26atitle%3DStructure-based%2520design%2520and%2520development%2520of%2520%2528benz%2529imidazole%2520pyridones%2520as%2520JAK1-selective%2520kinase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D1803%26epage%3D1808%26doi%3D10.1016%2Fj.bmcl.2016.02.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6h"><span><span class="NLM_label">(h) </span><div class="note"><p class="first last">For a review of JAK inhibitors in the clinic, see:</p></div><span class="NLM_contrib-group">Roskoski, R.,  Jr</span><span> </span><span class="NLM_article-title">Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases</span> <span class="citation_source-journal">Pharmacol. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">784</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span><span class="refDoi"> DOI: 10.1016/j.phrs.2016.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1016%2Fj.phrs.2016.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=27473820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6h&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12jurzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=784-803&author=R.+Roskoski&title=Janus+kinase+%28JAK%29+inhibitors+in+the+treatment+of+inflammatory+and+neoplastic+diseases&doi=10.1016%2Fj.phrs.2016.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6hR"><div class="casContent"><span class="casTitleNuber">6h</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases</span></div><div class="casAuthors">Roskoski, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">784-803</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The Janus kinase (JAK) family of non-receptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (tyrosine kinase-2).  Each of these proteins contains a JAK homol. pseudokinase (JH2) domain that regulates the adjacent protein kinase domain (JH1).  JAK1/2 and TYK2 are ubiquitously expressed whereas JAK3 is found predominantly in hematopoietic cells.  The Janus kinase family is regulated by numerous cytokines including interleukins, interferons, and hormones such as erythropoietin, thrombopoietin, and growth hormone.  Ligand binding to cytokine and hormone receptors leads to the activation of assocd. Janus kinases, which then mediate the phosphorylation of the receptors.  The SH2 domain of STATs (signal transducers and activators of transcription) binds to the receptor phosphotyrosines thereby promoting STAT phosphorylation by the Janus kinases and consequent activation.  STAT dimers are translocated to the nucleus where they participate in the regulation of the expression of thousands of proteins.  JAK-STAT dysregulation results in autoimmune disorders such as rheumatoid arthritis, ulcerative colitis, and Crohn disease.  JAK-STAT dysregulation also plays a role in the pathogenesis of myelofibrosis, polycythemia vera, and other myeloproliferative illnesses.  An activating JAK2 V617F mutation occurs in 95% of people with polycythemia vera and in a lower percentage of people with other neoplasms.  JAK1/3 signaling participates in the pathogenesis of inflammatory afflictions while JAK1/2 signaling participates in the development of several malignancies including leukemias and lymphomas as well as myeloproliferative neoplasms.  Tofacitinib is a pan-JAK inhibitor that is approved by the FDA for the treatment of rheumatoid arthritis and ruxolitinib is a JAK1/2 inhibitor that is approved for the treatment of polycythemia vera and myelofibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGov32m4UjOrv7Vg90H21EOLACvtfcHk0liXanaBoydi5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12jurzJ&md5=a45fba1bb110eff4d5c1b31b78c1b3ac</span></div><a href="/servlet/linkout?suffix=cit6h&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DJanus%2520kinase%2520%2528JAK%2529%2520inhibitors%2520in%2520the%2520treatment%2520of%2520inflammatory%2520and%2520neoplastic%2520diseases%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D784%26epage%3D803%26doi%3D10.1016%2Fj.phrs.2016.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Brubaker, J.</span><span> </span><span class="NLM_article-title">Discovery of an orally bioavailable JAK1 inhibitor for validation of JAK1-selective hypothesis</span>. Presented at Applied Pharmaceutical Chemistry Conference; Boston, MA, March 4,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=J.+Brubaker&title=Discovery+of+an+orally+bioavailable+JAK1+inhibitor+for+validation+of+JAK1-selective+hypothesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DBrubaker%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520an%2520orally%2520bioavailable%2520JAK1%2520inhibitor%2520for%2520validation%2520of%2520JAK1-selective%2520hypothesis%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Moy, L.; Chiu, C-S.; Faltus, R.; Zielstorff, M.; Chakravarthy, K.; Deshmukh, S.; Kariv, I.; Klappenbach, J.; Brubaker, J.; Liu, D.; Siu, T.; Young, J.; Yu, H.; Elwood, F.; Cicmil, M.</span><span> </span><span class="NLM_article-title">Efficacy of a novel orally bioavailable JAK1 selective compound in a preclinical rat collagen-induced arthritis model</span>. Presented at ACR/ARHP Annual Meeting; Boston, MA, November 14–19,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=L.+Moy&author=C-S.+Chiu&author=R.+Faltus&author=M.+Zielstorff&author=K.+Chakravarthy&author=S.+Deshmukh&author=I.+Kariv&author=J.+Klappenbach&author=J.+Brubaker&author=D.+Liu&author=T.+Siu&author=J.+Young&author=H.+Yu&author=F.+Elwood&author=M.+Cicmil&title=Efficacy+of+a+novel+orally+bioavailable+JAK1+selective+compound+in+a+preclinical+rat+collagen-induced+arthritis+model"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DMoy%26aufirst%3DL.%26atitle%3DEfficacy%2520of%2520a%2520novel%2520orally%2520bioavailable%2520JAK1%2520selective%2520compound%2520in%2520a%2520preclinical%2520rat%2520collagen-induced%2520arthritis%2520model%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="note"><p class="first last">Human dose predication was based achieving exposure needed to achieve 15% pit improvements in ACR50 over 10 mg BID tofacitinib. PK/PD modeling for the required exposure will be disclosed in a future publication.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Dack, K.</span> <span class="citation_source-book">Reducing Attrition Risk: Evolution of an in silico “compound safety evaluator” designing safer medicines in discovery</span>. <span class="NLM_publisher-name">SCI</span>: <span class="NLM_publisher-loc">London</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=K.+Dack&title=Reducing+Attrition+Risk%3A+Evolution+of+an+in+silico+%E2%80%9Ccompound+safety+evaluator%E2%80%9D+designing+safer+medicines+in+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDack%26aufirst%3DK.%26btitle%3DReducing%2520Attrition%2520Risk%253A%2520Evolution%2520of%2520an%2520in%2520silico%2520%25E2%2580%259Ccompound%2520safety%2520evaluator%25E2%2580%259D%2520designing%2520safer%2520medicines%2520in%2520discovery%26pub%3DSCI%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Uetrecht, J.</span><span> </span><span class="NLM_article-title">Idiosyncratic drug reactions: current understanding</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">539</span><span class="refDoi"> DOI: 10.1146/annurev.pharmtox.47.120505.105150</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1146%2Fannurev.pharmtox.47.120505.105150" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=16879083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1altb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=513-539&author=J.+Uetrecht&title=Idiosyncratic+drug+reactions%3A+current+understanding&doi=10.1146%2Fannurev.pharmtox.47.120505.105150"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Idiosyncratic drug reactions: current understanding</span></div><div class="casAuthors">Uetrecht, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">513-539</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Clin. characteristics and circumstantial evidence suggest that idiosyncratic drug reactions are caused by reactive metabolites and are immune-mediated; however, there are few definitive data and there are likely exceptions.  There are three principal hypotheses for how reactive metabolites might induce an immune-mediated idiosyncratic reaction: the hapten hypothesis, the danger hypothesis, and the PI hypothesis.  It has been proposed that some idiosyncratic reactions, esp. those involving the liver, represent metabolic idiosyncrasy; however, there are even less data to support this hypothesis.  The unpredictable nature of these reactions makes mechanistic studies difficult.  There is a very strong assocn. with specific human leukocyte antigen (HLA) genes for certain reactions, but this has only been demonstrated for very few drugs.  Animal models represent a very powerful tool for mechanistic studies, but the no. of valid models is also limited.  There may be biomarkers of risk; however, much more work needs to be done.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwjyupTxgQMrVg90H21EOLACvtfcHk0lhRYyTKZm5mPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1altb0%253D&md5=587b03e88f3b881c87d383818bea7f47</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pharmtox.47.120505.105150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pharmtox.47.120505.105150%26sid%3Dliteratum%253Aachs%26aulast%3DUetrecht%26aufirst%3DJ.%26atitle%3DIdiosyncratic%2520drug%2520reactions%253A%2520current%2520understanding%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2007%26volume%3D47%26spage%3D513%26epage%3D539%26doi%3D10.1146%2Fannurev.pharmtox.47.120505.105150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Chalasani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjornsson, E.</span><span> </span><span class="NLM_article-title">Risk factors for idiosyncratic drug-induced liver injury</span> <span class="citation_source-journal">Gastroenterology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">2246</span><span class="NLM_x">–</span> <span class="NLM_lpage">2259</span><span class="refDoi"> DOI: 10.1053/j.gastro.2010.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1053%2Fj.gastro.2010.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=20394749" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnslaku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2010&pages=2246-2259&author=N.+Chalasaniauthor=E.+Bjornsson&title=Risk+factors+for+idiosyncratic+drug-induced+liver+injury&doi=10.1053%2Fj.gastro.2010.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">Risk factors for idiosyncratic drug-induced liver injury</span></div><div class="casAuthors">Chalasani, Naga; Bjornsson, Einar</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2246-2259</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Idiosyncratic drug-induced liver injury (DILI) is a rare disorder that is not related directly to dosage and little is known about individuals who are at increased risk.  There are no suitable preclin. models for the study of idiosyncratic DILI and its pathogenesis is poorly understood.  It is likely to arise from complex interactions among genetic, nongenetic host susceptibility, and environmental factors.  Nongenetic risk factors include age, sex, and other diseases (eg, chronic liver disease or human immunodeficiency virus infection).  Compd.-specific risk factors include daily dose, metab. characteristics, and propensity for drug interactions.  Alc. consumption has been proposed as a risk factor for DILI from medications, but there is insufficient evidence to support this.  Many studies have explored genetic defects that might be involved in pathogenesis and focused on genes involved in drug metab. and the immune response.  Multicenter databases of patients with DILI (the United States Drug Induced Liver Injury Network, DILIGEN, and the Spanish DILI registry) are important tools for clin. and genetic research.  A genome-wide assocn. study of flucloxacillin hepatotoxicity has yielded groundbreaking results and many similar studies are underway.  Nonetheless, DILI is challenging to investigate because of its rarity, the lack of exptl. models, the no. of medications that might cause it, and challenges to diagnosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8ybOkEsO25rVg90H21EOLACvtfcHk0lhRYyTKZm5mPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnslaku7c%253D&md5=ed4fc7b289b9ffadeca654a26f4f2d5d</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2010.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2010.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DChalasani%26aufirst%3DN.%26aulast%3DBjornsson%26aufirst%3DE.%26atitle%3DRisk%2520factors%2520for%2520idiosyncratic%2520drug-induced%2520liver%2520injury%26jtitle%3DGastroenterology%26date%3D2010%26volume%3D138%26spage%3D2246%26epage%3D2259%26doi%3D10.1053%2Fj.gastro.2010.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Tujios, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fontana, R. J.</span><span> </span><span class="NLM_article-title">Mechanisms of drug-induced liver injury from bedside to bench</span> <span class="citation_source-journal">Nat. Rev. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span><span class="refDoi"> DOI: 10.1038/nrgastro.2011.22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1038%2Fnrgastro.2011.22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=21386809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktFKntro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=202-211&author=S.+Tujiosauthor=R.+J.+Fontana&title=Mechanisms+of+drug-induced+liver+injury+from+bedside+to+bench&doi=10.1038%2Fnrgastro.2011.22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10dR"><div class="casContent"><span class="casTitleNuber">10d</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of drug-induced liver injury: from bedside to bench</span></div><div class="casAuthors">Tujios, Shannan; Fontana, Robert J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Gastroenterology & Hepatology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">202-211</span>CODEN:
                <span class="NLM_cas:coden">NRGHA9</span>;
        ISSN:<span class="NLM_cas:issn">1759-5045</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The mechanisms of drug-induced liver injury (DILI) are not well understood.  In this Review, the authors propose that a bedside to bench approach involving the study of clinicopathol. features of patients with DILI can provide insight into the mechanisms underlying this condition.  The authors also discuss the potential role of several factors, including mitochondrial toxicity and the host immune system, in the etiopathogenesis of DILI.  The low incidence of idiosyncratic drug-induced liver injury (DILI), together with the lack of a reliable diagnostic biomarker and robust preclin. and in vitro toxicol. test systems for the condition have limited our ability to define the mechanisms of DILI.  A notable exception is acetaminophen hepatotoxicity, which is assocd. with the formation of a well-characterized and highly reactive intermediate metabolite, N-acetyl-p-benzoquinone imine.  However, studies have also suggested a role for the host immune response and variation in the expression of the lymphocyte CD44 gene in the pathogenesis of acetaminophen hepatotoxicity.  A careful review of the lab., clin. and histol. phenotype of patients with DILI can provide potential clues to the mechanisms of disease pathogenesis, as obsd. with fialuridine and valproate hepatotoxicity.  In addn., the use of transcriptomic and genomic approaches in patients with well-characterized DILI has provided important insights into the involvement of the host immune response in the pathogenesis of hepatotoxicity assocd. with the administration of flucloxacillin, lumiracoxib or ximelagatran.  This Review highlights new developments regarding the potential role of reactive metabolites, mitochondrial toxicity, host immune-response pathways and biliary transporters in the etiopathogenesis of DILI.  Going forward, a bedside-to-bench approach could improve our understanding of the mechanisms and risk factors for DILI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKmG8kDlaH5bVg90H21EOLACvtfcHk0lhu-1mB87U7ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktFKntro%253D&md5=cd55bdf561cea3f34c62f998ebed98fc</span></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1038%2Fnrgastro.2011.22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrgastro.2011.22%26sid%3Dliteratum%253Aachs%26aulast%3DTujios%26aufirst%3DS.%26aulast%3DFontana%26aufirst%3DR.%2BJ.%26atitle%3DMechanisms%2520of%2520drug-induced%2520liver%2520injury%2520from%2520bedside%2520to%2520bench%26jtitle%3DNat.%2520Rev.%2520Gastroenterol.%2520Hepatol.%26date%3D2011%26volume%3D8%26spage%3D202%26epage%3D211%26doi%3D10.1038%2Fnrgastro.2011.22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Oh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curl, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amidon, G. L.</span><span> </span><span class="NLM_article-title">Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1023/A:1018947113238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1023%2FA%3A1018947113238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=8456075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADyaK3sXhs1SmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1993&pages=264-270&author=D.+Ohauthor=R.+L.+Curlauthor=G.+L.+Amidon&title=Estimating+the+fraction+dose+absorbed+from+suspensions+of+poorly+soluble+compounds+in+humans%3A+a+mathematical+model&doi=10.1023%2FA%3A1018947113238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model</span></div><div class="casAuthors">Oh, Doo Man; Curl, Rane L.; Amidon, Gordon L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">264-70</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">A microscopic mass balance approach has been developed to predict the fraction dose absorbed of suspensions of poorly sol. compds.  The math. model includes four fundamental dimensionless parameters to est. the fraction dose absorbed: initial satn. (Is), absorption no. (An), dose no. (Do), and dissoln. no. (Dn).  The fraction dose absorbed (F) increases with increasing Is, An, and Dn and with decreasing Do.  At higher Dn and lower Do, the fraction dose absorbed reaches the maximal F, which depends only on An.  The dissoln. no. limit on F can appear at both lower Do and lower Dn.  It is shown that the extent fo drug absorption is expected to be highly variable when Dn and Do are approx. one.  Furthermore, by calcg. these dimensionless groups for a given compd., a formulation scientists can est. not only the extent of drug absorption but also the effect, if any, of particle size redn. on the extent of drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopaxhSvKyLwrVg90H21EOLACvtfcHk0liverDR50ylOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhs1SmsLw%253D&md5=a83a50cd018fc09bd4b3142305199fa9</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1023%2FA%3A1018947113238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1018947113238%26sid%3Dliteratum%253Aachs%26aulast%3DOh%26aufirst%3DD.%26aulast%3DCurl%26aufirst%3DR.%2BL.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26atitle%3DEstimating%2520the%2520fraction%2520dose%2520absorbed%2520from%2520suspensions%2520of%2520poorly%2520soluble%2520compounds%2520in%2520humans%253A%2520a%2520mathematical%2520model%26jtitle%3DPharm.%2520Res.%26date%3D1993%26volume%3D10%26spage%3D264%26epage%3D270%26doi%3D10.1023%2FA%3A1018947113238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Dahan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amidon, G. L.</span><span> </span><span class="NLM_article-title">Prediction of solubility and permeability class membership: provisional BCS classification of the world top oral drugs</span> <span class="citation_source-journal">AAPS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">740</span><span class="NLM_x">–</span> <span class="NLM_lpage">746</span><span class="refDoi"> DOI: 10.1208/s12248-009-9144-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1208%2Fs12248-009-9144-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=740-746&author=A.+Dahanauthor=J.+M.+Millerauthor=G.+L.+Amidon&title=Prediction+of+solubility+and+permeability+class+membership%3A+provisional+BCS+classification+of+the+world+top+oral+drugs&doi=10.1208%2Fs12248-009-9144-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1208%2Fs12248-009-9144-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-009-9144-x%26sid%3Dliteratum%253Aachs%26aulast%3DDahan%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DJ.%2BM.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26atitle%3DPrediction%2520of%2520solubility%2520and%2520permeability%2520class%2520membership%253A%2520provisional%2520BCS%2520classification%2520of%2520the%2520world%2520top%2520oral%2520drugs%26jtitle%3DAAPS%2520J.%26date%3D2009%26volume%3D11%26spage%3D740%26epage%3D746%26doi%3D10.1208%2Fs12248-009-9144-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Kerns, E. H.; Di, Li.</span> <span class="citation_source-book">Drug-Like Properties: Concepts, Structure Design and Methods: From ADME to Toxicity Optimization</span>; <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>p  <span class="NLM_fpage">223</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=223&author=E.+H.+Kerns&author=Li.+Di&title=Drug-Like+Properties%3A+Concepts%2C+Structure+Design+and+Methods%3A+From+ADME+to+Toxicity+Optimization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DKerns%26aufirst%3DE.%2BH.%26btitle%3DDrug-Like%2520Properties%253A%2520Concepts%252C%2520Structure%2520Design%2520and%2520Methods%253A%2520From%2520ADME%2520to%2520Toxicity%2520Optimization%26pub%3DAcademic%2520Press%26date%3D2008%26spage%3D223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><div class="note"><p class="first last">The MK499 IC<sub>50</sub> values were acquired by radio ligand binding competition experiments using membrane preparations from human embryonic kidney cells that express hERG. IC<sub>50</sub> values are reported as the averages of at least two independent determinations; standard deviations are within ±25–50% of IC<sub>50</sub> values. For assay detail, see</p></div><span class="NLM_contrib-group">Bell, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallicchio, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beshore, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buser, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Culberson, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davide, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis-Hutchings, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernandes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbs, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbrook, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homnick, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huff, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassahun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koblan, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohl, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lobell, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. J.,  Jr</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Omer, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigues, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, T. M.</span><span> </span><span class="NLM_article-title">Design and biological activity of (S)-4-{[1-(3-chlorobenzyl-2-oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethylbenzonitrile, a 3-Aminopyrrolidine farnesyltransferase inhibitor with excellent cell potency</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">2933</span><span class="NLM_x">–</span> <span class="NLM_lpage">2949</span><div class="note"><p class="first last">and references therein</p></div><span class="refDoi"> DOI: 10.1021/jm010156p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010156p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=2933-2949&author=I.+M.+Bellauthor=S.+N.+Gallicchioauthor=M.+Abramsauthor=D.+C.+Beshoreauthor=C.+A.+Buserauthor=J.+C.+Culbersonauthor=J.+Davideauthor=M.+Ellis-Hutchingsauthor=C.+Fernandesauthor=J.+B.+Gibbsauthor=S.+L.+Grahamauthor=G.+D.+Hartmanauthor=D.+C.+Heimbrookauthor=C.+F.+Homnickauthor=J.+R.+Huffauthor=K.+Kassahunauthor=K.+S.+Koblanauthor=N.+E.+Kohlauthor=R.+B.+Lobellauthor=J.+J.+Lynchauthor=P.+A.+Millerauthor=C.+A.+Omerauthor=A.+D.+Rodriguesauthor=E.+S.+Walshauthor=T.+M.+Williams&title=Design+and+biological+activity+of+%28S%29-4-%7B%5B1-%283-chlorobenzyl-2-oxopyrrolidin-3-ylamino%5Dmethyl%7Dimidazol-1-ylmethylbenzonitrile%2C+a+3-Aminopyrrolidine+farnesyltransferase+inhibitor+with+excellent+cell+potency&doi=10.1021%2Fjm010156p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm010156p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010156p%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DI.%2BM.%26aulast%3DGallicchio%26aufirst%3DS.%2BN.%26aulast%3DAbrams%26aufirst%3DM.%26aulast%3DBeshore%26aufirst%3DD.%2BC.%26aulast%3DBuser%26aufirst%3DC.%2BA.%26aulast%3DCulberson%26aufirst%3DJ.%2BC.%26aulast%3DDavide%26aufirst%3DJ.%26aulast%3DEllis-Hutchings%26aufirst%3DM.%26aulast%3DFernandes%26aufirst%3DC.%26aulast%3DGibbs%26aufirst%3DJ.%2BB.%26aulast%3DGraham%26aufirst%3DS.%2BL.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DHeimbrook%26aufirst%3DD.%2BC.%26aulast%3DHomnick%26aufirst%3DC.%2BF.%26aulast%3DHuff%26aufirst%3DJ.%2BR.%26aulast%3DKassahun%26aufirst%3DK.%26aulast%3DKoblan%26aufirst%3DK.%2BS.%26aulast%3DKohl%26aufirst%3DN.%2BE.%26aulast%3DLobell%26aufirst%3DR.%2BB.%26aulast%3DLynch%26aufirst%3DJ.%2BJ.%26aulast%3DMiller%26aufirst%3DP.%2BA.%26aulast%3DOmer%26aufirst%3DC.%2BA.%26aulast%3DRodrigues%26aufirst%3DA.%2BD.%26aulast%3DWalsh%26aufirst%3DE.%2BS.%26aulast%3DWilliams%26aufirst%3DT.%2BM.%26atitle%3DDesign%2520and%2520biological%2520activity%2520of%2520%2528S%2529-4-%257B%255B1-%25283-chlorobenzyl-2-oxopyrrolidin-3-ylamino%255Dmethyl%257Dimidazol-1-ylmethylbenzonitrile%252C%2520a%25203-Aminopyrrolidine%2520farnesyltransferase%2520inhibitor%2520with%2520excellent%2520cell%2520potency%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D2933%26epage%3D2949%26doi%3D10.1021%2Fjm010156p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Redfern, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlsson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palethorpe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegl, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strang, I</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallis, R.</span><span> </span><span class="NLM_article-title">Relationship between preclinical cardiac electrophysiology, clinical QT interval prolongation and Torsade de Pontes for a broad range of drugs: evidence for provisional safety margin in drug development</span> <span class="citation_source-journal">Cardiovasc. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">32</span><span class="NLM_x">–</span> <span class="NLM_lpage">45</span><span class="refDoi"> DOI: 10.1016/S0008-6363(02)00846-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1016%2FS0008-6363%2802%2900846-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=32-45&author=W.+S.+Redfernauthor=L.+Carlssonauthor=A.+S.+Davisauthor=W.+G.+Lynchauthor=I.+MacKenzieauthor=S.+Palethorpeauthor=P.+Sieglauthor=I+Strangauthor=A.+Sullivanauthor=R.+Wallis&title=Relationship+between+preclinical+cardiac+electrophysiology%2C+clinical+QT+interval+prolongation+and+Torsade+de+Pontes+for+a+broad+range+of+drugs%3A+evidence+for+provisional+safety+margin+in+drug+development&doi=10.1016%2FS0008-6363%2802%2900846-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1016%2FS0008-6363%2802%2900846-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6363%252802%252900846-5%26sid%3Dliteratum%253Aachs%26aulast%3DRedfern%26aufirst%3DW.%2BS.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DA.%2BS.%26aulast%3DLynch%26aufirst%3DW.%2BG.%26aulast%3DMacKenzie%26aufirst%3DI.%26aulast%3DPalethorpe%26aufirst%3DS.%26aulast%3DSiegl%26aufirst%3DP.%26aulast%3DStrang%26aufirst%3DI%26aulast%3DSullivan%26aufirst%3DA.%26aulast%3DWallis%26aufirst%3DR.%26atitle%3DRelationship%2520between%2520preclinical%2520cardiac%2520electrophysiology%252C%2520clinical%2520QT%2520interval%2520prolongation%2520and%2520Torsade%2520de%2520Pontes%2520for%2520a%2520broad%2520range%2520of%2520drugs%253A%2520evidence%2520for%2520provisional%2520safety%2520margin%2520in%2520drug%2520development%26jtitle%3DCardiovasc.%2520Res.%26date%3D2003%26volume%3D58%26spage%3D32%26epage%3D45%26doi%3D10.1016%2FS0008-6363%2802%2900846-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Trepakova, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malik, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imredy, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penniman, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dech, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salata, J. J.</span><span> </span><span class="NLM_article-title">Application of PatchXpress planar patch clamp technology to the screening of new drug candidates for cardiac KCNQ1/KCNE1 (I Ks) activity</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">627</span><span class="refDoi"> DOI: 10.1089/adt.2007.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1089%2Fadt.2007.091" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2007&pages=617-627&author=E.+S.+Trepakovaauthor=M.+G.+Malikauthor=J.+P.+Imredyauthor=J.+R.+Pennimanauthor=S.+J.+Dechauthor=J.+J.+Salata&title=Application+of+PatchXpress+planar+patch+clamp+technology+to+the+screening+of+new+drug+candidates+for+cardiac+KCNQ1%2FKCNE1+%28I+Ks%29+activity&doi=10.1089%2Fadt.2007.091"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1089%2Fadt.2007.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2007.091%26sid%3Dliteratum%253Aachs%26aulast%3DTrepakova%26aufirst%3DE.%2BS.%26aulast%3DMalik%26aufirst%3DM.%2BG.%26aulast%3DImredy%26aufirst%3DJ.%2BP.%26aulast%3DPenniman%26aufirst%3DJ.%2BR.%26aulast%3DDech%26aufirst%3DS.%2BJ.%26aulast%3DSalata%26aufirst%3DJ.%2BJ.%26atitle%3DApplication%2520of%2520PatchXpress%2520planar%2520patch%2520clamp%2520technology%2520to%2520the%2520screening%2520of%2520new%2520drug%2520candidates%2520for%2520cardiac%2520KCNQ1%252FKCNE1%2520%2528I%2520Ks%2529%2520activity%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2007%26volume%3D5%26spage%3D617%26epage%3D627%26doi%3D10.1089%2Fadt.2007.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Morissette, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepakova, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imredy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagrutta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaves, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoagland, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoe, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zrada, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travis, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zingaro, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerenser, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedrichs, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salata, J. J.</span><span> </span><span class="NLM_article-title">The anesthetized guinea pig: an effective early cardiovascular derisking and lead optimization model</span> <span class="citation_source-journal">J. Pharmacol. Toxicol. Methods</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">137</span><span class="NLM_x">–</span> <span class="NLM_lpage">149</span><span class="refDoi"> DOI: 10.1016/j.vascn.2013.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1016%2Fj.vascn.2013.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=23649000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFKkt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=137-149&author=P.+Morissetteauthor=M.+Nishidaauthor=E.+Trepakovaauthor=J.+Imredyauthor=A.+Lagruttaauthor=A.+Chavesauthor=K.+Hoaglandauthor=C.+L.+Hoeauthor=M.+M.+Zradaauthor=J.+J.+Travisauthor=G.+J.+Zingaroauthor=P.+Gerenserauthor=G.+Friedrichsauthor=J.+J.+Salata&title=The+anesthetized+guinea+pig%3A+an+effective+early+cardiovascular+derisking+and+lead+optimization+model&doi=10.1016%2Fj.vascn.2013.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">The anesthetized guinea pig: An effective early cardiovascular derisking and lead optimization model</span></div><div class="casAuthors">Morissette, Pierre; Nishida, Masahiro; Trepakova, Elena; Imredy, John; Lagrutta, Armando; Chaves, Alysia; Hoagland, Kimberly; Hoe, Chao-Min Lei; Zrada, Matthew M.; Travis, Jeffrey J.; Zingaro, Gloria J.; Gerenser, Pamela; Friedrichs, Greg; Salata, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological and Toxicological Methods</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">137-149</span>CODEN:
                <span class="NLM_cas:coden">JPTMEZ</span>;
        ISSN:<span class="NLM_cas:issn">1056-8719</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In recent years, the anesthetized guinea pig was used increasingly to evaluate the cardiovascular effects of drug-candidate mols. during lead optimization prior to conducting longer, more resource intensive safety pharmacol. and toxicol. studies.  The aim of these studies was to evaluate the correlations between pharmacol.-induced ECG changes in the anesthetized cardiovascular guinea pig (CVGP) with ECG changes in conscious non-rodent telemetry models, human clin. studies, and effects on key cardiac ion channels.  We compared the effects of 38 agents on ion channel inhibition to their ECG effects in the CVGP.  26 Of these agents were also evaluated in non-rodent telemetry and compared to the results in the CVGP.  The CVGP was highly sensitive for detecting QTc, PR, and QRS interval prolongation mediated by inhibition of hERG, hCav1.2 and hNav1.5, resp.  There were robust correlations between ion channel inhibitory potencies and the free blood plasma concns. (Cu) producing prolongation of the QTc, PR, or QRS interval.  Further evaluation showed that ECG changes in the CVGP were predictive of their effects on the QTc, PR, and QRS intervals in non-rodent telemetry models with 92%, 92%, and 100% accuracy, resp.  The CVGP proved to be 100% specific and 88%, 75%, and 100% sensitive for QTc, PR, and QRS interval prolongation, resp.  Similarly, the Cu that prolonged the QTc, PR, and QRS in CVGP and humans correlated well.  The CVGP is a sensitive model for assessing QTc, PR, and QRS prolongation elicited by effects on hERG, hCav1.2, and hNav1.5, resp.  ECG changes in the CVGP are predictive of changes in non-rodent telemetry models and in humans (QTc).  ECG parameters can be reliably evaluated with the CVGP model which increases the efficiency of CV derisking.  Importantly, the design and implementation of this model is consistent with the "3Rs" for animal research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpk3tOc0LoFCbVg90H21EOLACvtfcHk0lg91nsoO87dvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFKkt74%253D&md5=ad6704867172f645536eca06fbe40080</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1016%2Fj.vascn.2013.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.vascn.2013.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DMorissette%26aufirst%3DP.%26aulast%3DNishida%26aufirst%3DM.%26aulast%3DTrepakova%26aufirst%3DE.%26aulast%3DImredy%26aufirst%3DJ.%26aulast%3DLagrutta%26aufirst%3DA.%26aulast%3DChaves%26aufirst%3DA.%26aulast%3DHoagland%26aufirst%3DK.%26aulast%3DHoe%26aufirst%3DC.%2BL.%26aulast%3DZrada%26aufirst%3DM.%2BM.%26aulast%3DTravis%26aufirst%3DJ.%2BJ.%26aulast%3DZingaro%26aufirst%3DG.%2BJ.%26aulast%3DGerenser%26aufirst%3DP.%26aulast%3DFriedrichs%26aufirst%3DG.%26aulast%3DSalata%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520anesthetized%2520guinea%2520pig%253A%2520an%2520effective%2520early%2520cardiovascular%2520derisking%2520and%2520lead%2520optimization%2520model%26jtitle%3DJ.%2520Pharmacol.%2520Toxicol.%2520Methods%26date%3D2013%26volume%3D68%26spage%3D137%26epage%3D149%26doi%3D10.1016%2Fj.vascn.2013.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fermini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossa, A. A.</span><span> </span><span class="NLM_article-title">The impact of drug-induced QT interval prolongation on drug discovery and development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span><span class="refDoi"> DOI: 10.1038/nrd1108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1038%2Fnrd1108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=439-447&author=B.+Ferminiauthor=A.+A.+Fossa&title=The+impact+of+drug-induced+QT+interval+prolongation+on+drug+discovery+and+development&doi=10.1038%2Fnrd1108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1038%2Fnrd1108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1108%26sid%3Dliteratum%253Aachs%26aulast%3DFermini%26aufirst%3DB.%26aulast%3DFossa%26aufirst%3DA.%2BA.%26atitle%3DThe%2520impact%2520of%2520drug-induced%2520QT%2520interval%2520prolongation%2520on%2520drug%2520discovery%2520and%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D439%26epage%3D447%26doi%3D10.1038%2Fnrd1108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Roden, D. M.</span><span> </span><span class="NLM_article-title">Drug-induced prolongation of the QT interval</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">1013</span><span class="NLM_x">–</span> <span class="NLM_lpage">1022</span><span class="refDoi"> DOI: 10.1056/NEJMra032426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1056%2FNEJMra032426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=14999113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFGjs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=1013-1022&author=D.+M.+Roden&title=Drug-induced+prolongation+of+the+QT+interval&doi=10.1056%2FNEJMra032426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15bR"><div class="casContent"><span class="casTitleNuber">15b</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-induced prolongation of the QT interval</span></div><div class="casAuthors">Roden, Dan M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1013-1022</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA8PoMXlMg57Vg90H21EOLACvtfcHk0ljk6Vf7z_EmJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFGjs7Y%253D&md5=a020a545700649d9914ed8dc61910244</span></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1056%2FNEJMra032426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra032426%26sid%3Dliteratum%253Aachs%26aulast%3DRoden%26aufirst%3DD.%2BM.%26atitle%3DDrug-induced%2520prolongation%2520of%2520the%2520QT%2520interval%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D1013%26epage%3D1022%26doi%3D10.1056%2FNEJMra032426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poluzzi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Ponti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span> </span><span class="NLM_article-title">Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">3844</span><span class="NLM_x">–</span> <span class="NLM_lpage">3853</span><span class="refDoi"> DOI: 10.1021/jm0208875</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0208875" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD38XlsFalsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=3844-3853&author=A.+Cavalliauthor=E.+Poluzziauthor=F.+De+Pontiauthor=M.+Recanatini&title=Toward+a+pharmacophore+for+drugs+inducing+the+long+QT+syndrome%3A+insights+from+a+CoMFA+study+of+HERG+K%2B+channel+blockers&doi=10.1021%2Fjm0208875"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16aR"><div class="casContent"><span class="casTitleNuber">16a</span><div class="casTitle"><span class="NLM_cas:atitle">Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers</span></div><div class="casAuthors">Cavalli, Andrea; Poluzzi, Elisabetta; De Ponti, Fabrizio; Recanatini, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3844-3853</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this paper, we present a pharmacophore for QT-prolonging drugs, along with a 3D QSAR (CoMFA) study for a series of very structurally variegate HERG K+ channel blockers.  The blockade of HERG K+ channels is one of the most important mol. mechanisms through which QT-prolonging drugs increase cardiac action potential duration.  Since QT prolongation is one of the most undesirable side effects of drugs, we first tried to identify the min. set of mol. features responsible for this action and then we attempted to develop a quant. model correlating the 3D stereoelectronic characteristics of the mols. with their HERG blocking potency.  Having considered an initial set of 31 QT-prolonging drugs for which the HERG K+ channel blocking activity was measured on mammalian transfected cells, we started the construction of a theor. screening tool able to predict whether a new mol. can interact with the HERG channel and eventually induce the long QT syndrome.  This in silico tool might be useful in the design of new drug candidates devoid of the physicochem. features likely to cause the above-mentioned side effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7WFt3kf6ZVLVg90H21EOLACvtfcHk0ljk6Vf7z_EmJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlsFalsrk%253D&md5=5e980476ccc9a8a6244aaab230eeb701</span></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=10.1021%2Fjm0208875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0208875%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DPoluzzi%26aufirst%3DE.%26aulast%3DDe%2BPonti%26aufirst%3DF.%26aulast%3DRecanatini%26aufirst%3DM.%26atitle%3DToward%2520a%2520pharmacophore%2520for%2520drugs%2520inducing%2520the%2520long%2520QT%2520syndrome%253A%2520insights%2520from%2520a%2520CoMFA%2520study%2520of%2520HERG%2520K%252B%2520channel%2520blockers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D3844%26epage%3D3853%26doi%3D10.1021%2Fjm0208875" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Jamieson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moir, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G.</span><span> </span><span class="NLM_article-title">Medicinal Chemistry of hERG optimizations: highlights and hang-ups</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5029</span><span class="NLM_x">–</span> <span class="NLM_lpage">5046</span><span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+Chemistry+of+hERG+optimizations%3A+highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16bR"><div class="casContent"><span class="casTitleNuber">16b</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lihWhoEcEwEqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520Chemistry%2520of%2520hERG%2520optimizations%253A%2520highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hopkins, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groom, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alex, A.</span><span> </span><span class="NLM_article-title">Ligand efficiency: A useful metric for lead selection</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">430</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1016/S1359-6446(04)03069-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1016%2FS1359-6446%2804%2903069-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=15109945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=430-431&author=A.+L.+Hopkinsauthor=C.+R.+Groomauthor=A.+Alex&title=Ligand+efficiency%3A+A+useful+metric+for+lead+selection&doi=10.1016%2FS1359-6446%2804%2903069-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency: a useful metric for lead selection</span></div><div class="casAuthors">Hopkins Andrew L; Groom Colin R; Alex Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">430-1</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdMyKW_d6RPeIHSmpohpd0fW6udTcc2eb-xFZ_WWJJdrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c3ht1ygtw%253D%253D&md5=eb19a1bca53247d0bd9adcb99d5817e6</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903069-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903069-7%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DGroom%26aufirst%3DC.%2BR.%26aulast%3DAlex%26aufirst%3DA.%26atitle%3DLigand%2520efficiency%253A%2520A%2520useful%2520metric%2520for%2520lead%2520selection%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D430%26epage%3D431%26doi%3D10.1016%2FS1359-6446%2804%2903069-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Abad-Zapatero, C.</span><span> </span><span class="NLM_article-title">Ligand efficiency indices for effective drug discovery</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">488</span><span class="refDoi"> DOI: 10.1517/17460441.2.4.469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1517%2F17460441.2.4.469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=23484756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmtVCqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=469-488&author=C.+Abad-Zapatero&title=Ligand+efficiency+indices+for+effective+drug+discovery&doi=10.1517%2F17460441.2.4.469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand efficiency indices for effective drug discovery</span></div><div class="casAuthors">Abad-Zapatero, Cele</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">469-488</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Successful drug discovery requires the optimization of a large no. of variables ranging from strictly physicochem. parameters such as mol. wt. to more complex parameters related to toxicity and bioavailability.  Presently, structure-based methodologies influence many aspects of the drug discovery process from lead discovery to the final preclin. characterization.  However, crit. biol. issues along the path to the market have diminished the impact and power of this methodol.  The physicochem. properties of the novel chem. entities designed and guided by structural methods have become the subject of intense scrutiny from lead discovery to drug candidate.  The idea of ligand efficiency (binding energy/non-hydrogen atoms) has recently emerged as a useful guide to optimize fragment and lead selection in the discovery process.  More generalized concepts of ligand efficiency, related to efficiency per dalton and per unit of polar surface area, have also been introduced and will be discussed in the broader context.  Preliminary results and trends obtained using ligand efficiencies as guides are reviewed and their future application to guide drug discovery will be discussed, as well as their integration into the structure-based drug design methods to make them more effective and numerically robust.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmKduo41JcS7Vg90H21EOLACvtfcHk0liikdUgKdl10w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmtVCqsL4%253D&md5=a1682fbc4545d8eab3a44417c0e88869</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1517%2F17460441.2.4.469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2.4.469%26sid%3Dliteratum%253Aachs%26aulast%3DAbad-Zapatero%26aufirst%3DC.%26atitle%3DLigand%2520efficiency%2520indices%2520for%2520effective%2520drug%2520discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2007%26volume%3D2%26spage%3D469%26epage%3D488%26doi%3D10.1517%2F17460441.2.4.469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">1420</span><span class="NLM_x">–</span> <span class="NLM_lpage">1456</span><span class="refDoi"> DOI: 10.1021/tx200211v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200211v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlCitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1420-1456&author=N.+A.+Meanwell&title=Improving+drug+candidates+by+design%3A+a+focus+on+physicochemical+properties+as+a+means+of+improving+compound+disposition+and+safety&doi=10.1021%2Ftx200211v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1420-1456</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of small mol. drug candidates from the discovery phase to a marketed product continues to be a challenging enterprise with very low success rates that have fostered the perception of poor productivity by the pharmaceutical industry.  Although there have been significant advances in preclin. profiling that have improved compd. triaging and altered the underlying reasons for compd. attrition, the failure rates have not appreciably changed.  As part of an effort to more deeply understand the reasons for candidate failure, there has been considerable interest in analyzing the physicochem. properties of marketed drugs for the purpose of comparing with drugs in discovery and development as a means capturing recent trends in drug design.  The scenario that has emerged is one in which contemporary drug discovery is thought to be focused too heavily on advancing candidates with profiles that are most easily satisfied by mols. with increased mol. wt. and higher overall lipophilicity.  The preponderance of mols. expressing these properties is frequently a function of increased arom. ring count when compared with that of the drugs launched in the latter half of the 20th century and may reflect a preoccupation with maximizing target affinity rather than taking a more holistic approach to drug design.  These attributes not only present challenges for formulation and absorption but also may influence the manifestation of toxicity during development.  By providing some definition around the optimal physicochem. properties assocd. with marketed drugs, guidelines for drug design have been developed that are based largely on calcd. parameters and which may readily be applied by medicinal chemists as an aid to understanding candidate quality.  The physicochem. properties of a mol. that are consistent with the potential for good oral absorption were initially defined by Lipinski, with addnl. insights allowing further refinement, while deeper analyses have explored the correlation with metabolic stability and toxicity.  These insights have been augmented by careful analyses of physicochem. aspects of drug-target interactions, with thermodn. profiling indicating that the signature of best-in-class drugs is a dependence on enthalpy to drive binding energetics rather than entropy, which is dependent on lipophilicity.  Optimization of the entropic contribution to the binding energy of a ligand to its target is generally much easier than refining the enthalpic element.  Consequently, in the absence of a fundamental understanding of the thermodn. complexion of an interaction, the design of mols. with increased lipophilicity becomes almost inevitable.  The application of ligand efficiency, a measure of affinity per heavy atom, group efficiency, which assesses affinity in the context of structural changes, and lipophilic ligand efficiency, which relates potency to lipophilicity, offer less sophisticated but practically useful anal. algorithms to assess the quality of drug-target interactions.  These parameters are readily calcd. and can be applied to lead optimization programs in a fashion that helps to maximize potency while minimizing the kind of lipophilic burden that has been dubbed "mol. obesity".  Several recently described lead optimization campaigns provide illustrative, informative, and productive examples of the effect of paying close attention to carefully controlling physicochem. properties by monitoring ligand efficiency and lipophilic ligand efficiency.  However, to be successful during the lead optimization phase, drug candidate identification programs will need to adopt a holistic approach that integrates multiple parameters, many of which will have unique dependencies on both the drug target and the specific chemotype under prosecution.  Nevertheless, there are many important drug targets that necessitate working in space beyond that which has been defined by the retrospective analyses of marketed drugs and which will require adaptation of some of the guideposts that are useful in directing lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQrUfIwZiIR7Vg90H21EOLACvtfcHk0liikdUgKdl10w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlCitLs%253D&md5=9ddcf6dc81bf8ab0441df5037979ff4e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Ftx200211v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200211v%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DImproving%2520drug%2520candidates%2520by%2520design%253A%2520a%2520focus%2520on%2520physicochemical%2520properties%2520as%2520a%2520means%2520of%2520improving%2520compound%2520disposition%2520and%2520safety%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1420%26epage%3D1456%26doi%3D10.1021%2Ftx200211v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span><span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision+making+in+medicinal+chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision%2520making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span> </span><span class="NLM_article-title">Role of physicochemical properties and ligand lipophilicity in addressing drug safety risks</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span><span class="refDoi"> DOI: 10.1016/S0065-7743(10)45023-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1016%2FS0065-7743%2810%2945023-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=381-391&author=M.+P.+Edwardsauthor=D.+A.+Price&title=Role+of+physicochemical+properties+and+ligand+lipophilicity+in+addressing+drug+safety+risks&doi=10.1016%2FS0065-7743%2810%2945023-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1016%2FS0065-7743%2810%2945023-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-7743%252810%252945023-X%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DRole%2520of%2520physicochemical%2520properties%2520and%2520ligand%2520lipophilicity%2520in%2520addressing%2520drug%2520safety%2520risks%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D381%26epage%3D391%26doi%3D10.1016%2FS0065-7743%2810%2945023-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Tarcsay, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nyiri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keseru, G. M.</span><span> </span><span class="NLM_article-title">Impact of lipophilic efficiency on compound quality</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1252</span><span class="NLM_x">–</span> <span class="NLM_lpage">1260</span><span class="refDoi"> DOI: 10.1021/jm201388p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201388p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVKjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1252-1260&author=A.+Tarcsayauthor=K.+Nyiriauthor=G.+M.+Keseru&title=Impact+of+lipophilic+efficiency+on+compound+quality&doi=10.1021%2Fjm201388p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19cR"><div class="casContent"><span class="casTitleNuber">19c</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of Lipophilic Efficiency on Compound Quality</span></div><div class="casAuthors">Tarcsay, Akos; Nyiri, Kinga; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1252-1260</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lipophilic efficiency indexes such as LLE and LELP were suggested to support balanced optimization of potency and ADMET profile.  Here we investigated the performance of LLE and LELP on multiple data sets representing different stages of drug discovery including fragment and HTS hits and leads, development candidates, phase II compds., and launched drugs.  Analyzing their impact on ADME and safety properties and binding thermodn., we found that both LLE and LELP help identifying better quality compds.  LLE is sensible for the development stages but does not prefer fragment-type hits, while LELP has an advantage for this class of compds. and discriminates preferred starting points effectively.  Both LLE and LELP have significant impact on ADME and safety profiles; however, LELP outperforms LLE in risk assessment at least on the present data set.  On the basis of the results reported here, monitoring lipophilic efficiency metrics could contribute significantly to compd. quality and might improve the output of medicinal chem. programs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxB8xs6-5DL7Vg90H21EOLACvtfcHk0liJ852kYcJXUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVKjsQ%253D%253D&md5=2536abef781f52806013016971c78bcb</span></div><a href="/servlet/linkout?suffix=cit19c&amp;dbid=16384&amp;doi=10.1021%2Fjm201388p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201388p%26sid%3Dliteratum%253Aachs%26aulast%3DTarcsay%26aufirst%3DA.%26aulast%3DNyiri%26aufirst%3DK.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26atitle%3DImpact%2520of%2520lipophilic%2520efficiency%2520on%2520compound%2520quality%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1252%26epage%3D1260%26doi%3D10.1021%2Fjm201388p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Anderson, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tundel, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Monodentate phosphines provide highly active catalysts for Pd-catalyzed C-N bond-forming reactions of heteroaromatic halides/amines and (H)N-heterocycles</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">6523</span><span class="NLM_x">–</span> <span class="NLM_lpage">6527</span><span class="refDoi"> DOI: 10.1002/anie.200601612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1002%2Fanie.200601612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWgsrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=6523-6527&author=K.+W.+Andersonauthor=R.+E.+Tundelauthor=T.+Ikawaauthor=R.+A.+Altmanauthor=S.+L.+Buchwald&title=Monodentate+phosphines+provide+highly+active+catalysts+for+Pd-catalyzed+C-N+bond-forming+reactions+of+heteroaromatic+halides%2Famines+and+%28H%29N-heterocycles&doi=10.1002%2Fanie.200601612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Monodentate phosphines provide highly active catalysts for Pd-catalyzed C-N bond-forming reactions of heteroaromatic halides/amines and (H)N-heterocycles</span></div><div class="casAuthors">Anderson, Kevin W.; Tundel, Rachel E.; Ikawa, Takashi; Altman, Ryan A.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">6523-6527</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Highly reactive catalysts based on palladium and dialkylbiarylphosphino ligands provide unprecedented reactivity and selectivity in C-N bond-forming processes.  The bulky monophosphine catalyst system Pd2(dba)3/I is effective for the reaction of aryl/heteroaryl halides bearing primary amides and 2-aminoheterocycles, thus showing that monodentate phosphines are viable alternatives to, and sometimes superior to, chelating ligands.  E.g., amination of 3-chlorobenzamide by morpholine gave 81% II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwitHXua7pPbVg90H21EOLACvtfcHk0liJ852kYcJXUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWgsrnP&md5=5958e76b262517af3527cea57573210a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fanie.200601612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200601612%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DK.%2BW.%26aulast%3DTundel%26aufirst%3DR.%2BE.%26aulast%3DIkawa%26aufirst%3DT.%26aulast%3DAltman%26aufirst%3DR.%2BA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DMonodentate%2520phosphines%2520provide%2520highly%2520active%2520catalysts%2520for%2520Pd-catalyzed%2520C-N%2520bond-forming%2520reactions%2520of%2520heteroaromatic%2520halides%252Famines%2520and%2520%2528H%2529N-heterocycles%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2006%26volume%3D45%26spage%3D6523%26epage%3D6527%26doi%3D10.1002%2Fanie.200601612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="note"><p class="first last"><a class="ref internalNav" href="#fig6" aria-label="Figures 6">Figures 6</a> and <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a> were generated using</p></div><div class="NLM_citation" id="rightTab-cit21"><span>Tibco Spotfire 7.0.1, <a href="http://spotfire.tibco.com" class="extLink">spotfire.tibco.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Tibco+Spotfire+7.0.1%2C+spotfire.tibco.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">van de Waterbeemd, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D. K.</span><span> </span><span class="NLM_article-title">Property-based design: optimization of drug absorption and pharmacokinetics</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">1313</span><span class="NLM_x">–</span> <span class="NLM_lpage">1333</span><span class="refDoi"> DOI: 10.1021/jm000407e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000407e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD3MXit1Whu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=1313-1333&author=H.+van+de+Waterbeemdauthor=D.+A.+Smithauthor=K.+Beaumontauthor=D.+K.+Walker&title=Property-based+design%3A+optimization+of+drug+absorption+and+pharmacokinetics&doi=10.1021%2Fjm000407e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22aR"><div class="casContent"><span class="casTitleNuber">22a</span><div class="casTitle"><span class="NLM_cas:atitle">Property-based design: optimization of drug absorption and pharmacokinetics</span></div><div class="casAuthors">van de Waterbeemd, Han; Smith, Dennis A.; Beaumont, Kevin; Walker, Don K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1313-1333</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 223 refs.  The authors discuss some aspects of the properties of biol. barriers.  In different sections the estn. of drug absorption via important barriers including gastrointestinal tract, blood-brain barrier, and skin are reviewed.  Various approaches for the measurement and computation of physicochem. and mol. properties currently used in the optimization of absorption as well as the use of physicochem. properties in the design of optimal pharmacokinetic profiles are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaQwsmoX0-mbVg90H21EOLACvtfcHk0liJ852kYcJXUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXit1Whu7c%253D&md5=3183baedca70020f4ce27f306ba0997e</span></div><a href="/servlet/linkout?suffix=cit22a&amp;dbid=16384&amp;doi=10.1021%2Fjm000407e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000407e%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bde%2BWaterbeemd%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DBeaumont%26aufirst%3DK.%26aulast%3DWalker%26aufirst%3DD.%2BK.%26atitle%3DProperty-based%2520design%253A%2520optimization%2520of%2520drug%2520absorption%2520and%2520pharmacokinetics%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D1313%26epage%3D1333%26doi%3D10.1021%2Fjm000407e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">van de Waterbeemd, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B. C.</span><span> </span><span class="NLM_article-title">Lipophilicity in pk design: methyl, ethyl, futile</span> <span class="citation_source-journal">J. Comput.-Aided Mol. Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span><span class="refDoi"> DOI: 10.1023/A:1008192010023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1023%2FA%3A1008192010023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2001&pages=273-286&author=H.+van+de+Waterbeemdauthor=D.+A.+Smithauthor=B.+C.+Jones&title=Lipophilicity+in+pk+design%3A+methyl%2C+ethyl%2C+futile&doi=10.1023%2FA%3A1008192010023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22b&amp;dbid=16384&amp;doi=10.1023%2FA%3A1008192010023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1008192010023%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bde%2BWaterbeemd%26aufirst%3DH.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DJones%26aufirst%3DB.%2BC.%26atitle%3DLipophilicity%2520in%2520pk%2520design%253A%2520methyl%252C%2520ethyl%252C%2520futile%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2001%26volume%3D15%26spage%3D273%26epage%3D286%26doi%3D10.1023%2FA%3A1008192010023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, A. M.</span><span> </span><span class="NLM_article-title">Time-related differences in the physical property profiles of oral drugs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6338</span><span class="NLM_x">–</span> <span class="NLM_lpage">6348</span><span class="refDoi"> DOI: 10.1021/jm049717d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049717d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpt1Sksbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6338-6348&author=P.+D.+Leesonauthor=A.+M.+Davis&title=Time-related+differences+in+the+physical+property+profiles+of+oral+drugs&doi=10.1021%2Fjm049717d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22cR"><div class="casContent"><span class="casTitleNuber">22c</span><div class="casTitle"><span class="NLM_cas:atitle">Time-Related Differences in the Physical Property Profiles of Oral Drugs</span></div><div class="casAuthors">Leeson, Paul D.; Davis, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">6338-6348</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Comparisons of the calcd. physicochem. properties of oral drugs launched prior to 1983 (864 drugs) and between 1983 and 2002 (329 drugs) show that mean values of lipophilicity, percent polar surface area and H-bond donor count are the same, suggesting that these are the most important oral drug-like phys. properties.  In contrast, mean values of mol. wt. and the nos. of O + N atoms, H-bond acceptors, and rotatable bonds and rings have increased in 1983-2002 drugs (by 13-29%).  Anal. of the 1983-2002 oral drugs by therapy area shows that anti-infectives and nervous system drugs have the most extreme phys. property profiles.  Cardiovascular drugs show increasing mol. wt. with year of publication, primarily a consequence of focusing on clin. proven mechanisms, with limited chem. diversity.  Drug classes other than anti-infectives show comparable distributions of lipophilicity, suggesting that this property in oral drugs is important irresp. of the drug's target.  The results suggest that the balance between polar and nonpolar drug properties is an important, unchanging feature of oral drug mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtNkiWH6Bl6bVg90H21EOLACvtfcHk0lgVr3jO0PzLHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpt1Sksbg%253D&md5=edd5cceab1ccfe3542cb4df180e3c160</span></div><a href="/servlet/linkout?suffix=cit22c&amp;dbid=16384&amp;doi=10.1021%2Fjm049717d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049717d%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DDavis%26aufirst%3DA.%2BM.%26atitle%3DTime-related%2520differences%2520in%2520the%2520physical%2520property%2520profiles%2520of%2520oral%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6338%26epage%3D6348%26doi%3D10.1021%2Fjm049717d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit22d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Lazerwith, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bahador, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canales, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerffler, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisenberg, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matles, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mertzman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morganelli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickley, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tessler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirunagari, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, W. J.</span><span> </span><span class="NLM_article-title">Optimization of pharmacokinetics through manipulation of physicochemical properties in a series of HCV inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">715</span><span class="NLM_x">–</span> <span class="NLM_lpage">719</span><span class="refDoi"> DOI: 10.1021/ml200163b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200163b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVyhu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=715-719&author=S.+E.+Lazerwithauthor=G.+Bahadorauthor=E.+Canalesauthor=G.+Chengauthor=L.+Chongauthor=M.+O.+Clarkeauthor=E.+Doerfflerauthor=E.+J.+Eisenbergauthor=J.+Hayesauthor=B.+Luauthor=Q.+Liuauthor=M.+Matlesauthor=M.+Mertzmanauthor=M.+L.+Mitchellauthor=P.+Morganelliauthor=B.+P.+Murrayauthor=M.+Robinsonauthor=R.+G.+Strickleyauthor=M.+Tesslerauthor=N.+Tirunagariauthor=J.+Wangauthor=Y.+Wangauthor=J.+R.+Zhangauthor=X.+Zhengauthor=W.+Zhongauthor=W.+J.+Watkins&title=Optimization+of+pharmacokinetics+through+manipulation+of+physicochemical+properties+in+a+series+of+HCV+inhibitors&doi=10.1021%2Fml200163b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22dR"><div class="casContent"><span class="casTitleNuber">22d</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Pharmacokinetics through Manipulation of Physicochemical Properties in a Series of HCV Inhibitors</span></div><div class="casAuthors">Lazerwith, Scott E.; Bahador, Gina; Canales, Eda; Cheng, Guo-Feng; Chong, Lee; Clarke, Michael O.; Doerffler, Edward; Eisenberg, Eugene J.; Hayes, Jaclyn; Lu, Bing; Liu, Qi; Matles, Mike; Mertzman, Michael; Mitchell, Michael L.; Morganelli, Philip; Murray, Bernard P.; Robinson, Margaret; Strickley, Robert G.; Tessler, Megan; Tirunagari, Neeraj; Wang, Jian-Hong; Wang, Yu-Jin; Zhang, Jennifer R.; Zheng, Xu-Bin; Zhong, Wei-Dong; Watkins, William J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">715-719</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of HCV replication inhibitors based on a pyrido[3,2-d]pyrimidine core were optimized for pharmacokinetics (PK) in rats.  Several assocns. between physicochem. properties and PK were identified and exploited to guide the design of compds.  In addn., a simple new metric that may aid in the prediction of bioavailability for compds. with higher polar surface area is described (3*HBD-cLogP).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9QmQ7Imm6ALVg90H21EOLACvtfcHk0lhsUJvvE3qziw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVyhu7w%253D&md5=a9aee94fa770dc39e9180c79e1cd1ef8</span></div><a href="/servlet/linkout?suffix=cit22d&amp;dbid=16384&amp;doi=10.1021%2Fml200163b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200163b%26sid%3Dliteratum%253Aachs%26aulast%3DLazerwith%26aufirst%3DS.%2BE.%26aulast%3DBahador%26aufirst%3DG.%26aulast%3DCanales%26aufirst%3DE.%26aulast%3DCheng%26aufirst%3DG.%26aulast%3DChong%26aufirst%3DL.%26aulast%3DClarke%26aufirst%3DM.%2BO.%26aulast%3DDoerffler%26aufirst%3DE.%26aulast%3DEisenberg%26aufirst%3DE.%2BJ.%26aulast%3DHayes%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMatles%26aufirst%3DM.%26aulast%3DMertzman%26aufirst%3DM.%26aulast%3DMitchell%26aufirst%3DM.%2BL.%26aulast%3DMorganelli%26aufirst%3DP.%26aulast%3DMurray%26aufirst%3DB.%2BP.%26aulast%3DRobinson%26aufirst%3DM.%26aulast%3DStrickley%26aufirst%3DR.%2BG.%26aulast%3DTessler%26aufirst%3DM.%26aulast%3DTirunagari%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%2BR.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DZhong%26aufirst%3DW.%26aulast%3DWatkins%26aufirst%3DW.%2BJ.%26atitle%3DOptimization%2520of%2520pharmacokinetics%2520through%2520manipulation%2520of%2520physicochemical%2520properties%2520in%2520a%2520series%2520of%2520HCV%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D715%26epage%3D719%26doi%3D10.1021%2Fml200163b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Fleming, F. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ravikumar, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shook, B. C.</span><span> </span><span class="NLM_article-title">Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7902</span><span class="NLM_x">–</span> <span class="NLM_lpage">7917</span><span class="refDoi"> DOI: 10.1021/jm100762r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100762r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2kurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7902-7917&author=F.+F.+Flemingauthor=L.+Yaoauthor=P.+C.+Ravikumarauthor=L.+Funkauthor=B.+C.+Shook&title=Nitrile-containing+pharmaceuticals%3A+efficacious+roles+of+the+nitrile+pharmacophore&doi=10.1021%2Fjm100762r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore</span></div><div class="casAuthors">Fleming, Fraser F.; Yao, Lihua; Ravikumar, P. C.; Funk, Lee; Shook, Brian C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7902-7917</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review is structured according to the nature of the nitrile-bearing substituent.  As the no. of nitrile-contg. drug leads is vast, the review has focused on launched nitrile-contg. pharmaceuticals and currently active clin. candidates.  Most nitrile-contg. pharmaceuticals are aroms. with aliph.-, alkene-, and nitrogen-bearing nitriles being progressively less frequent.  Within each class, the bioactive nitriles are collated according to common structural elements and mode of action.  The hope is that this survey will allow greater deployment of this versatile functionality within drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR6kPPdWVuvLVg90H21EOLACvtfcHk0lhsUJvvE3qziw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2kurvP&md5=040bbaebd9e8c9999d195b9a22221fea</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm100762r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100762r%26sid%3Dliteratum%253Aachs%26aulast%3DFleming%26aufirst%3DF.%2BF.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DRavikumar%26aufirst%3DP.%2BC.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DShook%26aufirst%3DB.%2BC.%26atitle%3DNitrile-containing%2520pharmaceuticals%253A%2520efficacious%2520roles%2520of%2520the%2520nitrile%2520pharmacophore%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7902%26epage%3D7917%26doi%3D10.1021%2Fjm100762r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="note"><p class="first last">Selectivity folds were calculated based on estimated IC<sub>50</sub>’s from 3 point titrations (1, 100, and 1000 nM) and the internal JAK1 potencies; 265 kinases were screened at a Invitrogen at their respective <i>K</i><sub>M</sub>. For the full list of kinases, see <a href="/doi/suppl/10.1021/acs.jmedchem.7b01135/suppl_file/jm7b01135_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Cheng, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eksterowicz, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geuns-Meyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span> </span><span class="NLM_article-title">Analysis of kinase inhibitor selectivity using a thermodynamics-based partition index</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4502</span><span class="NLM_x">–</span> <span class="NLM_lpage">4510</span><span class="refDoi"> DOI: 10.1021/jm100301x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100301x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvVOisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4502-4510&author=A.+C.+Chengauthor=J.+Eksterowiczauthor=S.+Geuns-Meyerauthor=Y.+Sun&title=Analysis+of+kinase+inhibitor+selectivity+using+a+thermodynamics-based+partition+index&doi=10.1021%2Fjm100301x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Kinase Inhibitor Selectivity using a Thermodynamics-Based Partition Index</span></div><div class="casAuthors">Cheng, Alan C.; Eksterowicz, John; Geuns-Meyer, Stephanie; Sun, Yaxiong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4502-4510</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the quest for safe, efficacious kinase inhibitors as drugs, selectivity is often assessed early using kinase profiling panels.  Here we present a selectivity index based on thermodn. principles that can help in anal. of the resulting data.  The "partition" selectivity index is easy to calc. and is applicable in certain situations where other widely used indexes are not.  It is uniquely useful in anal. of small, focused selectivity panel data frequently encountered in medicinal chem. hit-to-lead and lead optimization.  For larger "kinome" panels, the partition index allows assessment of selectivity relative to a kinase or multiple kinases of interest.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFHFduiUmbgbVg90H21EOLACvtfcHk0lhsUJvvE3qziw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvVOisrk%253D&md5=d50d74d4224ccba3c3ea7bbe72fd22d1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm100301x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100301x%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DEksterowicz%26aufirst%3DJ.%26aulast%3DGeuns-Meyer%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DAnalysis%2520of%2520kinase%2520inhibitor%2520selectivity%2520using%2520a%2520thermodynamics-based%2520partition%2520index%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4502%26epage%3D4510%26doi%3D10.1021%2Fjm100301x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="note"><p class="first last">JAK1 kinase domain at 20 mg/mL was incubated with 1.6 mM adenosine and 3.2 mM DTT for 60 min then crystallized at 4 °C using vapor diffusion. Equal volumes of protein and reservoir were mixed and suspended over a 1 mL reservoir containing 30% w/v poly(ethylene glycol) 6000 and 100 mM MES buffer at pH 6.3. After streak-seeding, crystals appeared within 3 days. Crystals were soaked with 4 mM <b>28</b> for 5 days prior to flash cooling. Synchrotron data were collected at the Canadian Light Source</p></div><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Grochulski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fodje, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labiuk, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berg, R.</span><span> </span><span class="NLM_article-title">Beamline 08ID-1, the prime beamline of the Canadian Macromolecular Crystallography Facility</span> <span class="citation_source-journal">J. Synchrotron Radiat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">681</span><span class="NLM_x">–</span> <span class="NLM_lpage">684</span><span class="refDoi"> DOI: 10.1107/S0909049511019431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1107%2FS0909049511019431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=21685687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnslOqurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=681-684&author=P.+Grochulskiauthor=M.+N.+Fodjeauthor=J.+Gorinauthor=S.+L.+Labiukauthor=R.+Berg&title=Beamline+08ID-1%2C+the+prime+beamline+of+the+Canadian+Macromolecular+Crystallography+Facility&doi=10.1107%2FS0909049511019431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Beamline 08ID-1, the prime beamline of the Canadian Macromolecular Crystallography Facility</span></div><div class="casAuthors">Grochulski, Pawel; Fodje, Michel N.; Gorin, James; Labiuk, Shaunivan L.; Berg, Russ</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Synchrotron Radiation</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">681-684</span>CODEN:
                <span class="NLM_cas:coden">JSYRES</span>;
        ISSN:<span class="NLM_cas:issn">0909-0495</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Beamline 08ID-1 is the prime macromol. crystallog. beamline at the Canadian Light Source.  Based on a small-gap in-vacuum undulator, it is designed for challenging projects like small crystals and crystals with large cell dimensions.  Beamline 08ID-1, together with a second bending-magnet beamline, constitute the Canadian Macromol. Crystallog. Facility (CMCF).  This paper presents an overall description of the 08ID-1 beamline, including its specifications, beamline software and recent scientific highlights.  The end-station of the beamline is equipped with a CCD X-ray detector, on-axis crystal visualization system, a single-axis goniometer and a sample automounter allowing remote access to the beamline.  The general user program is guaranteed up to 55% of the useful beam time and is run under a peer-review proposal system.  The CMCF staff provide 'Mail-in' crystallog. service to the users with the highest-scored proposals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmQwWQ_1HgJrVg90H21EOLACvtfcHk0ljCltGb6Oxmmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnslOqurg%253D&md5=cba3bb23196a3b32d03179324a72bf0a</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1107%2FS0909049511019431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0909049511019431%26sid%3Dliteratum%253Aachs%26aulast%3DGrochulski%26aufirst%3DP.%26aulast%3DFodje%26aufirst%3DM.%2BN.%26aulast%3DGorin%26aufirst%3DJ.%26aulast%3DLabiuk%26aufirst%3DS.%2BL.%26aulast%3DBerg%26aufirst%3DR.%26atitle%3DBeamline%252008ID-1%252C%2520the%2520prime%2520beamline%2520of%2520the%2520Canadian%2520Macromolecular%2520Crystallography%2520Facility%26jtitle%3DJ.%2520Synchrotron%2520Radiat.%26date%3D2011%26volume%3D18%26spage%3D681%26epage%3D684%26doi%3D10.1107%2FS0909049511019431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">Data collection and refinement details are found in <a href="/doi/suppl/10.1021/acs.jmedchem.7b01135/suppl_file/jm7b01135_si_001.pdf" class="ext-link">Table S2</a>. Coordinates have been deposited with PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WO4">5WO4</a>. <a class="ref internalNav" href="#fig9" aria-label="Figures 9">Figures 9</a> and <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a> were generated using PyMOL (The PyMOL Molecular Graphics System, Schrödinger, LLC).</p></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="note"><p class="first last">JAK2 PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LPB">3LPB</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span>View Contacts, version 2.24, <span class="NLM_publisher-name">Desert Scientific Software</span>, <span class="NLM_publisher-loc">Norwest, Australia</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=View+Contacts%2C+version+2.24%2C+Desert+Scientific+Software%2C+Norwest%2C+Australia."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DView%2520Contacts%26pub%3DDesert%2520Scientific%2520Software" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Courtenay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayan, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosedale, B.</span><span> </span><span class="NLM_article-title">Immunization against heterologous type II collagen induces arthritis in mice. <i>Nature</i></span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">666</span><span class="NLM_x">–</span> <span class="NLM_lpage">668</span><span class="refDoi"> DOI: 10.1038/283666a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;key=10.1038%2F283666a0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1980&pages=666-668&author=J.+S.+Courtenayauthor=M.+J.+Dallmanauthor=A.+D.+Dayanauthor=A.+Martinauthor=B.+Mosedale&title=Immunization+against+heterologous+type+II+collagen+induces+arthritis+in+mice.+Nature&doi=10.1038%2F283666a0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2F283666a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F283666a0%26sid%3Dliteratum%253Aachs%26aulast%3DCourtenay%26aufirst%3DJ.%2BS.%26aulast%3DDallman%26aufirst%3DM.%2BJ.%26aulast%3DDayan%26aufirst%3DA.%2BD.%26aulast%3DMartin%26aufirst%3DA.%26aulast%3DMosedale%26aufirst%3DB.%26atitle%3DImmunization%2520against%2520heterologous%2520type%2520II%2520collagen%2520induces%2520arthritis%2520in%2520mice.%2520Nature%26jtitle%3DNature%26date%3D1980%26volume%3D283%26spage%3D666%26epage%3D668%26doi%3D10.1038%2F283666a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="note"><p class="first last"><a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a> was generated using</p></div><div class="NLM_citation" id="rightTab-cit30"><span>Prism 7, <a href="https://www.graphpad.com/scientific-software/prism/" class="extLink">https://www.graphpad.com/scientific-software/prism/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Prism+7%2C+https%3A%2F%2Fwww.graphpad.com%2Fscientific-software%2Fprism%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WO4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WO4','PDB','5WO4'); return false;">PDB: 5WO4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LPB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3LPB','PDB','3LPB'); return false;">PDB: 3LPB</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i40"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01135">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_41816"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01135">10.1021/acs.jmedchem.7b01135</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Kinase selectivity profile of key compounds in panel of 265 kinases and kinase selectivity for compounds <b>2</b>, <b>22</b>, and <b>28</b>, JAK biochemical HTRF assay protocol, cell based assay protocol, human whole blood STAT phosphorylation assay protocol, crystallographic data collection and refinement statistics for the complex of JAK1 with compound <b>28</b>, rat collagen induced arthritis (CIA) model, experimental procedure for compounds <b>2</b>, <b>3</b>, <b>4</b>, and <b>5</b>, high-throughput (HT) HPLC log D (pH 7.0) determination, high-throughput (HT) FaSSIF solubility determination, hepatocyte intrinsic clearance method, and references (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01135/suppl_file/jm7b01135_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01135/suppl_file/jm7b01135_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01135/suppl_file/jm7b01135_si_001.pdf">jm7b01135_si_001.pdf (638.14 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01135/suppl_file/jm7b01135_si_002.csv">jm7b01135_si_002.csv (2.33 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WO4">5WO4</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01135&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-23%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01135%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01135" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"667979dbbe67d1f3","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
